

Bijan Eghtesad, M.D.
Curriculum Vitae

BIJAN EGHTESAD, M.D.
CURRICULUM VITAE

Personal Data

Birth Date: March 25, 1953
Birth Place: IRAN
Citizenship: USA

Professional Address

Cleveland Clinic
Department of General Surgery
Hepato-Pancreato-Biliary/Liver Transplantation Surgery
9500 Euclid Avenue / Desk A100
Cleveland, OH 44195
Phone: 216-444-9898
Fax: 216-444-9375
Email: eghtesb@ccf.org

Bijan Eghtesad, M.D.
Curriculum Vitae

EDUCATION AND TRAINING

Dates Attended	Institution/Location	Major Advisor and Discipline
08/1992 – 12/1994	University of Pittsburgh Medical Center Transplantation Institute Pittsburgh, PA 15213	Fellowship, Multiorgan Transplant
07/1994 – 12/1994	Children's Hospital of Pittsburgh Division of Transplant Surgery Pittsburgh, PA 15213	Fellowship, Pediatric Multiorgan Transplant
1979 – 1982	Shiraz University Medical School Affiliated Hospitals Shiraz, Iran	Resident, General Surgery
1982 – 1983	Shiraz University Medical School Affiliated Hospitals Shiraz, Iran	Chief Resident
1972 – 1978	Pahlavi (Shiraz) University School of Medicine Shiraz, Iran	M.D., 1978 Medicine
11/1976 – 02/1977	Parkland Memorial Hospital University of Texas Health Science Center Southwestern Medical School Dallas, Texas	Visiting Student
1977 – 1978	Pahlavi University Medical School Affiliated Hospitals Shiraz, Iran	Rotating Internship
1970 – 1972	Pahlavi (Shiraz) University School of Medicine Shiraz, Iran	Pre-medicine
10/17/2022		

Bijan Eghtesad, M.D.
Curriculum Vitae

ACADEMIC APPOINTMENTS and POSITIONS

Years	Institution	Rank / Title
02/2005 – Present	Cleveland Clinic Foundation Department of General Surgery Liver Transplantation 9500 Euclid Avenue Cleveland, OH 44195	Staff Surgeon Liver Transplantation and Hepatobiliary Surgery Director, ASTS Fellowship Program
01/2003 – 01/2005	University of Pittsburgh Department of Surgery Division of Transplantation 3459 Fifth Avenue Pittsburgh, PA 15213	Associate Professor of Surgery Director, Living Donor Liver Transplant Program Co-Director, Adult Liver Transplant Program
12/2000 – 12/2002	University of Pittsburgh Department of Surgery Division of Transplantation 3601 Fifth Avenue Pittsburgh, PA 15213	Visiting Associate Professor Surgery Co-Director, Adult Liver Transplant Program
05/2000 – 11/2000	University of New Mexico Health Sciences Center Department of Surgery Section of Transplantation Albuquerque, NM 87131-5341	Associate Professor with Tenure Director, Transplantation Surgery and Hepatobiliary Surgery
11/1996 – 04/2000	University of New Mexico Health Sciences Center Department of Surgery Section of Transplantation Albuquerque, NM 87131-5341	Assistant Professor Director, Transplantation Surgery Hepatobiliary Surgery
08/1996 – 10/1996	University of New Mexico Health Sciences Center Department of Surgery Section of Transplantation Albuquerque, NM 87131-5341	Acting Director, Transplantation Assistant Professor

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

ACADEMIC APPOINTMENTS and POSITIONS

Years	Institution	Rank / Title
12/1994 – 08/1996	University of New Mexico Health Sciences Center Department of Surgery Section of Transplantation Albuquerque, NM 87131-5341	Assistant Professor
08/1992 – 12/1994	University of Pittsburgh Medical Center Transplantation Institute Pittsburgh, PA 15213	Instructor in Surgery Fellowship, Multiorgan Transplant
07/1994 – 12/1994	Children's Hospital of Pittsburgh Division of Transplant Surgery Pittsburgh, PA 15213	Instructor in Surgery Fellowship in Pediatric Multiorgan Transplant
01/1992 – 07/1992	University of Pittsburgh Medical Center Transplantation Institute Pittsburgh, PA 15213	Visiting Research Fellow
07/1988 – 12/1991	Arad General Hospital Tehran, Iran	General Surgeon (Private Practice)
10/1986 – 07/1988	Bandar-Abbas School of Medicine Bandar-Abbas, Iran	Associate Dean, Director of Anatomy Department
1983 – 1986	Mohammadi Hospital Bandar-Abbas, Iran	General Surgeon Chief of Department of Surgery Director of the Emergency Room and Trauma

10/17/2022

CERTIFICATION and LICENSURE

1977	Standard Certificate: ECFMG
1978	Doctorate of Medicine (MD)
1978	Visa Qualifying Exam (VQE, National Board Parts 1&2)
1983	Iranian Board of General Surgery
1988	Unrestricted License to practice Surgery and Medicine in Tehran/Iran
1992	Pennsylvania Limited Medical License
1992	FLEX – State of Pennsylvania
1994	Certificate of Fellowship in Transplant Surgery, (University of Pittsburgh Medical Center)
1994	Certificate of Fellowship in Pediatric Transplant Surgery, (Children's Hospital of Pittsburgh)
1994	New Mexico Medical License (Inactive)
2000	Pennsylvania Medical/Surgical License (Inactive)
2004	Ohio Medical/Surgical License (Active)
2015	Florida Medical License (Active)
2018	Fellow, American Association for the Study of Liver Diseases (FAASLD)

MEMBERSHIP

International Liver Transplantation Society (ILTS)
The Transplantation Society
Iranian Association of Surgeons
American Society of Transplant Surgeons (ASTS)
American Association for the Study of Liver Diseases (AASLD)
Academy of Medical Sciences of the Islamic Republic of Iran
International Pediatric Transplant Association (IPTA)
American Society of Transplantation (AST)
Cleveland Academy of Surgeons

Bijan Eghtesad, M.D.
Curriculum Vitae

Committee Membership – National/International Societies and Associations

Fellowship Training Committee - American Society of Transplant Surgeons (ASTS), 2013-2016

Surgery and Liver Transplantation Committee – American Association for the Study of Liver Diseases (AASLD), 2013-2016

Liver Transplantation and Surgery Special Interest Groups (SIG) Steering Committee - American Association for the Study of Liver Diseases (AASLD), 2017-2020

Surgery and Liver Transplantation Committee – American Association for the Study of Liver Diseases (AASLD), 2016-2019

Ambassador of the Transplantation Society for Iran. The Transplantation Society (TTS), 2016 – Present

International Liver Transplantation Society (ILTS), Council member, 2018-2022

Chair, Global Subcommittee, Liver Transplantation and Surgery, Special Interest Group (SIG) (AASLD) 2018-2020

Chair-Elect of the Surgery and Liver Transplantation Committee, American Association for the Study of Liver Diseases (AASLD), 2019-2020

Chair, Surgery and Liver Transplantation Committee, American Association for the Study of Liver Diseases (AASLD), 2020-2022

Chair, Membership and Communication Committee, International Liver Transplantation Society (ILTS), 2019-2020

International Liver Transplantation Society (ILTS), Award Committee, 2018-2021

American Association for the Study of Liver Diseases (AASLD), Scientific Program Committee, Annual Liver Meeting, 2020-2022

American Association for the Study of Liver Diseases (AASLD) writing group to develop a new practice guidance on the “Role of TIPS, BRTO, BATO, and CARTO in the Management of Gastroesophageal Varices”. 2021-2022

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

Chair of the Education Committee of the Ohio Solid Organ Transplant Consortium (OSOTC)
2020- Present

Education and Scholarship Committee, International Liver Transplantation Society (ILTS),
2020-2023

International Liver Transplantation Society (ILTS) writing group for new guideline
(ERAS4OLT), 2021-2022

HONORS

Excellence in Resident Education; the Chief Residents, Class of 1997, University of New Mexico, Department of Surgery

Affiliated Professor of Surgery, Tehran University of Medical Sciences (2010)

Fellow of the American Association for the Study of Liver Diseases FAASLD (2018)

Editorial Boards:

Editorial Board, Liver Transplantation 2005-2016

Editorial Board, World Journal of Gastroenterology 2005-2017

Co-Editor, International Journal of Organ Transplantation Medicine since 2009

Reviewer:

Transplantation
Liver Transplantation
World Journal of Gastroenterology
American Journal of Transplantation

10/17/2022

Bijan Egtesad, M.D.
Curriculum Vitae

Archives of Iranian Medicine
Clinical Transplantation
International Journal of Organ Transplantation Medicine
Annals of Surgery
World Journal of Surgery
World Journal of Hepatology
Nature

Meetings Organized / Scientific Committees

Dental Management of the Organ Transplant Patients
University of Pittsburgh, School of Dental Medicine, Oct. 15, 2003

Living Donor Solid Organ Transplant: State of the Art Summit
Cleveland Clinic, Sept. 29-30, 2006

HIV and Solid Organ Transplantation, Cleveland Clinic, Nov. 8, 2006

11th Congress of the Middle East Society of Transplantation (MESOT), Shiraz, Iran, Nov., 2008

Emerging Issues in Organ Transplantation – A Colloquium, Cleveland, Ohio, USA, October, 2009

10th Congress of the Iranian Society of Organ Transplantation (IRSOT), Shiraz, Iran, May 17-19, 2011

Emerging Issues in Organ Transplantation – A Colloquium, Cleveland, Ohio, USA, October 14-15, 2011

Emerging Issues in Organ Transplantation – A Colloquium, Kiawah Island, South Carolina, USA, September 23-24, 2013

World Transplant Congress. Sunrise Symposia. Segmental (living donor/split) liver transplantation: Variable recipient factors. July 26-31, 2014. San Francisco, USA

Emerging Issues in Organ Transplantation – A Colloquium, Charleston, South Carolina, USA, September 25-26, 2015

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

DDW Combined Clinical Symposium; Workshop on Assessment of Surgical Risk in the Patient with Liver Disease. Washington DC, USA, May 17, 2015

The 3rd Tehran Hepato-Pancreato-Biliary and Liver Transplant Congress, Tehran, Iran, (President of the Congress) November 4-6, 2015

AASLD, Surgery and Liver Transplantation Workshop, San Francisco, USA, November 14, 2015

Third International Congress of organ Transplantation. Shiraz, Iran, May 16-19, 2017

Seventh International Tehran Hepatitis Conference (THC7), Tehran, Iran, September 6-8, 2017

Emerging Issues in Organ Transplantation – A Colloquium, Cleveland, Ohio, USA, September 15-16, 2017

AASLD, Surgery and Liver Transplantation Workshop, Washington DC, USA, October 21, 2017

Fourth International Tehran Hepato-Pancreato-Biliary & Liver Transplant Congress. Tehran, Iran, October 31 – November 3, 2017

AASLD, Surgery and Liver Transplantation Workshop, San Francisco, USA, November 11, 2018

AASLD, Surgery and Liver Transplantation workshop, NASH and Liver Transplantation, Program Chair, Boston, USA, November 9, 2019

Fifth Tehran Hepato-Pancreato-Biliary and Liver Transplant Congress, Tehran, Iran, November 20-21, 2019

Program Committee, American Association for the Study of liver disease (AASLD), The Liver Meeting, November 2020

Ohio Solid Organ Transplant Consortium (OSOTC) “David Taylor” Transplant Educational Webinars focusing on the COVID-19 Epidemic and Transplantation Oct. 16 and 23, 2020

AASLD Annual Meeting, Liver Transplant and surgery Workshop (webinar) “COVID-19 and Liver Transplantation in United States and Europe” and Breakout Sessions. Nov 14, 2020

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

AASLD Annual Meeting, Surgery and Liver Transplantation Worksho, (Webinar), “Expanding the Donor Pool” November 13, 2021

Ohio Solid Organ Transplant Consortium (OSOTC) “David Taylor” Annual Transplant Educational (Webinar) October 15, 2021

PUBLICATIONS and PRESENTATIONS

A. Refereed Articles:

- 1) Ukah FO, Merhav H, Kramer D, **Eghtesad B**, Samimi F, Ferezza E, Linden P, Miele L, Selby R. Early Outcome of Liver Transplantation in Patients with a History of Spontaneous Bacterial Peritonitis. *Transplantation Proceedings* 25: 1113-1115, 1993.
- 2) Bronsther O, Ersoz S, Tugcu M, **Eghtesad B**, Gurkar A, Van Thiel DH. Liver Transplantation for HBV-related Disease Under Immunosuppression with Tacrolimus: An Experience of 78 Consecutive Cases. *Oklahoma State Medical Association* 88: 103-108, 1995.
- 3) **Eghtesad B**, Bronsther O, Irish W, Casavilla A, Abu-Elmagd K, Tzakis A, Fung JJ, Starzl TE. Disease Gravity and Urgency of Need as Guideline for Liver Allocation. *Hepatology* 20:56s-62s 1994.
- 4) Fung JJ, **Eghtesad B**, Todo S, Rakela J, Magnone M, Starzl TE. Hepatitis B Virus (HBV) Re-infection following Orthotopic Liver Transplantation: Theory and Practice. *Clinical Transplantation* 9: 262-268, 1995.
- 5) Hardee JT, Barnett AL, Thannoun A, **Eghtesad B**, Wheeler D, Jamal M. Propylthiouracil-Induced Hepatotoxicity: A Case Report and Discussion of Histopathology. *The Western Journal of Medicine* 165: 144-147, 1996.
- 6) Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, **Eghtesad B**, Iwatsuki S, Montalvo E, Rakela J, Fung JJ. Infectivity of Hepatic Allografts with Antibodies to Hepatitis B Virus. *Transplantation* 64: 1582-1584, 1997

10/17/2022

- 7) Harford AM, Gibel LJ, **Eghtesad B**, Smith AY, Malhotra D, Haq M, Carter C, Demarest P, Garretson L, Heister K. Single Kidney Transplants from Donors with Low Estimated Creatinine Clearance. *Transplantation Proceedings* 29: 3317-3318, 1997.
- 8) **Eghtesad B**, Malhotra D, Hecker W, Haq M, Gibel LJ, Wheeler D, Smith AY, Harford AM. Use of Tacrolimus as the Primary Immunosuppression After Renal Transplant in Native Americans and Hispanics. *Transplantation Proceedings*, 30: 1232-1233, 1998.
- 9) Hays WS, Wheeler DE, **Eghtesad B**, Glew RH, Johnston DE. Expression of Cytosolic beta-Glucosidase in Guinea Pig Liver Cells. *Hepatology*, 28: 156-163, 1998.
- 10) Samimi F, Irish WD, **Eghtesad B**, Demetris, AJ, Starzl TE, Fung JJ. Role of Splenectomy in Liver Transplantation under Modern Drug Immunosuppression. *Digestive Disease and Sciences*, 43: 1931-7, 1998.
- 11) **Eghtesad B**, Nezakatgoo N, Geraci LC, Jabbour N, Irish W, Marsh W, Fung JJ, Rakela J. Liver Transplantation for Wilson Disease; Single Center Experience. *Liver Transplantation and Surgery*, 5: 467-474, 1999
- 12) Jain A, Kashyap R, Demetris AJ, **Eghtesad B**, Pokharna R, Fung JJ. A Prospective Randomized Trial of Mycophenolate Mofetil in Liver Transplant Recipients with Hepatitis C. *Liver Transplantation* 8: 40-46, 2002.
- 13) Jain A, Kashyap R, Dodson F, Kramer D, Hamad I, Khan A, **Eghtesad B**, Starzl TE, Fung JJ. A Prospective Randomized Trial of Tacrolimus and Prednisone versus Tacrolimus, Prednisone and Mycophenolate Mofetil in Primary Adult Liver Transplantation: A Single Center Report. *Transplantation*, 72:1091-97, 2001
- 14) Fung JJ, Jain A, Ewak EJ, Kusne S, Dvorchik I, **Eghtesad B**. *De Novo* Malignancies Following Liver Transplantation – A Major Cause of Death. *Liver Transplantation*, 7: Supp 1, S109-S118, 2001
- 15) Albrecht RA, **Eghtesad B**, Gibel L, Locken J, Champlin A. Percutaneous Removal of Spilled Gallstones in Subhepatic Abscess. *The American Surgeon*, 68:193-195, 2002.
- 16) Jain A, Pokharna R, **Eghtesad B**, Potdar S, Kashyap R, Kingery L, Fung J. Question of Steroid Withdrawal Under Tacrolimus for Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis after Liver Transplantation and Long-term Survival *Transplantation Proceedings* 34: 1524-1525, 2002.
- 17) Jain A, Pokharna R, Abu-Elmagd K, Shapiro R, Scantlebury V, **Eghtesad B**, Fontes

Bijan Eghtesad, M.D.
Curriculum Vitae

P,Godamski M, Fung J. Use of Rituximab (Chimeric Anti CD-20 Antibody) in Post Transplant Lymphoproliferative Disorder (PTLD) After Liver Transplantation (in press, Transplantation Proceedings).

18) **Egtesad B**, Reyes JD, Ashrafi M, Fung JJ, Mazariegos GV. Incidence, Management and Outcome of Serious Pancreatitis Following Pediatric Liver Transplantation. A Single Center Experience. Transplantation 75:190-193, 2003.

19) Jain A, Pokharna R, Demetris, AJ, **Egtesad B**, Nestler K, Kashyap R, Fung JJ. Role of Mycophenolate Mofetil (MMF) in Liver Transplantation (LTX) for HCV-related End Stage Liver Failure; A Prospective Randomized Trial (in press, Transplantation Proceedings).

20) Kapoor V, Peterson MS, Baron RL, Patel S, **Egtesad B**, Fung JJ. Adult Living Liver Donor Intrahepatic Anatomy: Correlation Between Mangafodipir Trisodium-Enhanced Resonance Cholangiography and Intraoperative Cholangiography. American Journal of Radiology 179:1281-1286. 2002.

21) Demetris AJ, Ruppert K, Dvorchik I, Jain AK, Minervini M, Nalesnik M, Randhawa P, Wu T, Zeevi A, Abu-Elmagd K, **Egtesad B**, Fontes P, Cacciarelli T, Marsh W, Geller D, Fung J. Real-Time Monitoring of Acute Liver-Allograft Rejection Using the Banff Schema. Transplantation 74:1290-1296, 2002.

22) Jain A, **Egtesad B**, Venkatramanan R, Fontes P, Kashyap R, Dvorchik I, Shakil O, Kingerly L, Fung J. Ribavirin Dose Modification Based on Renal Function is Necessary to Reduce Hemolysis in Liver Transplant Patients with Hepatitis C Virus Infection. Liver Transplant 8:1007-1013, 2002.

23) Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, **Egtesad B**, Marsh W, Cacciarelli T, Fontes P, Abu-Elmagd K, Sindhi R, Demetris J, Fung J. Post-transplant Lymphoproliferative Disorder (PTLD) in Liver Transplantation: A Twenty Year Experience. Ann.Surg 236:429-437, 2002.

24) Starzl TE, Murase N, Abu-Elmagd K, Gray E, Shapiro R, **Egtesad B**, Jordan ML, Scantlebury VP, Potdar S, Corry RJ, Randhawa P, Wu T, Nalesnik MA, Trucco M, Demetris AJ, Fung JJ. Tolerogenic Immunosuppression for Organ Transplantation. Lancet, May 3, 361(9368):1502-10, 2003

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

- 25) Jain A, Reyes J, Marcos A, Mazariegos G, **Eghtesad B**, Fontes P, Cacciarelli T, Marsh W, Devera M, Rafail A, Starzl T, Fung J. Pregnancy After Liver Transplantation Under Tacrolimus. A Single Center Experience Update at 13 Years. *Transplantation*, 76:827-832, 2003
- 26) Guggenheimer J, **Eghtesad B**, Stock D. Dental Management of the (Solid) Organ Transplant Patient. *Oral Surg Oral Med Oral Path Oral Radiol Endod* 95:383-9, 2003
- 27) **Eghtesad B**, Jain AB, Fung JJ. Living Donor Liver Transplantation: Ethics and Safety. *Transplantation Proceedings*, 35:51-2, 2003
- 28) Jain AB, Venkatramanan R, **Eghtesad B**, Marcos A, Ragni M, Shapiro R, Rafail A, Fung JJ. Effect of Coadministered Lopinavir and Ritonavir (Kaletra) on Tacrolimus Blood Concentration in Liver Transplantation Patients. *Liver Transplantation*, 9:954-960, 2003
- 29) **Eghtesad B**, Marsh W, Cacciarelli T, Geller D, Reyes J, Jain A, Fontes P, DeVera M, Fung J. Liver Transplantation for Growing Teratoma Syndrome: Report of a Case. *Liver Transpl* 9:1222-1224, 2003
- 30) Metes D, Logar A, Rudert WA, Zeevi A, Woodward J, Demetris AJ, Abu-Elmagd K, **Eghtesad B**, Shapiro R, Fung JJ, Trucco M, Starzl TE. Four-color Flow Cytometric Analysis of Peripheral Blood Donor Cell Chimerism. *Hum Immunol*, 64:787-95, 2003
- 31) Demetris AJ, **Eghtesad B**, Marcos A, Ruppert K, Nalesnik MA, Rhandawa P, Wu T, Fontes P, Cacciarelli T, Shakil O, Murase N, Fung JJ, Starzl TE. Recurrent Hepatitis C in Allografts: Prospective Assessment of Diagnostic Accuracy and Observations on Pathogenesis. *Amer J Surg Path.* 28:658-669, 2004
- 32) Potdar S, Malek S, **Eghtesad B**, Shapiro R, Basu A, Patel K, Fung J. Initial Experience Using Histidine-Tryptophane-Ketoglutarate (HTK) Solution in Clinical Pancreas Transplantation. *Clinical Transplantation* 18:661-5, 2004
- 33) Fung M, Sheikh H, **Eghtesad B**, Lopez-Plaza I. Severe Hemolysis Resulting from Rh (D) Incompatibility in a Case of ABO-identical Liver Transplant. *Transfusion* 44:1635-9, 2004.
- 34) Starzl TE, Murase N, Demetris AJ, Trucco M, Abu-Elmagd K, Gray E, **Eghtesad B**, Shapiro R, Marcos A, Fung JJ. Lessons of Organ-Induced Tolerance Learned from Historical Clinical Experience. *Transplantation* 77:926-929, 2004

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

- 35) Marcos A, **Egtesad B**, Fung JJ, Fontes P, Patel K, deVera M, Marsh W, Gayowski T, Demetris A, Gray E, Flynn B, Murase N, Starzl TE. Use of Alemtuzumab and Tacrolimus Monotherapy for Cadaveric Liver Transplantation: with Particular Reference to Hepatitis C Virus. *Transplantation* 78:966-971, 2004
- 36) Planinsic R, Nicolau-Raducu R, **Egtesad B**, Marcos A. Diagnosis and Treatment of Intracardiac Thrombosis During Orthotopic Liver Transplantation. *Anesth Analg* 99:353-6, 2004.
- 37) Fung J, **Egtesad B**, Patel-Tom K, DeVera M, Chapman H, Ragni M. Liver Transplantation in Patients with HIV Infection. *Liver Transplantation* 10 (Number 10, Supplement 2) S39-S53, 2004.
- 38) Neff GW, Sherman KE, **Egtesad B**, Fung J. Current Status of Liver Transplantation in HIV-Infected Patients. *Aliment Pharmacol Ther*, 20:993-1000, 2004.
- 39) Guggenheimer, J, Meyer D, **Egtesad B**. A Survey of Dental Care Protocols Among U.S. Organ Transplant Centers. *Clin Transplant* 19:15-18, 2005
- 40) Fung JJ, Kelly D, Kadriy Z, Patel K, **Egtesad B**. Immunosuppression in Liver Transplantation: Beyond Calcineurin Inhibitors. *Liver Transpl* 11:267-280, 2005
- 41) Krasinskas AM, **Egtesad B**, Kamath PS, Demetris AJ, Abraham SC. Liver Transplantation for Severe Intrahepatic Noncirrhotic Portal Hypertension. *Liver Transpl* 11:627-634, 2005
- 42) Jain A, Marcos A, Reyes J, Mazariegos G, Kashyap R, **Egtesad B**, Marsh W, Fontes P, DeVera M, Costa G, Patel K, Gadomski M, Starzl T, Fung J. Tacrolimus for Primary Liver Transplantation: 12 to 15 Years Actual Follow-up with safety Profile. *Transpl Proc.* 37:1207-10, 2005.
- 43) Olson L, Kisthard J, Cravero L, Fung J, **Egtesad B**, Savo A, Levy A, Polissar N, Marks W. Livers Transplanted from Donors after Cardiac Death Occuring in the ICU or the Operating Room Have Excellent Outcomes. *Transpl Proc.* 37:1188-93, 2005.
- 44) **Egtesad B**, Kadry Z, Fung J. Technical Considerations in Liver Transplantation: What a Hepatologist Needs to Know (and Every Surgeon Should Practice). *Liver Transpl* 11:861-71, 2005.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

45) **Egtesad B**, Fung JJ, Demetris AJ, Murase N, Ness R, Bass DC, Gray EA, Shakil O, Flynn B, Marcos A, Starzl TE. Immunosuppression for Liver Transplantation in HCV-infected Patients: Mechanism-based Principles. *Liver Transpl* 11:1343-52, 2005.

46) Ragni MV, **Egtesad B**, Schlesinger KW, Dvorchik I, Fung JJ. Pretransplant Survival is Shorter in HIV-positive than HIV-negative Subjects with End-stage Liver Disease. *Liver Transpl* 11:1425-30, 2005.

47) Jain A, Vekatramanan R, **Egtesad B**, Gadomski M, Mohanka R, Marcos A, Fung JJ. Long-Term Outcome of Adding Mycophenolate Mofetil to Tacrolimus for Nephrotoxicity Following Liver Transplantation. *Transplantation* 80:859-864, 2005.

48) **Egtesad B**, Aucejo F, Fung JJ. Preservation solutions in liver transplantation.:what are the options? *Liver Transpl* 12:196-8, 2006.

49) **Egtesad B**, Miller CM. Extended follow-up of extended right lobe living donors: when is enough enough? *Liver Transpl* 12:199-200, 2006.

50) Habib S, Berk B, Chang CC, Demetris AJ, Fontes P, Dvorchik I, **Egtesad B**, Marcos A, Shakil AO. MELD and prediction of post-liver transplantation survival. *Liver Transpl* 12:440-7, 2006

51) Aucejo FN, Ortiz WA, Kelly D, Winans C, Vogt D, **Egtesad B**, Fung JJ, Miller CM. Expanding the donor pool: safe transplantation of a cadaveric liver allograft with a 10 cm cavernous hemangioma – a case report. *Liver Transpl* 12:687-9, 2006.

52) Aucejo FN, Winans C, Henderson JM, Vogt D, **Egtesad B**, Fung JJ, Miller CM. Isolated right hepatic vein obstruction after piggyback liver transplantation. *Liver Transpl* 12:808-12, 2006.

53) Demetris AJ, Kelly D, **Egtesad B**, Fontes P, Marsh WJ, Tom K, Tan HP, Shaw-Stiffel T, Boig L, Novelli P, Planinsic R, Fung JJ, Marcos A. Pathophysiologic observations and histopathologic recognition of the portal hyperperfusion or small-for-size syndrome. *Am J Surg Pathol* 30:986-93, 2006.

54) Aucejo FN, Miller C, Vogt D, **Egtesad B**, Nakagawa S, Stoller JK. Pulmonary hypertension after liver transplantation in patients with antecedent hepatopulmonary syndrome: a report of 2 cases and review of the literature. *Liver Transpl* 12:1278-82, 2006.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

55) Abraham SC, Kamath PS, **Eghtesad B**, Demetris AJ, Krasinskas AM. Liver transplantation in precirrhotic biliary tract disease: Portal hypertention is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. *Am J Surg Pathol* 30:1454-1461, 2006.

56) DeVera ME, Dvorchik I, Tom K, **Eghtesad B**, Thai N, Shakil O, Demetris AJ, Jain A, Fung JJ, Ragni MV. Survival of liver transplant patients coinfectd with HIV and HCV is adversely impacted by recurrent hepatitis C. *Am J Transplant* 6:2983-2993, 2006.

57) Guggenheimer J, **Eghtesad B**, Close JM, Shay C, Fung JJ. Dental health status of liver transplant candidates. *Liver Transpl* 13:280-286, 2007

58) Fung J, **Eghtesad B**, Patel-Tom K. Using livers from donation after cardiac death donors – A proposal to protect the true Achillis heel. *Liver Transpl.* 13:1633-1636, 2007

59) Huelsman S, **Eghtesad B**, Modlin C. Bioethics in solid organ transplantation. *Surg Technol.* 39:348-356, 2007

60) Cywinski J, Mascha E, Miller C, **Eghtesad B**, Nakagawa S, Vincent J, Pesa N, Na J, Fung JJ, Parker BM. Association between donor-recipient serum sodium differences and orthotopic liver transplant graft function. *Liver Transpl* 14:59-65,2008

61)Aucejo F, Hashimoto K, Quintini C, Kelly D, Vogt D, Winans C, **Eghtesad B**, Baker M, Fung J, Miller C. Triple-phase computed tomography and intraoperative flow measurements improve the management of portosystemic shunts during liver transplantation. *Liver Transpl* 14:96-99, 2008

62) Aucejo F, Ibrahim Z, Hashimoto K, Quintini C, Kelly D, Vogt D, **Eghtesad B**, Fung J, Miller C, Tuthill R. Cruveilhier-Baumgarten disease in a patient with Turner syndrome: Case report of a rare indication for liver transplantation. *Liver Transpl* 14:299-302, 2008

63) Quintini C, Hirose K, Hashimoto K, Diago T, Aucejo F, **Eghtesad B**, Vogt D, Pierce G, Baker M, Kelly D, Miller C. “Splenic artery steal syndrome” is a misnomer: The cause is portal hypertension, not arterial siphon. *Liver Transpl.* 14:374-379, 2008

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

- 64) Quintini C, Miller CM, Hashimoto K, Philop D, Uso TD, Aucejo F, Kelly D, Winans C, **Egtesad B**, Vogt D, Fung J. Side-to-side cavocavostomy with an endovascular stapler: Rescue technique for severe hepatic vein and/or inferior vena cava outflow obstruction after liver transplantation using piggyback technique. *Liver Transpl.* 15:49-53, 2009
- 65) Aucejo F, Kim R, Zein N, Quintini C, Uso TD, Lopez R, **Egtesad B**, Fung J, Miller C, Yerian L. Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan Criteria. *Liver Transpl.* 15:169-76, 2009
- 66) Stotler CJ, **Egtesad B**, His E, Silver B. Rapid resolution of GVHD after orthotopic liver transplantation in a patient treated with alefacept. *Blood* 21:5365-6, 2009
- 67) Guggenheimer J, Close J, **Egtesad B**. Sialadenosis in patients with advanced liver disease. *Head Neck Pathol.* 3: 100-105, 2009
- 68) Siemionow M, Papay F, Alam D, Bernard S, Djohan R, Gordon C, Hendrickson M, Lohman R, **Egtesad B**, Coffman K, Kodish E, Paradis C, Avery R, Fung J. Near-total human face transplantation for a severely disfigured patient in the USA. *Lancet*, 374: 203-209, July 18 2009
- 69) Askar M, Avery R, Corey R, Lopez R, Thomas D, Pidwel D, **Egtesad B**, Miller C, Fung J, Zein N. Lack of KIR2DS2 and KIR2DL2 is associated with poor responses to therapy of recurrent HCV in liver transplant recipients. *Liver Transpl* 15:1557-1563, 2009
- 70) Pagadala M, Dasarathy S, **Egtesad B**, McCullough A. Post Transplant Metabolic Syndrome: An epidemic waiting to happen. *Liver Transpl* 15:1662-1670, 2009
- 71) Gordon C, Siemionow M, Alam D, Bernard S, **Egtesad B**, Fung J, Zins J, Papay F. The Cleveland Clinic FACES score: A preliminary assessment tool for identifying the optimal face transplant candidate. *J Craniofac Surg* 20:1969-74, 2009
- 72) Alkhouri N, Carter-Kent C, Mayacy S, Hupertz V, **Egtesad B**, Quintini C, Fung J, Radhakrishnan K. Reversal of protein-losing enteropathy after liver transplantation in a child with idiopathic familial neonatal hepatitis.. *Liver Transpl* 15:1894-1896, 2009
- 73) Siemionow M, Papay F, Djohan R, Bernard S, Gordon CR, Alam D, Hendrickson M, Lohman R, **Egtesad B**, Fung J. First US near-total human face transplantation – a paradigm shift for massive complex injuries. *Plast Reconstr Surg* 125:111-22, 2010

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

74) Schilling A, Corey R, Leonard M, **Eghtesad B**. Acetaminophen: old drug, new warnings. *Cleve Clin J Med* 77:19-27, 2010

75) Hashimoto K, Miller C, Hirose K, Diago T, Aucejo F, Quintini C, **Eghtesad B**, Corey R, Yerian L, Lopez R, Zein N, Fung J. Measurement of CD4+ T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. *Clin Transpl* 24:701-708, 2010

76) Hashimoto K, Aucejo F, Quintini C, El-Gazzaz G, Hodgkinson P, Fujiki M, Diago T, Kelly D, Winans C, **Eghtesad B**, Fung J, Miller C. Liver Transplantation at Cleveland Clinic. *Clin Transpl* 24:195-206

77) Hashimoto K, Miller CM, Quintini C, Aucejo FD, Hirose K, Uso TD, Trenti L, Kelly D, Winans CG, Vogt D, **Eghtesad B**, Fung J. Is impaired hepatic arterial buffer response a risk factor for biliary anastomotic stricture in liver transplant recipients? *Surgery* 148:582-588, 2010

78) Hanouneh A, Zein N, Lopez R, Yerian L, Fung J, **Eghtesad B**. IL-2 receptor antagonist (Basiliximab) is associated with rapid fibrosis progression in patients with recurrent hepatitis C after liver transplantation using serial biopsy specimens. *Internat J Organ Transpl Med* 1:7-15, 2010

79) Guggenheimer J, Close JM, **Eghtesad B**, Shay C. Characteristics of oral abnormalities in liver transplant candidates. *Internat J Organ Transpl Med* 1:107-113, 2010

80) Hashimoto K, **Eghtesad B**, Gunasekaran G, Fujiki M, Uso T, Quintini C, Aucejo F, Kelly D, Winans C, Vogt D, Parker B, Irefin S, Miller C, Fung J. Use of tissue plasminogen activator in liver transplantation from donation after cardiac death donors. *Am J Transpl* 10: 2665-2672, 2010

81) Alkhouri N, Alamiry MR, Hupertz V, **Eghtesad B**, Zein N. Spur cell anemia as a cause of unconjugated hyperbilirubinemia after liver transplantation and its resolution after re-transplantation. *Liver Transpl* 17: 349-350, 2011

82) Askar M, Schold JD, **Eghtesad B**, Fleckner SM, Kaplan B, Klingman L, Zein N, Fung J, Srinivas TR. Combined liver-kidney transplant: Allosensitization and recipient outcomes. *Transplantation* 91:1286-1292, 2011

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

- 83) Hanouneh A, Macaron C, Lopez R, Felstein AE, Yerian L, **Eghtesad B**, Zein N. Recurrence of disease following liver transplantation: Nonalcoholic steatohepatitis vs hepatitis C virus. *Internat J Organ Transpl Med* 2:53-61, 2011
- 84) Quintini C, D'Amico G, Brown C, Aucejo F, Hashimoto K, Kelly D, **Eghtesad B**, Sands M, Fung JJ, Miller CM. Splenic artery embolization for the treatment of refractory ascites after liver transplantation. *Liver Transpl.* 17:668-673, 2011
- 85) Esfeh J, **Eghtesad B**, Hodgkinson P, Diago T, Fujiki M, Hashimoto K, Quintini C, Aucejo F, Kelly D, Winans C, Vogt D, Miller C, Fung J. Duct-to-duct biliary reconstruction in patients with primary sclerosing cholangitis undergoing liver transplantation. *HPB* 13:651-655, 2011
- 86) Fung J, Bollinger J, Miller C, **Eghtesad B**. Future prospects in immunosuppression for liver transplantation. *Liver Transpl.* 17: Suppl 3, S54-59, 2011
- 87) Kelly D, Shiba H, Nakagawa S, Irefin S, **Eghtesad B**, Quintini C, Aucejo F, Hashimoto K, Fung J, Miller C. Hepatic blood flow plays an important role in ischemia-reperfusion injury. *Liver Transpl.* 12:1448-1456, 2011
- 88) Hicks CW, Hashimoto K, Uso TD, **Eghtesad B**, Miller C, Tzakis A, Quintini C. Use of 3-dimensional imaging reconstruction in the treatment of advanced intra-abdominal desmoids tumors. *Surgery* 151:625-627, 2012
- 89) Albeldawi M, Aggarwal A, Madhwal S, Cywinski J, Lopez R, **Eghtesad B**, Zein N. Cumulative risk of cardiovascular events after orthotopic liver transplantation. *Liver Transpl* 18:370-375, 2012
- 90) Kelly DM, Bennet R, Brown N, McCoy J, Boener D, Yu C, **Eghtesad B**, Barsoum W, Fung J, Kattan MW. Predicting the discharge status after liver transplantation at a single center: A new approach for a new era. *Liver Transpl* 18:796-802, 2012
- 91) Sourianayanane A, El-Gazzaz G, Sanabria JR, Menon KV, Quintini C, Hashimoto K, Kelly D, **Eghtesad B**, Miller C, Fung J, Aucejo F. Loco-regional therapy in patients with Milan Criteria-compliant Hepatocellular carcinoma and short waitlist time to transplant: An outcome analysis. *HPB* 14:325-332, 2012
- 92) Qiu J, Tsein C, Thapalya S, Narayanan A, Wehl CC, Ching JK, **Eghtesad B**, Singh K, Fu X, Dubyak GR, McDonal C, Almasan A, Hazen SL, Naga Prasad SV, Dasarathy S.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

Hyperammonemia mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. *Am J Physiol Endocrinol Metabol* 303(8): E983-93, Oct 15, 2012.

93) El-Gazzaz G, Sourianayanane A, Menon KV, Sanabria JR, Hashimoto K, Quintini C, Kelly D, **Egtesad B**, Miller C, Fung J, Aucejo F. Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies. *Hepatobiliary Pancreat Dis Int*. 12:34-41, 2013

94) Hanounch IA, Confer BD, Zein NN, Alkhouri N, **Egtesad B**. Recurrent upper gastrointestinal bleeding masquerading as gastric variceal bleeding on endoscopy after liver transplantation. *Liver Transpl*. 19:926-8, 2013

95) Taefi A, Abrishami A, Nasser-Moghaddam S, **Egtesad B**, Sherman M. Surgical resection versus transplant for patients with hepatocellular carcinoma. *Cochrane Database Syst Rev* June 29;6:CD006935, 2013

97) Zein NN, Hanounch IA, Bishop PD, Samaan M, **Egtesad B**, Quintini C, Miller C, Yerian L, Klatt R. Three-dimensional print of a liver for preoperative planning in living donor liver transplantation. *Liver Transpl* 19:1304-10, 2013

98) Watson MJ, Kundu M, Coppa C, Djohan R, Hashimoto K, **Egtesad B**, Fujiki M, Diago Uso T, Gandhi N, Nasser A, Abu-Elmagd K, Quintini C. Role of tissue expanders in patients with loss of abdominal domain awaiting intestinal transplantation. *Transpl Int* 26:1184-90, 2013

99) Qiu J, Thapaliya S, Runkana A, Yang Y, Mohan ML, Narayanan A, **Egtesad B**, Mozdziak PE, McDonald C, Stark GR, Welle S, Naga Prasad SV, Dasarathy S. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF- κ B-mediated mechanism. *Proc Natl Acad Sci USA* 110:18162-7, 2013

100) Waghray A, Nassar A, Hashimoto K, **Egtesad B**, Aucejo F, Krishnamurthi V, Uso TD, Srinivas T, Steiger E, Abu-Elmagd K, Quintini C. Combined intestine and kidney transplantation in a patient with encapsulating peritoneal sclerosis: Case report. *Am J Transplant* 13:3274-7, 2013

101) Alkhouri N, Singh G, Carey WD, Fung JJ, Zein NN, **Egtesad B**, Taefi A. The successful use of Telaprevir to treat hepatitis C recurrence after liver transplantation in an HIV co-infected patient. *Transplantation* 97:15-5, 2014

10/17/2022

Bijan Egtesad, M.D.
Curriculum Vitae

102) Tsien C, Garber A, Narayanan A, Shah SN, Barnes D, **Egtesad B**, Fung J, McCullough AJ, Dasarathy S. Post-liver transplantation sarcopenia in cirrhosis: A prospective evaluation. *J Gastroenterol Hepatol* 29:1250-1257, 2014

103) Jafarian A, Nassiri-Toosi M, Najafi A, Salimi J, Moini M, Azmoudeh-Ardalan F, Ahmadinejad Z, Davoudi S, Sattarzadeh R, Seifi S, Shariat Moharari R, Nejatiasafa AA, Tavakoli H, Rokni Yazdi H, Saberi H, Aminian A, Kazemeini AR, Fakhari N, Makarem J, Emami Meybodi SA, Ayoubi Yazdi N, Sohrabpour AA, Kasraianfard A, Mohagheghi MA, **Egtesad B**, Rabbani A. Establishing a liver transplantation program at Tehran University of Medical Sciences, Iran: A report of ten years of experience. *Arch Iran Med* 17:81-83, 2014

104) Levy G, Villamil FG, Nevens F, Metselaar HJ, Clavien PA, Klintmalm G, Jones R, Migliaccio M, Prestele H, Orsenigo R, REFINE Study Group. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. *Am J Transplant*, 14:635-646, 2014

105) Nassar A, Hashimoto K, Shay-Downer C, Bollinger J, Uso TD, Fujiki M, Askar M, Steiger E, **Egtesad B**, Abu-Elmagd K, Quintini C. Sequential split liver followed by isolated intestinal transplant: the “liver-first” approach: report of a case. *Transplantation* 97:17-19, 2014

106) Esfeh JM, Hanouneh IA, Koval CE, Kovacs C, Dalal DS, Ansari-Gilani K, Confer BD, **Egtesad B**, Zein NN, Menon KV. Impact of pretransplant rifaximin therapy on early post-liver transplant infections. *Liver Transp* 20:544-551, 2014

107) Dugum M, Askar M, Pai RK, Yerian L, Bennett A, McMahon J, Xie H, **Egtesad B**, Hanouneh I, Liu X. Re-examination of sinusoidal deposition of complement 4d in liver allografts: experience from a single institution. *Int J Clin Exp Pathol* 7:784-791, 2014

108) **Egtesad B**, Aucejo F. Liver transplantation for malignancies. *J Gastrointest Cancer* 45:353-362, 2014

109) Nassar A, Liu Q, Farias K, D’Amico G, Buccini L, Urcuyo D, Kelly D, Hashimoto K, **Egtesad B**, Uso TD, Miller C, Quintini C. Role of vasodilation during normothermic machine perfusion of DCD porcine livers. *Int J Artif Organs* 37:165-172, 2014

110) Nassar A, Liu Q, Farias K, D’Amico G, Tom C, Grady P, Bennett A, Diago Uso T, **Egtesad B**, Kelly D, Fung J, Abu-Elmagd K, Miller C, Quintini C. Ex vivo normothermic machine perfusion is safe, simple, and reliable: Results from a large animal model. *Surg Innov* 2014

10/17/2022

Bijan Egtesad, M.D.
Curriculum Vitae

- 111) Hashimoto K, Quintini C, Aucejo F, Fujiki M, Diago T, **Egtesad B**, Kelly D, Fung J, Abu-Elmagd K, Miller C. Split liver transplantation using hemiliver graft in the MELD era: A single center experience in the United States. *Am J Transplant* 14:2072-2080, 2014
- 112) Zhang W, Kim R, Quintini C, Hashimoto K, Fujiki M, Diago T, **Egtesad B**, Miller C, Fung J, Tan A, Menon KV, Aucejo F. Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation. *Liver Transpl* 21:101-111, 2015
- 113) Baskar S, Georg PL, **Egtesad B**, Radhakrishnan K, Hupertz V, Aziz PF, Alkhouri N. Cardiovascular risk factors and cardiac disorders in long-term survivors of pediatric liver transplantation. *Pediatr Transplant* 19:48-55, 2015
- 114) Quintini C, Spaggiari M, Hashimoto K, Aucejo F, Diago T, Fujiki M, Winans C, D'Amico G, Trenti L, Kelly D, **Egtesad B**, Miller C. The safety and effectiveness of reno-portal bypass in patients with complete portal vein thrombosis: Our analysis on 10 patients. *Liver Transpl*.21:345-352, 2015
- 115) Ascha M, Ascha M, Zein NN, Alkhouri N, **Egtesad B**, Abu-Elmagd K, Diago T, Hanouneh IA. Treatment of recurrent Hepatitis C genotype 4 post liver transplantation with Sofosbuvir plus Simeprevir. *Int J Organ Transplant Med* 6:86-90, 2015
- 116) Dugum M, Hanouneh I, Lopez R, Aucejo F, **Egtesad B**, Zein N. Hepatocellular carcinoma in the setting of chronic hepatitis B virus infection: Tumor recurrence and survival after liver transplantation. *Transplant Proc* 47: 1939-1944, 2015
- 117) Firl DJ, Hashimoto K, O'Rourke C, Diago-Usó T, Fujiki M, Aucejo F, Quintini C, Kelly D, Miller C, Fung JJ, **Egtesad B**. Impact of donor age in liver transplantation from donation after circulatory death donors: A decade of experience at Cleveland Clinic. *Liver Transpl* 21:1494-1503, 2015
- 1118) Woodside KJ, Goldfarb DA, Rabets JC, Sanchez EQ, Lebovitz DJ, Schulak JA, Fung JJ, **Egtesad B**. Enhancing kidney function with thrombolytic therapy following donation after cardiac death: A multicenter quasi-blinded prospective randomized trial. *Clin Transplant* 29:1173-1180, 2015
- 119) Alkhouri n, Hanouneh I, Zein NN, Lopez R, Kelly D, **Egtesad B**, Fung JJ. Liver transplantation for nonalcoholic steatohepatitis (NASH) in young patients. *Transpl Int* 2016;29:418-424

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

120) Koval CE, Khanna A, Pallotta A, Spinner M, Taege AJ, **Eghtesad B**, Fujiki M, Hashimoto K, Rodriquez B, Morse G, Bennett A, Abu-Elmagd K. En bloc multivisceral and kidney transplantation in an HIV patient: First case report. *Am J Transplant* 2016;16:358-363

121) Shiba H, Hashimoto K, Kelly D, Fujiki M, Quintini C, Aucejo F, Uso TD, Yerian L, Yanaga K, Matsushima M, **Eghtesad B**, Fung J, Miller C. Risk stratification of allograft failure secondary to hepatitis C recurrence after liver transplantation. *Hepato Res*. 2016;46:1099-1106

122) Issa D, **Eghtesad B**, Zein NN, Yerian L, Cruise M, Alkhouri N, Adams R, Hanouneh IA. Sofosbuvir and Semipravir for the treatment of recurrent hepatitis C with fibrosing cholestatic hepatitis after liver transplantation. *Int J Organ Transplant* 2016;7:38-45

123) Zhu X, Shiba H, Zhu Y, Quintini C, **Eghtesad B**, Miller C, Fung JJ, Kelly DM. Adenosine increases hepatic artery flow in liver transplant recipients: A pilot study. *Transplant Proc* 2016;48:116-119

124) Dugum M, Hanouneh I, McIntyre T, Pai R, Aucejo F, **Eghtesad B**, Zein N. Sonic hedgehog signaling in hepatocellular carcinoma: A pilot study. *Mol Clin Oncol* 2016;4:369-374

125) Petit SE, Bollinger J, **Eghtesad B**. Antithymocyte globulin induction therapy in liver transplant : Old drug, new uses. *Ann Pharmacother* 2016;50:592-598

126) Elshamy M, Aucejo F, Menon KV, **Eghtesad B**. Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria. *World J Hepato* 2016;28:874-880

127) Elfeki M, Abou Mrad R, Modaresi Esfeh J, Zein N, **Eghtesad B**, Zervos X, Hanouneh I, O'Shea R, Carey W, Alkhouri N. Sofosbuvir/Ledipasvir without Ribavirin achieved high sustained virologic response for hepatitis C recurrence after liver transplantation: two-center experience. *Transplantation* 2016

128) Hashimoto K, Fujiki M, Quintini C, Aucejo F, Uso TD, Kelly DM, **Eghtesad B**, Fung JJ, Miller CM. Split liver transplantation in adults. *World J Gastroenterol* 2016;22:7500-7506

129) Hajifathalian K, Humberson A, Hanouneh MA, Barnes DS, Arora Z, Zein NN, **Eghtesad B**, Kelly D, Hanouneh AI. Ohio solid organ transplantation consortium criteria for liver transplantation in patients with alcoholic liver disease. *World J Hepatol* 2016;8:1149-1154

10/17/2022

Bijan Egtesad, M.D.
Curriculum Vitae

130) Firl D,J, Hashimoto K, O'Rourke C, Diago-Usó T, Fujiki M, Aucejo FN, Quintini C, Kelly DM, Miller CM, Fung JJ, **Egtesad B**. Role of donor hemodynamic trajectory in determining graft survival in liver transplantation from donation after circulatory death donors. *Liver Transpl* 2016;22:1469-1481

131) Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, Mohraz M, Marandi M, Fattahi MR, Poustchi H, Nikbin M, Nabavi M, Adibi P, Ziaee M, Behnava B, Rezaee-zavareh MS, Colombo M, Massoumi H, Bizri AR, **Egtesad B**, Amiri M, Namvar A, Hesamizadeh K, Malekzadeh R. Recommendations for the clinical management of hepatitis c in Iran: A consensus-based national guidelines. *Hepat Mon* 2016; August 13; 16(8)

132) Lankarani KB, Malek-Hosseini SA, Nikeghbalian S, Dehghani M, Pourhashemi M, Kazemi K, Janghorban P, Akbari M, Ghahramani S, **Egtesad B**, Moini M, Rahmi Jaber A, Shamsaifar A, Gholami S, Rahmanian F, Geramizadeh B. Fourteen Years of Experience of Liver Transplantation for Wilson's Disease; a Report on 107 Cases from Shiraz, Iran. *PLoS One*. 2016 Dec 8;11(12)

133) Ragni MV, Humar A, Stock PG, Blumberg EA, **Egtesad B**, Fung JJ, Stosor V, Nissen N, Wong MT, Sherman KE, Stablein DM, Barin B. Hemophilia Liver Transplantation Observational Study. *Liver Transpl*. 2017 Jun;23(6):762-768

134) Collyer E, Hupertz V, **Egtesad B**, Radhakrishnan K. Liver Transplantation as a Treatment for Severe Refractory Vitamin E Deficiency Related to Progressive Familial Intrahepatic Cholestasis Type 2 in a Pediatric Patient. *ACG Case Rep J*. 2016 Dec 21;3(4)

135) Flyckt R, Kotlyar A, Arian S, **Egtesad B**, Falcone T, Tzakis A. Deceased donor uterine transplantation. *Fertil Steril*. 2017 Mar;107(3)

136) Sasaki K, Firl DJ, Hashimoto K, Fujiki M, Diago-Usó T, Quintini C, Egtesad B, Fung JJ, Aucejo FN, Miller CM. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis. *Lancet Gastroenterol Hepatol*. 2017 Aug;2(8):595-603.

137) Fujiki M, Hashimoto K, Palaios E, Quintini C, Aucejo FN, Usó T, **Egtesad B**, Miller C. Probability, management, and long-term outcomes of biliary complications after hepatic artery thrombosis in liver transplant recipients. *Surgery*. 2017 Nov;162(5):1101-1111.

138) Kabbany MN, Conjeevaram Selvakumar PK, Guirguis J, Rivas J, Akkas Z, Lopez R, Hanouneh I, **Egtesad B**, Alkhouri N. Accuracy of Noninvasive Fibrosis Scores in Predicting

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

the Presence of Fibrosis in Patients after Liver Transplantation. *Exp Clin Transplant*. 2017 Sep 26.

139) Quintini C, Diago Uso T, Fujiki M, **Eghtesad B**, Iuppa G, Aucejo F, Miller C, Hashimoto K. Liver ‘lobe neutrality’ in the era of donor safety. Could “safe” be safer? *Transpl Int* 2018;31(6):588-589

140) Perez AJ, Haskins IN, Prabhu AS, Krapata DM, Tu C, Rosenblatt S, Hashimoto K, Diago T, **Eghtesad B**, Rosen M. Current umbilical hernia repair at the time of liver transplantation: A six-year experience from a single institution. *Int J Organ Transplant Med* 2018;9:20-25

141) Kwon JH, Hanouneh IA, Allende D, Yerian L, Diago T, **Eghtesad B**, Zein N. *Transplant Proc* 2018;50(5):1451-1456

142) Malek-Hosseini SA, Jafarian A, Nikeghbalian S, Poustchi H, Lankarani KB, Nasiri Toosi M, Salahi H, Dehghani M, Eshraghian A, Sharafkhah M, Eghtesad S, Motamed-Gorji N, Kazemi K, Salimi J, Moini M, Shamsaeifar A, Moini M, Dehghani M, B Khosravi M, Najafi A, Sattari H, Geramizadeh B, Shafiee M, Toutouni MN, Sanei B, Nejatollahi SM, Taghavi A, Bahador A, Aliakbarian M, **Eghtesad B**, Malekzadeh R. Liver transplantation status in Iran: a multi-center report on the main transplant indicators and survival rates. *Arch Iran Med* 2018;21:275-282

143) Petro CC, Haskins IN, Perez AJ, Tastaldi L, Strong AT, Llie RN, Tu C, Krapata DM, Prabhu AS, **Eghtesad B**, Rosen MJ. Hernia repair in patients with chronic liver disease – a 15-year single center experience. *Am J Surg* 2019;217:59-65

144) D’Amico G, Hassan A, Diago Uso T, Hashimoto K, Aucejo FN, Fujiki M, **Eghtesad B**, Sasaki K, Lindenmeyer CC, Miller CM, Quintini C. Renoportal anastomosis in liver transplantation and its impact on patient outcomes: A systematic literature review. *Transpl. Int* 2019;32:117-127

145) Matsushima H, Fujiki M, Sasaki K, Rotroff DM, Sands M, Bayona Molano MDP, Aucejo F, Diago Uso T, **Eghtesad B**, Miller CM, Quintini C, Hashimoto K. Predictive value of hepatic venous pressure gradient for graft hemodynamics in living donor liver transplantation. *Liver Transpl* 2019;25:1034-1042

146) Firl DJ, Sasaki K, McVay J, Hupertz V, Radhakrishnan K, Fujiki M, **Eghtesad B**, Miller CM, Quintini C, Hashimoto K. Improved survival following living donor liver transplantation for pediatric acute liver failure: Analysis of 20 years of US national registry data. *Liver Transpl* 2019;25:1241-1250

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

147) McVey JC, Sasaki K, Firl DJ, Fujiki M, Diago Uso T, Quintini C, **Eghtesad B**, Miller CM, Hashimoto K, Aucejo F. Prognostication of inflammatory cells in liver transplantation: Is the waitlist neutrophil-to-lymphocyte ratio really predictive of tumor biology? Clin Transplant 2019;33:

148) Sasaki K, MacVey JC, Firl DJ, Andreatos N, Moro A, Coromina Hernandez L, Matsushima H, Diego T, Fujiki M, Aucejo F, Quintini C, Kwon CD, **Eghtesad B**, Miller CM, Hashimoto K. Sufficient hepatic artery flow compensates for poor portal vein flow after liver transplantation in patients with portal vein thrombosis. Clin Transplant 2019;33:

149) Liu Q, Hassan A, Pezzati D, Soliman B, Lomaglio L, Grady P, Del Angel Diaz L, Simioni A, Kaikhor S, Etterling J, D'Amico G, Iuppa G, Diago Uso T, Hashimoto K, Aucejo F, Fujiki M, **Eghtesad B**, Sasaki K, Kwon CD, Cywinski J, Irefin S, Bennett A, Baldwin W, Miller CM, Quintini C. Ex-Site Liver machine perfusion: the impact of fresh frozen plasma. Liver Transpl 2020;26:215-226

150) Matsushima H, Sasaki K, Fujiki M, Diago Uso TD, Aucejo F, Kwon CHD, **Eghtesad B**, Miller CM, Quintini C, Hashimoto K. Too much, too little, or just right? The importance of allograft portal flow in deceased donor liver transplantation. Transplantation 2020;104:770-778

151) Flyckt R, Falcone T, Quintini C, Perni U, **Eghtesad B**, Richards EG, Farrel RM, Hashimoto K, Miller C, Ricci S, Ferrando CA, D'Amico G, Maikhor S, Priebe D, Chiessa-Vettero A, Heerema-McKenney A, Mawhorter S, Feldman MK, Tzakis A. First birth from deceased donor uterus in the United states: from severe allograft rejection to successful cesarean delivery. Am J Obstet Gynecol 2020;7:

152) Wood A, **Eghtesad B**, Lindenmeyer CC. Graft-versus-host disease after liver transplantation. Clin Liver Dis 2020;15:81-84

153) Modi AR, Koval CE, Taege AJ, Modaresi Esfeh J, **Eghtesad B**, Menon KVN, Quintini C, Miller C. Corona virus disease 2019 in an orthotopic liver transplant recipient living with human immunodeficiency virus. Transpl Infect Dis 2020

154) Matsushima H, Acevedo-Moreno LA, Sasaki K, Fujiki M, Kwon CHD, Uso TD, D'Amico G, Aucejo F, **Eghtesad B**, Miller C, Quintini C, Hashimoto K. Does graft hemodynamics affect risk of hepatocellular carcinoma recurrence after liver transplantation? Clin Transpl 2020 (Aug ; 34....

10/17/2022

Bijan Egtesad, M.D.
Curriculum Vitae

155) Wood A, **Egtesad B**, Menon KN, Fares M, Zhen-Yu Tong M, Sharma V, Lopez R, Esfeh JM. Safety and outcomes of combined liver transplantation and cardiac surgery in cirrhosis. *Ann Thorac Surg* 2020;111: 62-68

156) Matsushima H, Fujiki M, Sasaki K, Cywinski JB, D'Amico G, Uso TD, Aucejo F, Kwon CHD, **Egtesad B**, Miller C, Quintini C, Hashimoto K. Can pre-transplant TIPS be harmful in liver transplantation? A propensity score matching analysis. *Surgery* 2020; 168: 33-39

157) Sasaki K, Nair A, Firl DJ, McVey JC, El-Gazzaz G, Uso TD, Fujiki M, Aucejo F, Quintini C, Kwon CHD, Hashimoto K, Miller C, **Egtesad B**. Should we be utilizing more liver grafts from pediatric donation after circulatory death donors? A national analysis of SRTR from 2002-2017. *Transplantation*. 2021;105:1998-2006

158) D'Amico G, Quintini C, **Egtesad B**, Hashimoto K, Ricci S, Flyckt R, DelPrete L, Miller C, Falcone T, Tzakis A. Uterus recovery from deceased donor: Simple technique securing safety of vital organs and uterus graft. *J Am Coll Surg*. 2021;232:

159) Doi J, Fujiki M, **Egtesad B**, Quintini C, Menon KN, Hashimoto K, Sasaki K. Nutritional support in liver transplantation and postoperative recovery: The effect of vitamin D level and vitamin D supplementation in liver transplantation. *Nutrient* 2020; 12:3677

160) Nair A, Coromina Hernandez L, Shah S, Zervos X, Zimmerman M, Sasaki K, Diago T, Hashimoto K, Fujiki M, Aucejo F, Bollinger J, Kaiser TL, Miller CM, Quintini C, Fung JJ, **Egtesad B**. Induction therapy with antithymocyte globulin and delayed calcineurin inhibitor initiation for renal protection in liver transplantation: A multicenter, randomized, controlled phase II-B trial. *Transplantation* 2021

161) Coombs DM, Kwiecien GJ, Koval C, **Egtesad B**, Papay FA, Siemionow M, Gastman BR. Successful treatment of life-threatening COVID-19 infection in a face transplant recipient. *Ann Plast Surg*. 2021;87:105-106

162) Nair A, Sasaki K, Diago T, D'Amico G, **Egtesad B**, Aucejo F, Kwon CHD, Fujiki M, Miller C, Hashimoto K, Quintini C. The prognostic utility of intraoperative allograft vascular inflow measurement in donation after circulatory death liver transplantation. *Liver Transplant*. 2021;

163) Sanghi V, Romero-Marrero C, Flocco G, Graham RP, Abduljawad B, Niyazi F, Asfari MM, Hashimoto K, **Egtesad B**, Menon KVN, Aucejo F, Lopez R, Yerian LM, Allende DS.

10/17/2022

Bijan Egtesad, M.D.
Curriculum Vitae

The spectrum of histopathological findings after SVR to DDA for treatment of HCV infection in liver transplant recipients *Virchows Arch* 2022;480:335-347

164) D'Amico G, Matsushima H, Del Prete L, Diago T, Armanyous SR, Hashimoto K, **Egtesad B**, Fujiki M, Aucejo F, Sasaki K, Kwon CHD, Simioni A, Miller C, Quintini C. Long-term outcomes and complications of reno-portal anastomosis in liver transplantation: Result from a propensity score-based outcome analysis. *Transpl Int* 2021;34:1938-1947

165) Sasaki K, Nair A, Firl DJ, McVey JC, Moro A, Diago T, Fujiki M, Auceji F, Quintini C, Kwon CD, **Egtesad B**, Miller C, Hashimoto K. Conditional probability of graft survival in liver transplantation using donation after circulatory death graft – Aretrospective study. *Transpl Int* 2021;34:1433-1443

166) Kleb C, Jain V, Sheth C, Wolski K, Kapadia S, Grimm R, Desai M, Krishnaswamy A, Kassis N, Sheng C, Zheng H, Cywinski J, Menon KVN, **Egtesad B**, Diago Us T, Quintini C, Schoenhagen P, Harb S, Sharma V, Fares M. Comparison of coronary artery calcium scoring with dobutamine stress ECHO for detection of coronary artery disease before liver transplantation. *Ann Transpl* 2021;26:e934163

167) Liu Q, Prete LD, Hassan A, Pezzati D, Bilancini M, D'Amico G, Diago Uso T, Hashimoto K, Aucejo F, Fujiki M, Sasaki K, Kwon CHD, **Egtesad B**, Miller Charles, Quintini C. Two pumps or one pump? A comparison of human liver normothermic machine perfusion devices for transplantation. *Artificial Organs* 2021;00:1-8

168) Sharma V, Kleb C, Sheth C, Verma BR, Jain V, Sharma R, Parikh P, Cywinski J, Menon KVN, Esfeh JM, **Egtesad B**, Quintini C, Uso TD, Tong MZY, Nair R, Bhargava A, Fares M. Cardiac considerations in liver transplantation. *Cleve Clin J Med.* 2022;89:46-55

169) Quintini C, Del Prete L, Simioni A, Del Angel L, Diago Uso T, D'Amico G, Hashimoto K, Aucejo F, Fujiki M, **Egtesad B**, Sasaki K, Kwon CHD, Cywinski J, Bennet A, Bilancini M, Miller C, Liu Q. Transplantation of declined livers after normothermic perfusion. *Surgery* 2022;171:747-756

170) D'amico G, Del Prete L, **Egtesad B**, Hashimoto K, Miller C, Tzakis A, Quintini C, Falcone T. Immunosuppression in uterus transplantation: From transplant to delivery. *Expert Opin Pharmacother.* 2022;19:1-7

171) Laique SN, **Egtesad B**, Lindenmeyer CC. Surgical considerations regarding transplantation for the patient with acute-on-chronic liver failure. *Clin Liver Dis.* 2022;18:93-96

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

172) Nair A, Coromina Hernandez L, Shah S, Zervos X, Zimmerman M, Sasaki K, Diago T, Hashimoto K, Fujiki M, Aucejo F, Bollinger J, Kaiser TL, Miller CM, Quintini C, Fung JJ, **Egtesad B**. Induction therapy with antithymocyte globulin and delayed calcineurin inhibitor initiation for renal protection in liver transplantation: A multi-center, randomized, controlled phase IIB trial. *Transplantation* 2022;106:997-1003.

173) Knackstedt R, Bergfeld W, Sardina LA, **Egtesad B**, Siemionow M, Djohan R. Plasma cells and acute rejection of near-total face transplant: an incidental finding or an evolving plasma-cell-mediated rejection? *Br J Dermatol.* 2022;Aug Epub ahead of print, Aug 17

174) Kalisvaart M, deJonge J, Abt P, Orloff S, Muiesan P, Florman S, Spiro M, Raptis DA, **Egtesad B**. The role of t-tubes and abdominal drains on short-term outcomes in liver transplantation – A systematic review of the literature and expert panel recommendations. *Clin Transplant* 2022 Epub ahead of print, May 21.

175) Fujiki M, Hashimoto K, Quintini C, Aucejo F, Kwon CHD, Matsushima H, Sasaki K, Campos L, **Egtesad B**, Diago T, Iuppa G, D'Amico G, Kumar S, Liu P, Miller C, Pinna A. Living donor liver transplantation with augmented venous outflow and splenectomy: A promised land for small left lobe grafts. *Ann Surg.* 2022; Epub ahead of print July 27

176) Knackstedt R, Siemionow M, Djohan R, Schwarz G, Bassiri Gharb B, Rampazzo A, Bernard S, Doumit G, Gurunian R, **Egtesad B**, Bergfeld W, Priebe D, Papay F, Gastman BR. Youngest composite full-face transplant : A model for vascularized composite allograft in younger population. *Ann Plast Surg* 2022;89:564-572

B. Publications: Books:

1) *Surgical Procedures on the Cirrhotic Patients.* **Egtesad B**, Fung JJ Editors, Springer International Publishing AG 2017

C. Publications (Review Chapters and Monographs):

1) Khanna A, Jain A, **Egtesad B**, Rakela J. Liver Transplantation for Metabolic Liver Diseases. *Surgical Clinics of North America*, 79: 153-162, 1999.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

2) Eason, J, **Eghtesad B**, Sanchez E, Tector A. Antithymocyte Globulin Induction in Liver Transplantation: Expanding the Paradigm in the MELD Era. Monograph published by Ochsner Clinic Foundation. 2004

D. Publications (Book Chapters):

1) Starzl TE, Murase N, Demetris AJ, Truco M, **Eghtesad B**, Fontes P, Abu-Elmagd K, Marcos , Fung JJ. Cell Migration, Chimerism, and Graft Acceptance, with Particular Reference to the Liver. Busuttil & Klintmalm (Editors), Liver Transplantation, 2nd Edition (2005), 1183-1198.

2) **Eghtesad B**, Fung JJ. Liver Transplantation. Zein & Lashner (Editors), The Year in Gastroenterology and Hepatology, Volume 2, 2007, 285-303

3) **Eghtesad B**, Winans C, Fung JJ. Living donor liver transplantation for acute liver failure. 30.12.4. Gruessner and Benedetti (Editors), Living Donor Organ Transplantation. (2008), 633-635.

4) **Eghtesad B**, Miller C, Fung J. Post-Liver Transplantation Management. W.D. Carey (Editor), Current Clinical Medicine. (2009), 601-607.

5) **Eghtesad B**, Kelly D, Fung J. Liver Transplantation in Children (Chapter 78). Robert Wyllie and Jeffrey S Hyams (Editors), Pediatric Gastrointestinal and Liver Disease, 4th ed. (2010), 853-865

6) **Eghtesad B**, Miller C, Fung J. Post-Liver Transplantation Management. W.D. Carey (Editor), Current Clinical Medicine. Current Clinical Medicine. 2011

7) **Eghtesad B**, Fung J. Immunosuppression in Composite Tissue Allotransplantation (Chapter 41). M. Siemionow (Editor), The Know How of Face transplantation. (2011), 427-437

8) **Eghtesad B**, Fung JJ. Liver Transplant Procedure (Chapter 46). E R Schiff, W C Maddrey, and M F Sorrell (Editors), Schiff's Diseases of the Liver (2012), 1137-1151

9) Fung J, Hashimoto K, **Eghtesad B**, Lebovitz D, Watson M. Deceased Donor Management (Chapter 20). A. Kirk Textbook of Organ Transplantation. Wiley-Blackwell (2014)

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

- 10) Starzl TE, Murase N, **Eghtesad B**, Fontes P, Abu-Elmagd K, Demetris AJ, Fung JJ. Cell Migration, Chimerism, and Graft Acceptance, with Particular Reference to the Liver. Busuttil & Klintmalm (Editors), Transplantation of the Liver, 3rd Edition (2015), 1227-1244.
- 11) Chinnakotla S, **Eghtesad B**, Klintmalm GBG. Graft-Versus-Host Disease. Busuttil & Klintmalm (Editors), Transplantation of the Liver, 3rd Edition (2015), 1257-1263.
- 12) **Eghtesad B**, Kelly D, Fung JJ. Liver Transplantation in Children. Wyllie, Hyams, and Kay (Editors), Pediatric Gastrointestinal and Liver Disease, 5th Edition (2015) 962-976.
- 13) **Eghtesad B**, Miller C. Recurrence of Metabolic Disorders after Liver Transplantation. P.J.Thuluvath (Editor), Disease recurrence after Liver Transplantation, (2015) 135-144.Springer
- 14) Hanounch I, **Eghtesad B**. Nonalcoholic Fatty Liver Disease Post-Liver Transplantation. P.J.Thuluvath (Editor), Disease recurrence after Liver Transplantation, (2015) 145-152. Springer
- 15) Hashimoto K, **Eghtesad B**. Split Liver Transplantation. C. Doria (Editor), Contemporary Liver Transplantation, Organ and Tissue Transplantation, 1-17. Springer International Publishing 2017
- 16) **Eghtesad B**, Hashimoto K, Fung JJ. Liver Transplant Procedure . E R Schiff, W C Maddrey, and M F Sorrell (Editors), Schiff's Diseases of the Liver 12th Edition, (2017), Chapter 45, Pp 1107-1126, Wiley Blackwell
- 17) **Eghtesad B**, Hashimoto K, Fung JJ. Liver Transplantation in Children. Wyllie, Hyams, and Kay (Editors), Pediatric Gastrointestinal and Liver Disease, 6th Edition (2020) Chapter 78, Pp 872-884, Elsevier
- 18) **Eghtesad B**, Fung J. Liver Surgery in Patients With Inflammatory Bowel Disease. Shen (Editor), Pouchitis and Ileal Pouch Disorders. (2019), Chapter 39, Pp 487-493, Elsevier
- 19) D'Amico G, Quintini C, **Eghtesad B**. Liver Transplantation. Connor Delaney (editor), Netter's Surgical Anatomy and Approaches. 2020, Chapter 18, Pp197-204
- 20) Diago-Usó T, **Eghtesad B**. Deceased Donor Organ Recovery. Connor Delaney (editor), Netter's Surgical Anatomy and Approaches. 2020, Chapter 24, Pp251-260

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

E. Abstracts (Published):

- 1) Bronsther O, Ersoz S, Tugcu M, **Eghtesad B**, Gurakar A, Van Thiel DH. The Incidence and Timing of Recurrent Hepatitis B Virus in Primary Orthotopic Liver Transplant Recipients Treated with FK-506. Poster presentation at the American Society of Transplant Physicians, Houston, Texas, May 17-19 , 1993. Abstract published in the Proceeding of A.S.T.P.
- 2) **Eghtesad B**, Scotti C, Irish W, Todo S, Samimi F, Aldrighetti L, Malek-Hosseini A, Rakela J, Starzl TE, Fung JJ. Liver Transplantation for Hepatitis B Surface Antigen Positive(HBsAg+) Chronic Liver Disease Under FK-506 (Tacrolimus). Poster presentation at the American Association for the Study of Liver Disease. Chicago, Illinois, November 11-15, 1994. (Abstract published in Hepatology 20: No. 4, Pt. 2, Abstract 135)
- 3) **Eghtesad B**, Nezakatgoo N, Geraci L.C, Reyes J, Jabbour N, Marsh W, Irish W, Ramos H, Rakela J, Starzl TE, Fung JJ. Liver Transplantation for Wilson Disease; Single Center Experience. Presented to the American Society of Transplant Physicians. Dallas, Texas, May 26-30, 1996. (Abstract published in the Proceedings of A.S.T.P.)
- 4) Issa S, Dodson SF, Araya V, Gayowski T, **Eghtesad B**, Rakela J, Fung JJ. Infectivity of Hepatic Allografts with Antibodies to Hepatitis B Virus. Abstract Presented and Published in the Proceedings of the American Society of Transplant Physicians (ASTP), May 10-14, 1997, Chicago, IL.
- 5) **Eghtesad B**, Harford AM, Gibel LJ, Ramos HC, Smith AY, Haq M, Demarest P, Malhotra D. Use of Tacrolimus as the Primary Immunosuppression After Renal Transplant in Native Americans and Hispanics. Abstract Published in the Proceedings of the International Congress on Immunosuppression. Dec.11-13, 1997, Orlando, FL.
- 6) Awan A, **Eghtesad B**, Arora S. Ischemic Injury to Bile Ducts During Cholecystectomy. Abstract published in the American Journal of Gastroenterology 92(9): Abstract no. 185, 1997
- 7) Mazariegos G V, **Eghtesad B**, Ashrafi M, Arzate J, Osorio G, Reyes J. Incidence, Management and Outcome of Serious Pancreatitis Following Pediatric Liver Transplantation. Abstract Published in the Proceedings of the American Society of Transplant Physicians (ASTP) 17th Annual Meeting, May 9-13, 1998, Chicago, IL.
- 8) Mazariegos GV, **Eghtesad B**, Ashrafi M, Arzate J, Osorio G, Reyes J. Incidence, Management and Outcome of Serious Pancreatitis Following Pediatric Liver Transplantation.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

Poster Presentation at the Third International Congress on Pediatric Transplantation. July 8-10, 1998, Boston, MA. Abstract published in *Pediatric Transplantation*, Volume 2, Supplement No. 1, Abstract No. 78, 1998.

9) **Eghtesad B**, Mazariegos GV, Geraci L, Cacciarelli T, Reyes J. Liver Transplantation in Pediatric Patients for Wilson Disease. Poster presentation at the Third International Congress on Pediatric Transplantation, July 8-10, 1998, Boston, MA. . Abstract published in *Pediatric Transplantation*, Volume 2, Supplement No. 1, Abstract No. 188, 1998.

10) Mazariegos G V, **Eghtesad B**, Ashrafi M, Arzate J, Osorio G, Reyes J. Incidence, Management and Outcome of Serious Pancreatitis Following Pediatric Liver Transplantation. Paper presented to the American Society of Transplant Physicians (ASTP) 17th Annual Meeting, May 9-13, 1998, Chicago, IL. Abstract published in: *Transplantation*, 65: No. 12, Abstract No. 344, June 1998.

11) Hays SW, VanderJact DJ, Glew RH, Johnston DE, **Eghtesad B**. CDNA Sequence of Cytosolic Beta-Glucosidase from Human Liver. *Hepatology* 28, 28: No. 4, Pt. 2, Abstract no. 1780, 1998.

12) Hays SW, Glew RH, Hecker W, Morris DM, Fry DE, **Eghtesad B**. Cytosolic Beta-Glucosidase as a Marker of Reperfusion Injury in Liver Transplantation. *Hepatology* 28, No. 4, Pt. 2, Abstract no. 2340, 1998.

13) **Eghtesad B**, Varghese E, Brand J, Hecker W, Narva A, Gibel L Malhotra D, Harford A. Increased Incidence of Post-transplant Diabetes in Pediatric Native American Kidney Transplant Recipients on Tacrolimus. *Acta Diabetologica*, 36:211, 2000.

14) Jain A, Kashyap R, **Eghtesad B**, Costa G, Fung JJ. Question of Steroid Withdrawal under Tacrolimus for Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) after Liver Transplantation and Long-term Survival. Poster presentation. International Liver transplantation Society Meeting July 11-13, 2001, ELTA Licage Berlin, Germany. *Liver transplantation* 7(6) c-57 Abstract 228, 2001.

15) Jain A, Kashyap R, **Eghtesad B**, Khan A, Obiad S, Fung JJ. Need for Ribavirin Dose Adjustment in Relation to Renal Function for Treatment of Recurrent HCV Infection in Post Liver Transplant Patients. Poster Presentation. International Liver transplantation Society meeting July

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

11-13, 2001, ELTA Licage Berlin, Germany. Liver transplantation 7(6) c-33 Abstract 130, 2001.

16) Cacciarelli, TV, Jain AK, **Egtesad B**, Planinsic Raymond, Kormos R, Fung JJ. Simultaneous Heart-Liver Transplantation: A Worthwhile Effort? Hepatology, 36, No. 4, Pt. 2, Abstract 123, 2002.

17) Jain AK, Nalesnik MA, Reyes, JD, Pokharna R, Mazariegos G, Cacciarelli TV, **Egtesad B**, Fung JJ. The Incidence of Post-Transplant Lymphoproliferative Disorder (PTLD) in Children and Adults under Tacrolimus : 2000 Cosecut6ive Liver Transplant Patients. Hepatology 36, No.4, Pt 2, Abstract 1998, 2002.

18) **Egtesad B**, Fontes P, Cacciarelli TV, Jain AK, Sindhi R, Geller D, Marsh W, Broznik B, Fung JJ. Comparison of Histidine-Tryptophan-Ketoglutarate (HTK) Solution Versus University of Wisconsin (UW) Solution for Organ Preservation in Liver Transplantation. Hepatology 36, No 4, Pt. 2, Abstract 2052, 2002.

19) **Egtesad B**, Daly I, Broznick BA, Geller DA, Cacciarelli TV, Fontes P, Bonham CA, Dodson SF, Jain AK, Marsh WJ, Fung JJ. Utilization of Livers from Non-heart-beating Donors – A Single Center Experience. Transplantation 74: 4, Abstract No. 1664, 2002.

20) Jain AK, Venkataramanan R, Shapiro R, Scantlebury V, **Egtesad B**, Potdar S, Ragni M, Fung J. Profound Interaction Between Tacrolimus , Sirolimus and Anti-HIV Drugs in Liver and Kidnet Transplant Patients. Transplantation 74: 4, Abstract No. 172, 2002.

21) Pettiford B, Caciarelli TV, **Egtesad B**, Jain AK, Planinsic R, Reyes J, Fung J, Kormos R. Simultaneous Heart-Liver Transplantation – A Worthwhile Effort. Transplantation 74: 4, Abstract 622, 2002.

22) Jain AK, Scantlebury V, Shapiro R, **Egtesad B**, Pokharna R, Reyes J, Potdar S, Flohr J, Fung J. Pregnancy post Liver, Kidney and Kidney + Pancreas Transplant under Tacrolimus. Transplantation 74:4, Abstract No. 2106, 2002.

23) Aggarwal S, Planinsic R, Boucek C, Chalasani A, Pretto E, Hilmi I, Abu-Elmagd K, **Egtesad B**, Martin C. In Vitro Study: Effect of Incremental Doses of Thymoglobulin on Coagulation. Transplantation 74: 4, Abstract No. 3072, 2002.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

- 24) Cacciarelli T, Vesta F, **Eghtesad B**, Fung J. Disease Recurrence and Long-Term outcome of Patients Undergoing Liver Transplantation for Budd-Chiari Syndrome. Am J Transpl 5:3, Abstract No. 376. 2003.
- 25) **Eghtesad B**, Broznick B, Patel K, Malek S, Cacciarelli T, Jain A, DeVera M, Fontes P, Gayowski T, Marsh W, Marcos A, Fung J. Comparison of Histidine-Tryptophan-Ketoglutarate (HTK) Solution versus University of Wisconsin(UW) Solution for Organ Preservation in Liver Transplantation. Am J Transpl. 5:3, Abstract No.1172, 2003.
- 26) DeVera M, **Eghtesad B**, Jain A, Fung J. Progression and Treatment of Recurrent Hepatitis C after Liver Transplantation in Patients Co-Infected with HIV. Hepatology 38:4, Suppl 1., Abstract No. 12, 2003.
- 27) **Eghtesad B**, Marcos A, Flynn B, Fontes P, Cacciarelli T, Marsh W, DeVera M, Shakil O, Murase N, Demetris A, Fung J, Starzl T. Liver Transplantation under a Teratogenic Regimen of Preconditioning with Alemtuzumab and Post-Transplant Tacrolimus. Hepatology, 38: 4, Suppl. 1. Abstract No. 438 , 2003.
- 28) Demetris A, **Eghtesad B**, Marcos A, Nalesnik M, Fontes P, Cacciarelli T, Randhawa, P, Wu T, Krasinskas A, Fung J, Starzl T. Prospective and Rigorous Testing of the Ability to Distinguish between Recurrent Hepatitis C and Acute and Chronic Rejection During a Tolerance Induction Trial. Hepatology, 38:4, Suppl. 1, Abstract 771, 2003.
- 29) Cacciarelli T, Vesta F, **Eghtesad B**, Fung J. Disease Recurrence and Long-Term outcome of Patients Undergoing Liver Transplantation for Budd-Chiari Syndrome. Liver Transpl. 9:6, Abstract No. 147. 2003.
- 30) Kelly D, Demetris J, **Eghtesad B**, Marsh W, Patel K, Novelli P, Planinsic R, Fung J, Marcos A. The Pathologic End of the Spectrum of Small-for-Size Graft Syndrome in Adult Living Donor Liver Transplantation. Amer J of Transpl, 4: Suppl 8, Abstract No. 83, 2004.
- 31) **Eghtesad B**, Mayher D, Guggenheimer J. A Survey of Dental Care Protocols Among U.S. Organ Transplant Centers. Am J Transpl, 4: Suppl 8, Abstract No. 665, 2004.
- 32) Jain A, Venkataramana R, **Eghtesad B**, Shakil O, Kashyap R, Marcos A, Fung J. Prevalence of Ribavirin Concentration in Plasma/Blood in Post Liver Transplant Patients Infected with Hepatitis C. Amer J of Transpl, 4: Suppl 8, Abstract No. 727, 2004.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

33) Murase N, Metes D, Zeevi A, Bentlejewski C, Guaspari D, Macedo C, Farren A, McGregor P, **Eghtesad B**, Fontes P, Marcos A, Woodward J, Demetris A, Fung J, Starzl T. Immunomonitoring of Liver Recipients Treated with Tolerance-Enhancing Regimen of Immunosuppression. Amer J of Transpl, 4: Suppl 8, Abstract No. 886, 2004.

34) Kwak E, Husain S, Paterson D, Fontes P, Cacciarelli T, Marcos A, Fung J, **Eghtesad B**. Efficacy of CMV Antigenemia Directed Preemptive Therapy with Ganciclovir at One Year in Liver Transplant Recipients Pretreated with Thymoglobulin or Alemtuzumab. Amer J of Transpl, 4: Suppl 8, Abstract No. 1258, 2004.

35) Vasta F, Fung J, **Eghtesad B**, Blisard D, Demetris A, Cacciarelli T. Short- and Long-term Outcome of Orthotopic Liver Transplantation Using Hepatitis C Virus-Infected Allografts. Amer J of Transpl, 4: Suppl 8, Abstract No. 1311, 2004.

36) **Eghtesad B**, Patel K, deVera M, Thai N, Blisard D, Soltys K, Fontes P, Cacciarelli T, Gayowski T, Marsh W, Demetris A, Macos A, Fung J. Utilization of Livers from Controlled Non-Heart-Beating Donors (NHBD) – A Single Center Experience on 55 Liver Transplants over a 10-Year Period. Amer J of Transpl, 4: Suppl 8, Abstract No. 1510, 2004.

37) Jain A, Reyes J, Kashyap R, Marcos A, Mazariegos G, **Eghtesad B**, Fontes P, Cacciarelli T, Marsh W, deVera M, Fung J. Early and Late, Surgical/Non-surgical, Immunological/Non-immunological Complications after Liver Transplantation and its Impact on Graft and Patient Survival in Adults and Children: An Analysis of 1000 Consecutive Patients with more than 10 Years Mean Follow-up. Liver Transpl, 10: 6, Abstract No. 46, 2004.

38) deVera M, Patel K, Fontes P, Marsh W, **Eghtesad B**, Marcos A, Fung J. Long-Term Impact of Steatotic Donor Livers on Patient and Allograft Survival. Liver Transpl, 10: 6, Abstract No. 63, 2004.

39) **Eghtesad B**, Patel K, deVera M, Thai N, Blisard D, Soltys K, Fontes P, Cacciarelli T, Gayowski T, Marsh W, Demetris A, Macos A, Fung J. Utilization of Livers from Controlled Non-Heart-Beating Donors (NHBD) – A Single Center Experience on 55 Liver Transplants over a 10-Year Period. . Liver Transpl, 10: 6, Abstract No. 139, 2004.

40) deVera M, Patel K, Fontes P, Marsh W, **Eghtesad B**, Marcos A, Fung J. Liver Transplantation for Methotrexate-Induced Cirrhosis. . Liver Transpl, 10: 6, Abstract No. 203, 2004.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

- 41) Jain A, Venkataramana R, **Eghtesad B**, Kashyap R, Yelochin B, Marcos A, Fung J. Value of Ribavirin Concentration Measurement in Plasma/Blood in Post Liver Transplant Patients with Hepatitis C Virus Infection. . Liver Transpl, 10: 6, Abstract No. 253, 2004.
- 42) **Eghtesad B**, Marcos, A, Fung J, Fontes P, Ton K, DeVera M, Marsh W, Gayowski T, Shakil O, Demetris A, Murase N, Starzl T. The Use of Alemtuzumab Induction and Tacrolimus Monotherapy in Liver Transplantation. Hepatology 40: No. 4, Supp 1, Abstract No 895, Oct. 2004.
- 43) Shakil O, Shahid H, Berk B, **Eghtesad B**, Marcos A, Fung J. A Trial of Pegylated Interferon and Ribavirin among Liver Transplant recipients with Hepatitis C: Reasons for Screening Failure and Low Enrollment. Hepatology 40: No. 4, Supp 1, Abstract No 450, Oct. 2004.
- 44) Murase N, Metes D, Zeevi A, Bentlejewski C, Guaspari D, Van Dyke A, McGregor P, **Eghtesad B**, Shapiro R, Fontes P, Marcos A, Woodward J, Demetris AJ, Starzl TE. Immunomonitoring in Allograft Recipients Treated with Depleting Antibodies. Amer J Transpl No 5, Supp 11, Abstract No. 1241, May 2005.
- 45) DeVera ME, **Eghtesad B**, Tom K, Lignoski P, Fontes P, Marsh W, Marcos A. Liver Transplantation of HBcAb-positive and HCV-positive Allografts. Amer J Transpl No 5, Supp 11, Abstract No. 1138, May 2005.
- 46) Randhawa PS, Patel S, Uhrmacher J, Pasculle W, Vats Abhay, Shapiro R, **Eghtesad B**, Weck K. Comparative Analysis of JC and BK Polyomavirus Load in Solid Organ Transplant Recipients and Non-transplant Controls. Amer J Transpl No 5, Supp 11, Abstract No. 460, May 2005.
- 47) Nakagava S, Kelly D, Aucejo FN, Parker B, **Eghtesad B**, Winans C, Vogt D, Henderson JM, Fung JJ, Miller CM. Liver transplantation for extended criteria recipient. Liver Transpl 12 (5) Abstract # 217, May 2006.
- 48) Nakagava S, Aucejo F, Parker B, Winans C, **Eghtesad B**, Vogt D, Henderson JM, Miller CM, Fung JJ. Hepatic blood flow in ischemia reperfusion injury. Liver transplantation 12 (5) Abstract # 360, May 2006.
- 49) de Vera M, Tom K, Thai N, Fung J, **Eghtesad B**, Ragni M. Impact of hepatitis C after liver transplantation in HIV and HCV co-infected patients. Amer. J Transpl 6 (5) Abstract # 951, May 2006.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

51) Nakagawa S, Aucejo F, Ahmed N, Parker B, Alster J, Winans C, **Egtesad B**, Vogt D, Henderson M, Miller C, Fung J, Kelly D. Hepatic blood flow in ischemia reperfusion injury. *Amer J Transpl* 6(5) Abstract # 407, May 2006.

52) Rohaninejad M, **Egtesad B**, Tom K, Kadry Z, Morshedi M, Gruttadauri ,Marsh W, Fung J, Gridelli B, Marcos A. Biliary duct complications in right lobe living donor liver transplantation. *Amer J Transpl* 6(5) Abstract #1928, May 2006.

53) Popescu L, Macedo C, Hua Y, Abu-Elmagd K, Shapiro R, **Egtesad B**, Fung J, Metes D. Ex vivo generation of EBV-specific CTLs using peptide pulsed DC1 from solid organ transplant recipients results in expansion of CD8+ type-1 like regulatory (IFN-gamma and IL-10) fox P3= T cells. *Amer J Transp* 6(5) Abstract # 410, May 2006.

54) Kelly DM, Hussain S, Karapetian A, Cocieru A, Alster J, Corry R, **Egtesad B**, Vogt D, Winans C, Cooke D, Miller C, Fung JJ. Basiliximab induction negates effect of a positive T-cell cross-match on acute rejection rates in liver transplant recipients receiving tacrolimus based immunosuppression. *Hepatology* 44 (4) Supp 1 Abstract # 596, October 2006.

55) Avery R, Corey R, Long J, Hall G, Gordon S, Schmitt S, Mossad S, Mawhorter S, Fung J, Miller C, Fraser T, Fatica C, Johnson L, **Egtesad B**. Persistence of VRE infection in liver transplant recipients treated with Daptomycin. *Am J Transpl* 7 Supp 2 Abstract # 1381, May 2007.

56) Corey R, Schmitt S, **Egtesad B**, Miller C, Gordon S, Fatica C, Fraser T, Mawhorter S, Mossad S, Winans C, Vogt D, Aucejo F, Johnson L, Fung J, Avery R. Infections in liver transplant recipients undergoing in-hospital re-transplantation and/or pre-transplant hospitalization. *Am J Transpl* 7 Supp 2 Abstract # 1387, May 2007.

57) Aucejo F, Nakagawa S, Quintini C, Hashimoto K, Hirose K, **Egtesad B**, Vogt D, Winans C, Kelly D, Fung F, Miller C. Triple-phase computer tomography (CT) and intra-operative flow measurements (IFM) are essential in the management of porto-systemic shunts during liver transplantation. *Am J Transpl* 7 Supp 2 Abstract # 1551, May 2007.

58) Hirose K, Aucejo F, Hashimoto K, Quintini C, Nakagawa S, Corey R, Bescath K, **Egtesad B**, Kelly D, Fung J, Miller C. Very low values of Cylex immune cell function assay is associated with early post-operative death following liver transplantation. *Am J Transpl* 7 Supp 2 Abstract # 1569, May 2007.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

- 59) Hirose K, Aucejo F, Quintini C, Hashimoto K, Nakagawa S, Bennett R, Winans C, **Eghtesad B**, Vogt D, Fung J, Miller C. Outcomes of liver transplantation for hepatocellular carcinoma under the MELD allocation system. Liver Transpl 13, Supp 1 Abstract # 56, June 2007
- 60) Nakagawa S, Ahmed N, Aucejo F, **Eghtesad B**, Kelly D, Fung J, Miller C. Diagnosis and management of post-transplant portal vein stenosis. Liver Transpl 13, Supp 1 Abstract # 106, June 2007
- 61) Kelly, D, Hussein S, Karapetian A, Coceiru A, Alster J, Corey R, **Eghtesad B**, Miller C, Fung J. Basiliximab induction negates the effect of a positive T-cell cross-match on acute rejection rates in liver transplant recipients. Liver Transpl 13, Supp 1 Abstract # 180, June 2007
- 62) Aucejo F, Hashimoto K, Quintini C, Hirose K, Nakagawa S, Diago T, **Eghtesad B**, Kelly D, Winans C, Vogt D, Fung J, Miller C. Splenic steal syndrome: Reality or myth? A case report suggesting the role of portal hypertension. Liver Transpl 13, Supp 1 Abstract # 187, June 2007
- 63) Hirose K, Aucejo F, Hashimoto K, Quintini C, Nakagawa S, Corey R, Bescath K, **Eghtesad B**, Kelly D, Fung J, Miller C. Very low values of Cylex immune cell function assay is associated with early post-operative death following liver transplantation. Liver Transpl 13, Supp 1 Abstract # 231, June 2007
- 64) Quintini C, Cocieru A, Aucejo F, Hirose K, Hashimoto K, Nakagawa S, Diego Uso T, **Eghtesad B**, Winans C, Vogt D, Kelly D, Fung J, Miller C. Alcoholic cirrhosis as a risk factor for development of biliary complications in liver transplantation. Liver Transpl 13, Supp 1 Abstract # 267, June 2007
- 65) Aucejo F, Nakagawa S, Hashimoto K, Hirose K, Quintini C, Kelly D, **Eghtesad B**, Fung J, Miller C. Computed tomography (CT) and intraoperative flow measurements (IFM) in the management of portosystemic shunts during liver transplantation. Liver Transpl 13, Supp 1 Abstract # 291, June 2007
- 66) Avery R, Corey R, Long J, Hall G, Gordon S, Schmitt S, Mossad S, Mawhorter S, Fung J, Miller C, Fraser T, Johnson L, **Eghtesad B**. Persistence of VRE infection in liver transplant recipients treated with Daptomycin. Liver Transpl 13, Supp 1 Abstract # 313, June 2007
- 67) Hashimoto K, Quintini C, Hirose K, Nakagawa S, Diago Uso T, Cocieru A, Aucejo F, **Eghtesad B**, Kelly D, Winans C, Vogt D, Fung J, Miller C. High portal flow and low hepatic artery buffer response is associated with early biliary anastomotic strictures in liver transplantation. Liver Transpl 13, Supp 1 Abstract # 356, June 2007

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

68) Quintini C, Aucejo F, Hashimoto K, Hirose K, Diago Uso T, Nakagawa S, Sopko N, Rosenblum J, **Egtesad B**, Kelly D, Winans C, Vogt D, Fung J, Miller C. Outcomes of liver transplantation in the morbidly obese. *Liver Transpl* 13, Supp 1 Abstract # 468, June 2007

69) Corey R, Schmitt S, **Egtesad B**, Miller C, Gordon S, Fatica C, Fraser T, Mawhorter S, Mossad S, Winans C, Vogt D, Aucejo F, Johnson L, Fung J, Avery R. Infections in liver transplant recipients undergoing in-hospital re-transplantation and /or with re-transplant hospitalization. *Liver Transpl* 13, Supp 1 Abstract # 519, June 2007

70) Aucejo F, Kim R, Zein N, Diago T, Quintini C, Hashimoto K, Hirose K, Hanouneh I, Lopez R, Kelly D, **Egtesad B**, Fung J, Miller C, Yerian L. Vascular endothelial growth factor receptor 2 (VEGFR2) expression in non-tumorous cirrhotic liver is higher when hepatocellular carcinoma (HCC) is beyond Millan Criteria. *AmJTranspl* 8, Supp2, Abstract #302, May 2008

71) Quintini C, Kauzman L, Hashimoto K, Ding P, Diago T, Sopko N, Rosenblum J, Aucejo F, Winans C, Kelly D, **Egtesad B**, Vogt D, Fung J, Miller C. Liver transplantation in morbidly obese (BMI > 40). *AmJTranspl* 8, Supp2, Abstract #309, May 2008

72) Lopez-Solis R, **Egtesad B**, Tom K, Sharma V, Patel S, Marsh W, Fontes P, Marcos A, deVera M. Orthotopic liver transplantation with allografts from DCD donors. *AmJTranspl* 8, Supp2, Abstract #473, May 2008

73) Askar M, Avery R, Corey R, Dawn T, Pidwell D, Zein N, **Egtesad B**, Fung J, Miller C. The association between immunoglobulin-like receptor “B” haplotype and post-transplant infections among liver transplant recipients. *AmJTranspl* 8, Supp2, Abstract 1499, May 2008

74) Askar M, Corey R, Avery R, Dawn T, Pidwell D, **Egtesad B**, Miller C, Fung J, Zein N. Lack of killer immunoglobulin-like receptor KIR2DS2 and possibly other genes within the “B” haplotype predict poor response to antiviral therapy in liver transplant recipients with recurrent HCV infection. *AmJTranspl* 8, Supp2, Abstract #1500, May 2008

75) Hashimoto K, Hirose K, Diago T, Aucejo F, Quintini C, Ding P, Corey R, **Egtesad B**, Kelly D, Fung J, Miller C. Impact of Cylex immune cell function assay in predicting acute cellular rejection and recurrence of HCV in liver transplantation. *AmJTranspl* 8, Supp2, Abstract #1636, May 2008

76) Lopez-Solis R, **Egtesad B**, Tom K, Sharma V, deVera M. DCD donor allografts for use in liver transplantation. *Liver Transpl*, Supp 1, Abstract # 604, July 2008

10/17/2022

Bijan Egtesad, M.D.
Curriculum Vitae

- 77) Quintini C, Kauzman L, Hashimoto K, Ding P, Diago T, Sopko N, Rosenblum J, Aucajo F, Winans C, Kelly D, **Egtesad B**, Vogt D, Fung J, Miller C. Liver transplantation in morbidly obese (BMI > 40). *Liver Transpl, Supp 1, Abstract # 283, July 2008*
- 78) Aucejo F, Kim R, Zein N, Diago T, Quintini C, Hashimoto K, Hirose K, Hanouneh I, Lopez R, Kelly D, **Egtesad B**, Fung J, Miller C, Yerian L. Vascular endothelial growth factor receptor 2 (VEGFR2) expression in non-tumorous cirrhotic liver is higher when when hepatocellular carcinoma (HCC) is beyond Millan Criteria. *Liver Transpl, Supp 1, Abstract # 202, July 2008*
- 79) Hashimoto K, Hirose K, Diago T, Aucejo F, Quintini C, Ding P, Corey R, **Egtesad B**, Kelly D, Fung J, Miller C. Impact of Cylex immune cell function assay in predicting acute cellular rejection and recurrence of HCV in liver transplantation. *Liver Transpl, Supp 1, Abstract # 161, July 2008*
- 80) Aucejo F, Zein N, Diago T, Quintini C, Hashimoto K, **Egtesad B**, Fung J, Miller C, Yerian L. Liver vascular endothelial growth factor receptor 2 (VEGFR2) expression is unrelated to hepatitis C (HCV) infection in hepatocellular carcinoma (HCC)/cirrhosis. *Liver Transpl, Supp 1, Abstract # 203, July 2008*
- 81) Alkhouri N, Hupertz V, **Egtesad B**, Fung J, Carter-kent C, Radhakrishnan K. Reversal of protein-losing enteropathy after liver transplantation in a child with idiopathic familial neonatal hepatitis. *Pediatric Transplantation. Vol 13, Suppl 1, Abstract # 296, April 2009*
- 82) Ahmed N, Quintini C, Hashimoto K, **Egtesad B**. Impact of transplant rotation on surgical resident training. *Liver Transplantation. Vol 15, Suppl. 1, Abstract # 110, July, 2009*
- 83) Tellioglu G, **Egtesad B**, Alster J, Yao D, Lin S, Fung J. Histidine-tryptophan-ketoglutarate solution vs. University of Wisconsin solution for deceased donor liver transplantation: Analysis of UNOS database. *Liver Transplantation. Vol 15, Suppl. 1, Abstract # 281, July, 2009*
- 84) Hupertz V, Gulati R, **Egtesad B**. Liver transplantation reverses portal hypertension associated hypoalbuminemia and growth failure in a patient with ARPKD. *Liver Transplantation. Vol 15, Suppl. 1, Abstract # 322, July, 2009*
- 85) Hashimoto K, **Egtesad B**, Ahmad N, Gunasekaran G, Quintini C, Aucejo F, Kelly D, Winans C, Vogt D, Parker B, Irefin S, Miller C, Fung J. Use of tissue plasminogen activator in donor hepatic artery of donation after cardiac death donors: can we lower the risk of ischemic –

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

type biliary stricture after liver transplantation. Liver Transplantation. Vol 15, Suppl 1, Abstract # 156, July 2009

86) Ahmed N, Hashimoto K, Aucejo F, Quintini C, Miller C, **Egtesad B**. Impact of transplant rotation on surgical resident training. Am J Transpl Vol 9, Suppl 2, Abstract#LB12, 2009

87) Terrault N, Barin B, Schiano TD, Poordad F, Wong M, De Vera ME, Simon D, Rosenthal L, Jayaweera D, Johnson LB, Olthoff KM, Stosor V, Sherman KE, **Egtesad B**, Harland R, Regenstein F, Hamilton JP, Pruett TL, Roland M, Stock P. Survival and risk of severe hepatitis C virus (HCV) recurrence in liver transplant (LT) recipients coinfectd with human immunodeficiency virus (HIV) and HCV. (NIH multicenter study). Hepatology 50: Supp 4, Abstract # 195, October 2009

88) Shiba H, Hashimoto K, Kelly D, Fujiki M, Arakawa Y, **Egtesad B**, Miller C, Fung J. Risk stratification of hepatitis C virus recurrence after liver transplantation by a new scoring system. Am J Transpl Vol 10, Suppl 4, Abstract # 122, 2010

89) Askar M, Avery R, Corey R, Schold J, **Egtesad B**, Flechner S, Klingman L, Teresi G, Pidwell D, Fung J, Srinivas T. Allosensitization is associated with increased risk of infectious complications post simultaneous liver/kidney transplantation. Am J Transpl Vol 10, Abstract #191, 2010

90) Painter W, Mossad S, Siemionow M, **Egtesad B**, Djohan R, Papay F, Avery R. First use of CMX001, a novel antiviral drug for suppression of cytomegalovirus infection in solid organ transplant patients. Am J Transpl Vol 10, Suppl 4, Abstract # LB10, 2010

91) Kelly D, Shiba H, Irefin S, Zhu X, **Egtesad B**, Quintini C, Zhu X, Egtesad B, Quintini C, Aucejo F, Vogt D, Winans C, Hashimoto K, Miller C, Fung J. Hepatic blood flow following reperfusion is an important predictor of ischemia/reperfusion injury. Am J Transpl Vol 10, Suppl 4, Abstract # 1060, 2010

92) Hashimoto K, Quintini C, **Egtesad B**, Radhakrishnan K, Feinberg L, Hupertz V, Tzakis A, Miller C, Fung J. Near total enterectomy for life-threatening complications of intestinal failure: a potential option as a bridge to intestinal transplantation. Am J Transpl Vol 10, Suppl 4, Abstract # 1190, 2010

93) Gordon C, Siemionow M, **Egtesad B**, Fung J. A novel cadaver study quantifying the potential antigenic skin component accompanying face and upper extremity transplantation. Am J Transpl Vol 10, Suppl 4, Abstract # 1325, 2010

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

94) Corey R, Van Duin D, Budev M, Starling R, Goldfarb D, **Egtesad B**, Fung J, Avery R. Infections in recipients of both thoracic and abdominal organ transplant. Am J Transpl Vol 10, Suppl 4, Abstract #1355, 2010

95) Fujiki M, **Egtesad B**, Diago T, Gunasekaran G, Hashimoto K, Quintini C, Kelly D, Fung J, Miller C, Aucejo F. Absolute absence of hepatocellular carcinoma enhancement in post TACE CT scan is not synonym of complete tumor necrosis. Am J Transpl Vol 10, Suppl 4, Abstract #1456, 2010

96) Kelly D, Shiba H, Irefin S, Zhu X, **Egtesad B**, Quintini C, Zhu X, Egtesad B, Quintini C, Aucejo F, Vogt D, Winans C, Hashimoto K, Miller C, Fung J. Hepatic blood flow following reperfusion is an important predictor of ischemia/reperfusion injury. Liver Transpl Vol 16, Suppl 1, Abstract # O-75, 2010

97) Hashimoto K, **Egtesad B**, Gunasekaran G, Fujiki M, Diago T, Quintini C, Aucejo F, Kelly D, Winans C, Vogt D, Parker B, Irefin S, Miller C, Fung J. Update report of the effect of tissue plasminogen activator in liver transplantation from donation after cardiac death donors. Liver Transpl Vol 16, Suppl 1, Abstract # O-105, 2010

98) Shiba H, Hashimoto K, Kelly D, Fujiki M, Arakawa Y, **Egtesad B**, Miller C, Fung J. Risk stratification of hepatitis C virus recurrence after liver transplantation. Liver Transpl Vol 16, Suppl 1, Abstract # P-219, 2010

99) Fujiki M, **Egtesad B**, Diago T, Gunasekaran G, Hashimoto K, Quintini C, Kelly D, Fung J, Miller C, Aucejo F. Absolute absence of hepatocellular carcinoma enhancement in post TACE CT scan is not synonym of complete tumor necrosis. Liver Transpl Vol 15, Suppl 1, Abstract # P-423, 2010

100) Modaresi J, Diago T, Fujiki M, Hodgkinson P, Hashimoto K, Quintini C, Aucejo F, Kelly D, Winans C, Vogt D, Miller C, Fung J, **Egtesad B**. Duct-to-duct biliary reconstruction in patients with primary sclerosing cholangitis undergoing liver transplantation. HPB Vol 13, Suppl 1, Page 47, 2011

101) Askar M, Smith G, Schold J, Klingman L, Flechner S, **Egtesad B**, Miller Z, Fung J, Srinivas T. Positive T-cell flow crossmatch post liver transplantation is a predictor of increased risk of antibody mediated rejection of the kidney in recipients of combined liver-kidney transplant: single center 15 years' experience. Am J Transpl Vol 11, Suppl 2, Abstract # 199, 2011

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

102) El Gazzaz G, Ibarra R, Sanabria J, Menon N, **Eghtesad B**, Hashimoto K, Quintini C, Miller C, Fung J, Aucejo F. Radiologic-histological correlation of hepatocellular carcinoma (HCC) treated via pre-liver transplant locoregional therapy. Am J Transpl Vol 11, Suppl 2, Abstract # 279, 2011

103) Brown C, Quintini C, Diago T, Hashimoto K, Aucejo F, **Eghtesad B**, Kelly D, Fung J, Miller C. Intraoperative flow measurements facilitate the detection of celiac axis stenosis in patients undergoing orthotopic liver transplantation. Am J Transpl Vol 11, Suppl 2, Abstract # 400, 2011

104) Modaresi J, Diago T, Fujiki M, Hodgkinson P, Hashimoto K, Aucejo F, Kelly D, Quintini C, Winans C, Vogt D, Zein N, Miller C, Fung J, **Eghtesad B**. Duct-to-duct biliary reconstruction in patients with primary sclerosing cholangitis undergoing liver transplantation. Am J Transpl Vol 11, Suppl 2, Abstract # 401, 2011

105) Askar M, Fung J, Miller C, **Eghtesad B**, Zein N, Schold J. The impact of positive T-cell crossmatch on liver transplant recipient outcomes. Am J Transpl Vol 11, Suppl 2, Abstract # 505, 2011

106) **Eghtesad B**, Forrest K, Fujiki M, Diago T, Hodgkinson P, Hashimoto K, Quintini C, Aucejo F, Kelly D, Winans C, Vogt D, Miller C, Fung J. A pilot randomized controlled clinical trial of Thymoglobulin (r-ATG) induction with extended delay of calcineurin inhibitor therapy in liver transplantation. Am J Trans Vol 11, Suppl 2, Abstract # 777, 2011

107) Kelly D, Arakawa Y, Karpetian A, Quintini C, Hashimoto K, **Eghtesad B**, Aucejo F, Vogt D, Winans C, Miller C, Fung J. The impact of Basiliximab induction therapy negates the effect of positive T-cell crossmatch on ACR in adult OLT recipients. Am J Transpl Vol 11, Suppl2, Abstract # 783, 2011

108) Zhu X, Shiba C, Quintini C, Hashimoto K, Aucejo F, **Eghtesad B**, Miller C, Fung J, Kelly D. Low dose adenosine increases hepatic artery flow (HAF) in liver transplant recipients. Am J Transpl Vol 11, Suppl 2, Abstract # 1023, 2011

109) Diago T, Brown C, D'Amico G, Quintini C, Aucejo F, Hashimoto K, Kelly D, **Eghtesad B**, Miller C, Fung J. Reno-portal bypass in patients with severe portal vein thrombosis and large splenorenal shunts: Should it represent the revascularization of choice? Am J Transplant Vol 11, Suppl 2, Abstract # 1025, 2011

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

110) Quintini C, Brown C, D'Amico G, Diago T, Aucejo F, Hashimoto K, **Egtesad B**, Kelly D, Miller C, Fung J. Preliminary experience with side-to-side cavo-cavostomy in liver transplantation an endovascular stapler. Am J Transpl Vol 11, Suppl 2, Abstract # 1026, 2011

111) Kelly D, Bennett R, **Egtesad B**, Yu C, Boerner D, McCoy J, Brown N, Miller C, Fung J, Kattan M. A new approach in a new era: Predicting discharge disposition following liver transplantation. Am J Transpl Vol 11, Suppl 2, Abstract # 1358, 2011

112) Fujiki M, Aucejo F, Hicks C, Diago T, Hodgkinson P, Hashimoto K, Quintini C, Kelly D, Winans D, Vogt D, **Egtesad B**, Fung J, Miller C. Comparable analysis of trans-arterial chemoembolotherapy for Hepatocellular carcinoma before liver transplantation: Drug eluting beads (DEB) vs. trans-arterial chemoembolization. Am J Transpl Vol 11, Suppl 2, Abstract # 1491, 2011

113) **Egtesad B**, Forrest K, Fujiki M, Diago T, Hodgkinson P, Hashimoto K, Quintini C, Aucejo F, Kelly D, Winans C, Vogt D, Miller C, Fung J. A pilot randomized controlled clinical trial of Thymoglobulin (r-ATG) induction with extended delay of calcineurin inhibitor therapy in liver transplantation. Liver Transpl Vol 17, No 6, Suppl 1, Abstract # O-21, 2011

114) Miller C, D'Amico G, Brown C, Diago T, Hashimoto K, Aucejo F, **Egtesad B**, Kelly D, Fung J, Quintini C. Splenic artery embolization for the treatment of refractory ascites after liver transplantation. Liver Transpl Vol 17, No. 6, Suppl 1, Abstract # O-114, 2011

115) Brown C, Quintini C, D'Amico G, Diago T, Fujiki M, Hodgkinson P, Hashimoto K, Aucejo F, Kelly D, **Egtesad B**, Fung J, Miller C. Strategies to decrease the rate of hepatic artery thrombosis in liver transplant recipients: The importance of intraoperative flow measurements. Liver Transpl Vol 17, No. 6, Suppl 1, Abstract # P-113, 2011

116) Quintini C, Brown C, D'Amico G, Diago T, Fujiki M, Hodgkinson P, Hashimoto K, Aucejo F, Kelly D, **Egtesad B**, Fung J, Miller C. Splenic artery embolization is a safe procedure and improves intrahepatic arterial perfusion in liver transplant patients. Liver Transpl Vol 17, No. 6, Suppl 1, Abstract # P-169, 2011

117) Modaresi J, Diago T, Fujiki M, Hodgkinson P, Hashimoto K, Aucejo F, Kelly D, Quintini C, Winans C, Vogt D, Zein N, Miller C, Fung J, **Egtesad B**. Duct-to-duct biliary reconstruction in patients with primary schlerosing cholangitis undergoing liver transplantation. Liver Transpl Vol 17, No. 6, Suppl 1, Abstract # P-176, 2011

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

118) Fujiki M, Shiba H, Hasimoto K, Arakawa Y, Diago T, Quintini C, **Egtesad B**, Fung J, Miller C. donation after cardiac death liver allografts affect severe hepatitis C recurrence early after liver transplantation? Liver Transpl Vol 17, No. 6, Suppl 1, Abstract # P-248, 2011

119) Fujiki M, Aucejo F, Hicks C, Diago T, Hodgkinson P, Hashimoto K, Quintini C, Kelly D, Winans D, Vogt D, **Egtesad B**, Fung J, Miller C. Comparable analysis of trans-arterial chemoembolotherapy for Hepatocellular carcinoma before liver transplantation: Drug eluting beads (DEB) vs. trans-arterial chemoembolization. Liver Transpl Vol 17, No. 6, Suppl 1, Abstract # P-293, 2011

120) **Egtesad B**, Askar M, Bollinger K, Hashimoto K, Kelly D, Aucejo C, Quintini C, Avery R, Miller C, Fung J. Graft-Versus-Host disease (GVHD) following liver transplantation: Comparison of two eras. Liver Transpl Vol 18, No 5, Suppl 1, Abstract # O21, 2012

121) Kelly D, Bennett R, Vass K, McCoy J, Kerepesi K, Waby A, **Egtesad B**, Hashimoto K, Aucejo F, Quintini C, Miller C, Fung J. Liver transplantation in a new era: Improving quality of care and reducing length of stay. Liver Transpl Vol 18, No 5, Suppl 1, Abstract # O69, 2012

122) Hashimoto K, Quintini C, Aucejo F, Fujiki M, Diago T, Watson M, Kelly D, Winans C, **Egtesad B**, Fung J, Miller C. Split liver transplantation using hemiliver grafts: A single US center experience in the MELD era. Liver Transpl Vol 18, No 5, Suppl 1, Abstract # O103, 2012

123) El-Gazzaz G, Purysko A, Narayanan M, Hashimoto K, Quintini C, Kelly D, **Egtesad B**, Miller C, Fung J, Aucejo F, Remer E. Does radiological appearance of hepatocellular carcinoma (HCC) affect the outcome of locoregional therapy (LRT) in patients undergoing liver transplantation? Hepatology Vol 56, No 4, Suppl. Abstract # 530, 2012

124) Watson M, Fujiki M, Diago T, Hashimoto K, Kelly D, Aucejo F, Quintini C, Winans C, Bollinger J, Miller C, Fung J, **Egtesad B**. Induction with anti-thymocyte globulin and delayed calcineurin inhibitor therapy in patients with renal failure prior to liver transplant improves outcomes. Hepatology Vol 56, No 4, Suppl. Abstract # 641, 2012

125) Qui J, Thapaliya S, Runkana A, Yang Y, Tsien C, Mohan M, **Egtesad B**, Mozdziaik P, McDonald C, McCullough A, Nadga Prasad S, Dasarathy S. Sarcopenia of cirrhosis is mediated by hyperammonemia induced NF κ B regulated transcriptional upregulation of myostatin expression. Hepatology Vol 56, No 4, Suppl. Abstract # 1254, 2012

126) Qui J, Tsien C, Thapaliya S, Narayanan A, Almasaan A, **Egtesad B**, McCullough A, McDonald C, Nadga Prasad S, Wehl C, Singh K, Dasarathy S. Hyperammonemia mediated

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. *Hepatology* Vol 56, No 4, Suppl. Abstract # 1595, 2012

127) Zein NN, Hanouneh IA, Bishop PD, Samaan M, **Egtesad B**, Quintini C, Miller C, Yerian L, Klatte R. Three-dimensional print of a liver for preoperative planning in living donor liver transplantation. *Hepatology* Vol 58, No 4, Suppl. Abstract # 1180, 2013

128) Dugum M, Hanouneh IA, Lopez R, Aucejo F, **Egtesad B**, Zein NN. Hepatocellular carcinoma (HCC) in the setting of chronic hepatitis B virus infection (HBV): Recurrence and survival rates following liver transplantation. *Hepatology* Vol 58, No 4, Suppl. Abstract #2116, 2013

129) Kawamura N, Nazzal M, El-Gazzaz G, Spaggiari M, Fujiki M, Diago, T, Aucejo F, Hashimoto K, Quintini C, Winans C, **Egtesad B**, Miller C, Fung J, Alkouri N, Kelly D. Non-alcoholic fatty liver disease (NAFLD) recurrence after liver transplantation (OLT) for non-alcoholic steatohepatitis (NASH). *Hepatology* Vol 60, No 1, Suppl. Abstract # 864, 2014

130) Dugum M, Zein N, Lopez R, Romero-Morrero C, Aucejo F, **Egtesad B**, Confer B, Hanouneh I. Achieving equity among patients with and without hepatocellular carcinoma (HCC) who are listed for liver transplantation: A scoring system utilizing MELD and Alpha fetoprotein(AFP). *Hepatology* Vol 60, No 1, Suppl. Abstract # 167, 2014

131) Yaseen M, Hanouneh I, John B. Guirguis J, **Egtesad B**, Fung J, Zein N. Safety and efficacy of all-oral sofosbuvir-based regimen to treat HCV recurrence post-liver transplantation. *Hepatology* Vol 60, No 1, Suppl. Abstract # 1028, 2014

132) El-Gazza G, Schold J, Nazzal M, Kawamura N, Spaggiari M, Hashimoto K, Quintini C, Aucejo F, Kelly D, Fujiki M, Wians C, Diago T, Miller C, Fung J, **Egtesad B**. Liver transplantation using pediatric organ donation after circulatory death- An analysis of the national registry. Abstract book of the World Transplant Congress. Abstract # 2239. 2014

133) Liu Q, Nasser A, Kelly D, Hashimoto K, **Egtesad B**, Diago T, Irefin S, Cywinski J, Baldwin W, Fung J, Abu-Elmagd K, Miller C, Quintini C. Normothermic machine perfusion (NMP) promotes early graft function and biliary epithelial regeneration after liver transplantation of porcine liver undergoing 1hr warm ischemia (WI). Abstract book of the World Transplant Congress. Abstract # A5. 2014

134) Presser N, Watson M, Bollinger J, Fujiki M, Diago T, Aucejo F, Quintini C, Hashimoto K, Kelly D, Winans C, Miller C, Fung J, **Egtesad B**. Induction with antithymocyte globulin

10/17/2022

Bijan Egtesad, M.D.
Curriculum Vitae

(rATG) and delayed calcineurin inhibitor therapy in patients with acute renal failure/dysfunction pre-liver transplantation allows for sustained renal recovery post transplant. Abstract book of the World Transplant Congress. Abstract # A428. 2014

135) Firl D, Schold J, **Egtesad B**, Fung J. Recipient age modulates effect of donor risk on graft loss in deceased donor liver transplantation. Abstract book of the World Transplant Congress. Abstract # B1079. 2014

136) Bollinger J, Plavney D, Zein N, Hashimoto K, Diago T, Kelly D, Quintini C, Aucejo F, Fujiki M, Winans C, Kerepesi K, Waby A, Miller C, Fung J, **Egtesad B**. Liver transplantation using anti-HBc positive donors: A single center experience. Abstract book of the World Transplant Congress. Abstract # B1127. 2014

137) Nasser A, Liu Q, Urcuyo D, Mediaris S, El-Gazzaz G, **Egtesad B**, Fung J, Abu-Elmagd K, Miller C, Walsh M, Quintini C. Establishing an Ex-vivo pancreas perfusion model on discarded human grafts. Abstract book of the World Transplant Congress. Abstract # C2072. 2014

138) Zhang W, Kim R, Quintini C, Hashimoto K, Fujiki T, Diago T, **Egtesad B**, Miller C, Fung J, Tan A, Narayanan M, Aucejo F. Plasma vascular endothelial growth factor (VEGF) predicts vascular invasion in patients with hepatocellular carcinoma undergoing liver transplantation. Abstract book of the World Transplant Congress. Abstract # B3024. 2014

139) Know JH, Hanouneh I, Allende D, Yerian L, Diago T, **Egtesad B**, Zein N. DeNovo autoimmune hepatitis following liver transplantation. Abstract book of DDW 2015, Abstract # Su1021

140) Know HJ, Hanouneh I, Allende D, Yerian L, Diago T, **Egtesad B**, Zein N. Plasma cell hepatitis following liver transplantation in patients with chronic hepatitis C virus infection. Abstract book of DDW 2015, Abstract # Su1029

141) Alkhuri N, Hanouneh I, Zein N, Lopez R, Kelly D, **Egtesad B**, Fung J. Liver transplantation for nonalcoholic steatohepatitis (NASH) in children and young adults: The true burden of pediatric nonalcoholic fatty liver disease. Abstract book of DDW 2015, Abstract # Su1038

142) Samaan M, **Egtesad B**, Quintini C, Kissiedu J, Hanouneh I, Klatte R, Miller C, Zein N. #D printing liver models for precise resection of complex hepatic tumors. Hepatology Vol 62, No 1, Suppl. Abstract # 840

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

143) Louwers L, Palaios E, El-Gazzaz G, Spagiari M, **Eghtesad B**, Kelly D. Objective measurements of Karnofsky performance status in end stage liver disease patients. Hepatology Vol 62, No 1, Suppl. Abstract # 850

144) Dugum M, Zein N, Dugum A, Lopez R, **Eghtesad B**, Hanouneh I. Association of pre-transplant body mass index (BMI) with survival benefit of liver transplantation. Hepatology Vol 62, No 1, Suppl. Abstract # 855

145) Dugum M, Zein N, Dugum A, Lopez R, **Eghtesad B**, Hanouneh I. Predicting futility of liver transplantation: scoring system based on liver transplantation survival benefit. Hepatology Vol 62, No 1, Suppl. Abstract # 857

146) Hajifathalian K, Arora Z, Humberson A, Barnes D, McCullough A, Zein N, **Eghtesad B**, Hanouneh I. Ohio solid organ transplantation consortium (OSOTC) criteria for liver transplantation in patients with alcoholic liver disease. Hepatology Vol 62, No 1, Suppl. Abstract # 1265

147) Spaggiari M, Shaaban M, El-Gazzaz G, Louwers L, Palaios E, Quintini C, Aucejo F, Hashimoto K, Diago T, Fujiki M, **Eghtesad B**, Miller C, Perilla M, Kelly D. How intra-operative factors affect kidney recovery after simultaneous liver-kidney transplantation. Hepatology Vol 62, No 1, Suppl. Abstract # 1271

Oral Presentations:

1) **Eghtesad B**, Vaezzadeh K. Anthrax of Colon (case presentation). Presented at the 5th Congress of the Iranian Surgical Association, Tehran, Iran, 1988.

2) **Eghtesad B**. Carotid Body Tumor, residency thesis. Presented to the School of Medicine, Shiraz University, Preliminary of Iranian Board of Surgery Examination. 1982

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

- 3) **Eghtesad B**, Scotti C, Irish W, Todo S, Samimi F, aldrighetti L, Malek-Hosseini A, Rakela J, Starzl TE, Fung JJ. Liver Transplantation for Hepatitis B Surface Antigen Positive (HbsAg +) Chronic Liver Disease under FK-506. Presented at the Transplant Fellow Workshop, New Orleans, Louisiana, November 9-11, 1994.
- 4) **Eghtesad B**. Hepatitis B. Presentation at the: Inter-city Surgical Grand Rounds. Albuquerque, New Mexico, March 1995. (Invited Speaker)
- 5) **Eghtesad B**. FK-506 (Prograf) in Kidney Transplantation. The University of New Mexico, Division of Nephrology Conference. Aug. 1995. (Invited Speaker)
- 6) **Eghtesad B**, Nezakatgoo N, Geraci L.C, Reyes J, Jabbour N, Marsh W, Irish W, Ramos H, Rakela J, Starzl TE, Fung JJ. Liver Transplantation for Wilson Disease; Single Center Experience. Presented to the American Society of Transplant Physicians. Dallas, Texas, May 26-30, 1996. (Abstract published in the Proceedings of A.S.T.P.)
- 7) **Eghtesad B**. Fulminant Hepatic Failure; Recent trends in Management. The University of New Mexico, Division of Gastroenterology- Hepatology Conference. Aug. 21, 1996.
- 8) **Eghtesad B**. General Surgical Procedures in Patients with Liver Cirrhosis. Presentation at the Current Concepts in General Surgery. Albuquerque, New Mexico, July 17-19, 1996. (Invited Speaker)
- 9) **Eghtesad B**. Fulminant Hepatic Failure; Recent trends in Management. Presentation at the Advances in Liver Disease Conference. Albuquerque, New Mexico, July 27,1996. (Invited Speaker)
- 10) **Eghtesad B**. Management of Fulminant Hepatic Failure. Presentation at the Department of Pediatric grand round. The University of New Mexico. Nov. 21, 1996. (Invited Speaker)
- 11) Manicke M, Harford A, Greenberg R, Wheeler D, Malhotra D, Gibel L, Smith A, Ramos R, **Eghtesad B**. Recurrent Anti-tubular Basement Membrane Disease in a Renal Transplant Patient. Presented to the American College of Physicians, New Mexico Chapter Meeting. Albuquerque, New Mexico, Dec.5-6, 1996.
- 12) **Eghtesad B**. Liver Transplantation, from Fantasy to Reality. Presentation at the Department of Internal Medicine Grand Round, the University of New Mexico. Jan. 23, 1997. (Invited Speaker)

10/17/2022

Bijan Egtesad, M.D.
Curriculum Vitae

- 13) **Egtesad B.** Ascites and the Surgeon. Presentation at: Inter-city surgical grand round, Albuquerque, New Mexico, Jan. 31, 1997 (Invited Speaker)
- 14) **Egtesad B,** Harford AM, Ramos HC, Gibel LJ, Smith AY, Narva AS, Burrell K, Malhotra D. Increased Incidence of Posttransplant Diabetes Mellitus (PTDM) in Pediatric Native American Kidney Transplant Recipients on Tacrolimus. Presented to the Western Association of Transplant Surgeons (WATS), San Francisco, CA, Feb.21, 1997.
- 15) **Egtesad B,** Harford AM, Gibel LJ, Ramos HC, Smith AY, Haq M, Demarest P, Malhotra D. Use of Tacrolimus as the Primary Immunosuppression After Renal Transplant in Native Americans and Hispanics. Presented to the Western Association of Transplant Surgeons (WATS), San Francisco, CA, Feb.21, 1997.
- 16) Gibel LJ, **Egtesad B,** Smith AY, Malhotra D, Haq M, Harford AM. Single Kidney Transplants from Donors with Low Estimated Creatinine Clearance. Presented to the Western Association of Transplant Surgeons (WATS), San Francisco, CA, Feb.21, 1997.
- 17) Issa S, Dodson SF, Araya V, Gayowski T, **Egtesad B,** Rakela J, Fung JJ. Infectivity of Hepatic Allografts with Antibodies to Hepatitis B Virus. Presented to the American Society of Transplant Physicians. Chicago, Illinois, May 10-14, 1997. (Abstract published in the proceedings of ASTP)
- 18) **Egtesad B.** Management of Hepatic Trauma. Presented at the Current Concepts in General Surgery, Albuquerque, New Mexico, July 23-25, 1997. (Invited Speaker)
- 19) Harford A, Manicke M, Wheeler D, Malhotra D, **Egtesad B.** Recurrent Antitubular Basement Membrane Disease in a Renal Transplant Patient. Presentation at the International Society of Nephrology. Sydney, Australia, May 1997.
- 20) Adams P, Harford AM, **Egtesad B,** Kolosseus R, Gibel LJ, Smith AY, Malhotra D. Sulfadiazine-induced Obstructive Nephropathy in a Liver Transplant Recipient. Presented to the New Mexico Chapter of the American College of Physicians. Albuquerque, New Mexico, Dec. 7, 1997.
- 21) **Egtesad B.** Hepatitis C. Presented to the Albuquerque Inter-city Surgical Grand Rounds. Feb. 6, 1998. (Invited Speaker)
- 22) Mazariegos GV, **Egtesad B,** Ashrafi M, Arzate J, Osorio G, Reyes J. Incidence, Management and Outcome of Serious Pancreatitis Following Pediatric Liver Transplantation.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

Presented to the American Society of Transplant Physicians (ASTP) 17th Annual Meeting, May 9-13, 1998, Chicago, IL.

23) Putrakul K, **Egtesad B**. Use of Tacrolimus as the Primary Immunosuppressive Agent in Renal Transplantation; New Mexico experience. General Surgery Resident Research Presentation, University Of New Mexico, Department of Surgery. June 19, 1998

24) Kaplan D, **Egtesad B**. Utility of Renal Ultrasound and Renograms During the First Year After Renal Transplantation. General Surgery Resident Research Presentation, University Of New Mexico, Department of Surgery. June 19, 1998

25) **Egtesad B**. Current Management of Esophageal Varices. Presented at the Current Concepts in General Surgery. Albuquerque, New Mexico, August 5-7, 1998 (Invited Speaker)

26) **Egtesad B**. Liver Transplantation, Minimal Listing Criteria and Organ Allocation. CME Lecture for the Farmington Medical Society. Feb.24, 1999, Farmington, NM. (Invited Speaker)

27) **Egtesad B**. Liver Transplantation, Minimal Listing Criteria and Organ Allocation. CME Lecture for the Santa Fe Indian Health Services. Feb. 19, 1999, Santa Fe, NM. (Invited Speaker)

28) **Egtesad B**. Management of Esophageal Variceal Bleeding. Inter-city Surgical Grand Rounds. Albuquerque, NM, April 16, 1999. (Invited Speaker)

29) **Egtesad B**. Liver Transplantation, Minimal Listing Criteria and Organ Allocation. CME Lecture for the Las Cruces Medical Society. March 18, 1999. (Invited Speaker)

30) Kieran J, Coan S, Rossaro L, Hecker W, **Egtesad B**. Pattern of Referral for Liver Transplantation in New Mexico. General Surgery Resident Research Presentation, University of New Mexico, Department of Surgery, June 11, 1999

31) **Egtesad B**. Transplantation; is cost justified? Presented to the Seventh Annual Symposium Medical Futility: Hope and Common Sense. Albuquerque, NM, Oct. 14-16, 1999. (Invited Speaker)

32) **Egtesad B**. Immunosuppression, then, now and the future. Presented at the 4th Iranian Congress on Transplantation. Esfahan, Iran, Nov. 24-26. 1999. (Invited Speaker)

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

33) **Eghtesad B.** Hepatocellular Carcinoma: Current and Emerging Therapies. Presented at the Advances in Gastroenterology and Hepatology. Santa Fe, New Mexico, February 24-25, 2000 (Invited Speaker)

34) **Eghtesad B.** Surgical Management of Hepatic Metastasis from Colorectal Cancer. Presented to the New Mexico Society of Clinical Oncology. Albuquerque, New Mexico, April 8, 2000 (Invited Speaker)

35) **Eghtesad B.** Immunosuppression in Transplantation; recent advances. CME Lecture for the Farmington Medical Society. May 3, 2000, Farmington, NM, USA. (Invited Speaker)

36) **Eghtesad B.** Current Management of Non-resectable Hepatocellular Carcinoma. Presented at the Current Concept in General Surgery Conference. August 2-4, 2000, Albuquerque, New Mexico, USA. (Invited Speaker)

37) Jain A, Kashyap R, **Eghtesad B**, Potdar S, Fung JJ. Role of Mycophenolate Mofetil (MMF) in Liver Transplantation (LTX) for HCV-related End Stage Liver Failure; A Prospective Randomized Trial. Oral presentation. International Liver transplantation Society meeting, July 11-13, 2001, ELTA Licage, Berlin, Germany.

38) Jain A, ReyesJ, Kashyap R, **Eghtesad B**, Potdar S, Fung JJ. Tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation(LTx) in children and adults in long term follow-up. Accepted as oral presentation 10th European Society of Transplantation Congress (ESOT), October 6-11, 2001, Lisbon, Portugal.

39) **Eghtesad B.** Adult to adult living liver transplantation. Presented to The Golden Triangle Chapter of the International Transplant Nurses Society (ITNS) and the North American Transplant Coordinators Organization (NATCO), Pittsburgh, Pennsylvania, USA, October 19, 2001.

40) Jain A, Kashyap R, **Eghtesad B**, Fontes P, Godamski M, Nalesnik M, Fung J. Use of Rituximab (Chimeric Anti CD-20 Antibody) in Post Transplant Lymphoproliferative Disorder (PTLD) After Liver Transplantation. Presented to the 2nd International Congress on Immunosuppression. San Diego, California, USA, December 6-8, 2001.

41) Jain A, Kashyap R, **Eghtesad B**, Potdar S, Fung JJ. Role of Mycophenolate Mofetil (MMF) in Liver Transplantation (LTX) for HCV-related End Stage Liver Failure; A Prospective Randomized Trial. Presented to the 2nd International Congress on Immunosuppression. San Diego, California, USA, December 6-8, 2001.

10/17/2022

Bijan Egtesad, M.D.
Curriculum Vitae

42) **Egtesad B**, Fung JJ. Adult to adult living liver transplantation. Presented to the DHSS, Office of the Clinical Standards & Quality Coverage & Analysis Group, Center for Medicare and Medicaid Services. Baltimore, Maryland, USA, December 3, 2001.

43) **Egtesad B**, Dodson SF, Jain A, Shakil O, Bonham CA, Fontes P, Cacciarelli TV, Geller DA, Marsh WJ, Pokharna R, Fung JJ. Prevention of Recurrent Hepatitis B Virus after Liver Transplantation with Restricted Elimination of Hepatitis B Immune Globulin. Accepted for oral presentation at the American Transplant Congress April 26-May1, 2002, Washington D.C., USA.

44) De Vera ME, **Egtesad B**, Jain A, Dodson SF, Fung JJ, Bonham CA. Liver Transplantation in Patients Co-Infected with HIV and Hepatitis C. Accepted for oral presentation at the American Transplant Congress, April 26- May 1, 2002, Washington D.C., USA.

45) Albrecht RA, **Egtesad B**, Gibel L, Locken J, Champlin A. Percutaneous Removal of Spilled Gallstones in Subhepatic Abscess. Presented at the 53rd Annual Meeting of the Southwest Surgical Congress, April 30-May 3, 2000, Cancun, Mexico.

46) **Egtesad B**. Overview of Organ Donation and Donor Management. Transplantation Grand rounds, T.E. Starzl Transplantation Institute, Feb. 22, 2002, Pittsburgh, PA

47) **Egtesad B**, Daly I, Broznick BA, Geller DA, Cacciarelli TV, Fontes P, Bonham CA, Dodson SF, Jain AK, Marsh WJ, Fung JJ. Utilization of Livers from Non-heart-beating Donors – A Single Center Experience. Oral presentation at the International Liver transplantation Congress, June 13-15, 2002, Chicago, IL, USA

48) **Egtesad B**, Dodson SF, Jain A, Shakil O, Bonham CA, Fontes P, Cacciarelli TV, Geller DA, Marsh WJ, Pokharna R, Fung JJ. Prevention of Recurrent Hepatitis B Virus after Liver Transplantation with Restricted Elimination of Hepatitis B Immune Globulin. Oral presentation at the International Liver Transplantation Congress, June 13-15, 2002, Chicago, IL, USA.

49) Jain A, Venkataramanan R, Shapiro, Scantlebury V, **Egtesad B**, Potdar S, Ragni M, Fung J. Profound Interaction between Tacrolimus, Rapamycin and Anti-HIV Drugs in Liver and Kidney Transplant Patients. Oral presentation at the XIX International Congress of Transplantation Society, August 25-30, Miami, FL, USA.

50) Pettiford B, Cacciarelli TV, **Egtesad B**, Jain AK, Planinsic R, Reyes J, Fung J, Kormos R. Simultaneous Heart-Liver Transplantation – A Worthwhile Effort. Oral presentation at the XIX International Congress of Transplantation Society, August 25-30, Miami, FL, USA.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

51) **Eghtesad B.** Organ Preservation, Use of HTK in multiorgan recovery. Transplant Grand Rounds, Transplant Services, University of Florida, Gainseville, Oct. 29, 2002. (Invited Speaker)

52) DeVera M, **Eghtesad B**, Jain A, Fung J. Progression and Treatment of Recurrent Hepatitis C after Liver Transplantation in Patients Co-Infected with HIV. Oral presentation at the 54th Annual Meeting of the American Association for the Study of Liver Disease. October 24-28, 2003, Boston, MA, USA.

53) Demetris A, **Eghtesad B**, Marcos A, Nalesnik M, Fontes P, Cacciarelli T, Randhawa, P, Wu T, Krasinskas A, Fung J, Starzl T. Prospective and Rigorous Testing of the Ability to Distinguish between Recurrent Hepatitis C and Acute and Chronic Rejection During a Tolerance Induction Trial. Oral presentation at the 54th Annual Meeting of the American Association for the Study of Liver Disease. October 24-28, 2003, Boston, MA, USA.

54) **Eghtesad B**, Broznick B, Patel K, Malek S, Cacciarelli T, Jain A, DeVera M, Fontes P, Gayowski T, Marsh W, Marcos A, Fung J. Comparison of Histidine-Tryptophan-Ketoglutarate (HTK) Solution versus University of Wisconsin(UW) Solution for Organ Preservation in Liver. Oral presentation at the American Transplant Congress, May 30-June 4, 2003, Washington D.C., USA

55) Cacciarelli T, Vesta F, **Eghtesad B**, Fung J. Disease Recurrence and Long-Term outcome of Patients Undergoing Liver Transplantation for Budd-Chiari Syndrome. Oral presentation at the 9th annual meeting of the International Liver Transplantation Society, June 19-22, 2003, Barcelona, Spain

56) **Eghtesad B.** Current Status of Organ Transplantation in the US. Presented at the workshop on Dental Management of the Organ Transplant Patients. School of Dental Medicine, University of Pittsburgh. October 22, 2003, Pittsburgh, PA, USA.

57) Cacciarelli T, Vasta F, **Eghtesad B**, Fung JJ. Long-term Outcome and Disease Recurrence in Patients Undergoing Liver Transplantation for Budd-Chiari Syndrome. Oral presentation at the International Liver Transplantation Society (ILTS), June 19-22, 2003 Barcelona, Spain.

58) Jain AK, Venkatsramana R, **Eghtesad B**, Marcos A, Ragni M, Shapiro R, Rafail A, Fung JJ. Profound Drug Interaction with a Combination of two Protease inhibitors (PI: Ritonavir and Lopinavir: Kaletra) and Tacrolimus in Post Liver Transplant Patients with HIV Infection. Oral presentation at the International Liver Transplantation Society (ILTS), June 19-22, 2003 Barcelona, Spain.

10/17/2022

Bijan Egtesad, M.D.
Curriculum Vitae

- 59) **Egtesad B**, Patel K, DeVera M, Thai N, Blisard D, Soltys K, Fontes P, Cacciarelli T, Gayowski T, Marsh W, Marcos A, Fung J. Utilization of Livers from Non-heart Beating Donors – A Single Center Experience on 55 Liver Transplants over a 10-Year Period. Oral presentation at the American Transplant Conference, May 14-19, 2004, Boston, MA, USA
- 60) Jain A, Venkataramana R, **Egtesad B**, Kashyap R, Yelochin B, Marcos A, Fung J. Value of Ribavirin Concentration Measurement in Plasma/Blood in Post Liver Transplant Patients with Hepatitis C Virus Infection. Oral presentation at the International Liver Transplant Society conference, June 9-12, Kyoto, Japan.
- 61) **Egtesad B**, Patel K, DeVera M, Thai N, Blisard D, Soltys K, Fontes P, Cacciarelli T, Gayowski T, Marsh W, Marcos A, Fung J. Utilization of Livers from Non-heart Beating Donors – A Single Center Experience on 55 Liver Transplants over a 10-Year Period. Oral presentation at the International Liver Transplant Society conference, June 9-12, Kyoto, Japan.
- 62) **Egtesad B**. Non-Heart-Beating Donors Across the Transplant Continuum. Presented at: International Transplant Nurses Society; Golden Triangle Chapter. September 3, 2004, Pittsburgh, PA, USA. (Invited Speaker)
- 63) **Egtesad B**. Liver Transplantation, Past, Present, and Future. Presentation at the 4th International Iranian Association of Gastroenterology and Hepatology. December 5-7, 2004, Tehran, Iran. (Invited Speaker)
- 64) Randhawa PS, Patel S, Uhrmacher J, Pasculle W, Vats Abhay, Shapiro R, **Egtesad B**, Weck K. Comparative Analysis of JC and BK Polyomavirus Load in Solid Organ Transplant Recipients and Non-transplant Controls. Oral presentation at the American Transplant Conference, May 21-25, 2005, Seattle, WA, USA.
- 65) **Egtesad B**. The Surgeon and Human Immunodeficiency Virus. Oral presentation at the 29th Congress of the Iranian Association of Surgeons. May 14-18, 2005, Tehran, Iran. (Guest Speaker / State of the Art Lecture)
- 66) Nakagava S, Aucejo F, Parker B, Winans C, **Egtesad B**, Vogt D, Henderson JM, Miller CM, Fung JJ. Hepatic blood flow in ischemia reperfusion injury. Oral presentation at the International Liver Transplantation Society meeting, May 3-6 2006, Milan, Italy.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

67) **Egtesad B.** Liver Transplantation: what is new? Oral presentation at the 5th International Iranian Association of Gastroenterology and Hepatology. Dec 15-18 2005, Tehran, Iran. (Invited Speaker)

68) **Egtesad B.** Immunosuppression in liver transplantation. Oral presentation at the 5th International Iranian Association of Gastroenterology and Hepatology. Dec 15-18 2005, Tehran, Iran. (Invited Speaker)

69) **Egtesad B.** Liver transplantation from the Non-Heart-Beating Donors (NHBD). Oral presentation at the 5th International Iranian Association of Gastroenterology and Hepatology. Dec 15-18 2005, Tehran, Iran. (Invited Speaker)

70) Nakagava S, Auceji F, Ahmed N, Parker B, Alster J, Winans C, **Egtesad B**, Vogt D, Henderson M, Miller C, Fung J, Kelly D. Hepatic blood flow in ischemia reperfusion injury. Oral presentation at the International Liver Transplantation Society meeting, May 3-6, 2006, Milan, Italy.

71) **Egtesad B.** Post-transplant lymphoproliferative disorders (PTLD). Oral presentation at the Pediatric Gastroenterology/Hepatology Grand Rounds, Cleveland Clinic, Cleveland, OH, May 10, 2006. (Invited Speaker)

72) de Vera M, Tom K, Thai N, Fung J, **Egtesad B**, Ragni M. Impact of hepatitis C after liver transplantation in HIV and HCV co-infected patients. Oral presentation at the 2006 World Transplant Congress July 22-27, 2006, Boston, MA, USA.

73) Nakagava S, Auceji F, Ahmed N, Parker B, Alster J, Winans C, **Egtesad B**, Vogt D, Henderson M, Miller C, Fung J, Kelly D. Hepatic blood flow in ischemia reperfusion injury. Oral presentation at the 2006 World Transplant Congress July 22-27, 2006, Boston, MA, USA.

74) Popescu L, Macedo C, Hua Y, Abu-Elmagd K, Shapiro R, **Egtesad B**, Fung J, Metes D. Ex vivo generation of EBV-specific CTLs using peptide pulsed DC1 from solid organ transplant recipients results in expansion of CD8+ type-1 like regulatory (IFN-gamma and IL-10) fox P3= T cells. Oral presentation at the 2006 World Transplant Congress July 22-27, 2006, Boston, MA, USA.

75) **Egtesad B**, Yerian L, Cesario K. Hepatocellular carcinoma. Case presentation/discussion at the Viral Hepatitis Summit, Cleveland Clinic, August 24-26, 2006, Cleveland, OH, USA.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

76) **Egtesad B**, Fung JJ. Intestinal transplantation, Donor management and retrieval, recipient selection and outcome. Oral presentation Northeastern Ohio Organ Recovery Organization (LifeBanc), Cleveland, OH, September 7, 2006. (Invited Speaker)

77) **Egtesad B**. HIV and organ transplantation: Understanding the unknown. Oral presentation at the International Transplant Nurse Society (ITNS) Buckeye Chapter. Cleveland OH, Sept. 12, 2006. (Invited Speaker)

78) **Egtesad B**, Fung JJ. Solid organ transplantation from non-heart-beating donors (Donation after Cardiac Death). Oral presentation at the Northeastern Ohio Organ Recovery Organization (LifeBanc), Cleveland, OH, Sept. 19, 2006. (Invited Speaker)

79) **Egtesad B**. Solid organ transplantation from non-heart-beating donors (Donation after Cardiac Death). Oral Presentation at the UNOS Region 10 meeting, Columbus, OH, Sept 21, 2006. (Invited Speaker)

80) **Egtesad B**. Liver transplantation in HIV-positive patients. Oral presentation at the UNOS Region 7 meeting. Chicago IL, Oct. 5, 2006. (Invited Speaker)

81) **Egtesad B**. Liver transplantation from HCV-positive donors. Oral presentation at the summit on Organ Transplantation in Infected Patients. October 19-20, 2006, Varese, Italy. (Invited Speaker)

82) **Egtesad B**, Armstrong W, Fung JJ. HIV in solid organ transplantation. Cleveland Clinic, Cleveland, OH, November 8, 2006

83) **Egtesad B**. Solid organ transplantation from non-heart-beating donors (Donation after Cardiac Death). Transplant Grand Rounds, Integris Health Care System, Oklahoma City, Oklahoma, Feb 10, 2007. (Invited Speaker)

84) **Egtesad B**. Solid organ transplantation from non-heart-beating donors (Donation after Cardiac Death). Cleveland Clinic, May 30, 2007

85) **Egtesad B**. Solid organ transplantation from non-heart-beating donors (Donation after Cardiac Death). Ninth annual transplant research day, Cleveland Clinic, Cleveland, OH June 8, 2007. (Invited Speaker)

10/17/2022

Bijan Egtesad, M.D.
Curriculum Vitae

86) Kelly, D, Hussein S, Karapetian A, Coceiru A, Alster J, Corey R, **Egtesad B**, Miller C, Fung J. Basiliximab induction negates the effect of a positive T-call cross-match on acute rejection rates in liver transplant recipients. Oral presentation at the 13th annual meeting of the International Liver Transplantation Society, June 2007, Rio de Janeiro, Brazil.

87) Aucejo F, Hashimoto K, Quintini C, Hirose K, Nakagawa S, Diago T, **Egtesad B**, Kelly D, Winans C, Vogt D, Fung J, Miller C. Splenic steal syndrome: Reality or myth? A case report suggesting the role of portal hypertension. Oral presentation at the 13th annual meeting of the International Liver Transplantation Society, June 2007, Rio de Janeiro, Brazil.

88) Hashimoto K, Quintini C, Hirose K, Nakagawa S, Diago Uso T, Cocieru A, Aucejo F, **Egtesad B**, Kelly D, Winans C, Vogt D, Fung J, Miller C. High portal flow and low hepatic artery buffer response is associated with early biliary anastomotic strictures in liver transplantation. Oral presentation at the 13th annual meeting of the International Liver Transplantation Society, June 2007, Rio de Janeiro, Brazil.

89) **Egtesad B**. Solid organ transplantation from donation after cardiac death (DCD) donors. What have we learned, and what is the future? General surgery grand rounds, Department of Surgery, University of New Mexico. Albuquerque, NM, Aug 10, 2007. (Invited Speaker)

90) **Egtesad B**. Liver transplantation in children. Pediatric Liver Disease Symposium. Cleveland Clinic. Cleveland, OH Sept. 27, 2007. (Invited Speaker)

91) **Egtesad B**. Hepatopulmonary Syndrome. Transplant Rounds. Cleveland Clinic, Cleveland, OH, Oct. 16, 2007

92) **Egtesad B**. Immunosuppression in liver transplantation. Gastroenterology/Hepatology conference. Cleveland Clinic, Cleveland OH, March 17, 2008. (Invited Speaker)

93) Lopez-Solis R, **Egtesad B**, Tom K, Sharma V, Patel S, Marsh W, Fontes P, Marcos A, deVera M. Orthotopic liver transplantation with allografts from DCD donors. Oral presentation at the American Transplant Congress, May 2008, Toronto Canada.

94) Aucejo F, Kim R, Zein N, Diago T, Quintini C, Hashimoto K, Hirose K, Hanounch I, Lopez R, Kelly D, **Egtesad B**, Fung J, Miller C, Yerian L. Vacular endothelial growth factor receptor 2 (VEGFr2) expression in non-tumorous cirrhotic liver is higher when when hepatocellular carcinoma (HCC) is beyond Millan Criteria. Oral presentation at the American Transplant Congress, May 2008, Toronto, Canada.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

95) Quintini C, Kauzman L, Hashimoto K, Ding P, Diago T, Sopko N, Rosenblum J, Aucajo F, Winans C, Kelly D, **Egtesad B**, Vogt D, Fung J, Miller C. Liver transplantation in morbidly obese (BMI > 40). Oral presentation at the American Transplant Congress, May 2008, Toronto, Canada.

96) Hanouneh I, Zein N, Lopez R, Yerian L, Fung J, Egtesad B. IL-2 receptor antagonist (Basiliximab) in patients with hepatitis C after liver transplantation. Oral, plenary presentation at the Digestive Disease Week (DDW) Congress, May 2008, San Diego, USA

97) Lopez-Solis R, **Egtesad B**, Tom K, Sharma V, deVera M. DCD donor allografts for use in liver transplantation. Oral presentation at the 14th International Liver Transplantation Society congress, July 2008, Paris, France.

98) Jurcago R, **Egtesad B**, Schatz H, Thomas D, Kawczak P, Miller C, Fung J, Pidwell D, Askar M. Donor Lymphoid Chimerism Kinetics in A Successfully Treated Case of Acute Graft Versus Host Disease After Orthotopic Liver Transplantation. Oral presentation at the 34th Annual Meeting of the American Society of Histocompatibility and Immunogenetics (ASHI), Oct. 30, 2008, Toronto, Canada

99) **Egtesad B**. Use of livers from expanded criteria donors in liver transplantation. Oral presentation at the 11th Congress of the Middle East Society of Transplantation (MESOT), Nov. 2008, Shiraz, Iran (Invited Speaker)

100) **Egtesad B**. Management of patients with hepatocellular carcinoma while on the waiting list for liver transplantation. Oral presentation at the 11th Congress of the Middle East Society of Transplantation (MESOT), Nov. 2008, Shiraz, Iran (Invited Speaker)

101) Gordon CR, Siemionow M, Ciffman K, Alam D, **Egtesad B**, Bernard S, Zins J, Pryor L, Fung J, Papay F. The Cleveland clinic FACES score: A preliminary assessment tool for identifying the optimal face transplant candidate. Oral presentation at the 52nd Annual Meeting of the Ohio Valley Society of Plastic Surgeons. May 2009, Indianapolis, USA

102) **Egtesad B**. Face transplantation: A new era in facial reconstruction. Oral presentation at the International Transplant Nurse Society (ITNS), Golden Triangle Chapter. May 15, 2009, Pittsburgh, USA. (invited Speaker)

103) Hashimoto K, **Egtesad B**, Ahmad N, Gunasekaran G, Quintini C, Aucejo F, Kelly D, Winans C, Vogt D, Parker B, Irefin S, Miller C, Fung J. Use of tissue plasminogen activator in donor hepatic artery of donation after cardiac death donors: can we lower the risk of ischemic –

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

type biliary stricture after liver transplantation. Oral presentation at the 15th annual international Congress of the International Liver Transplantation Society. July 8-11, 2009, New York, USA

104) Terrault N, Barin B, Schiano TD, Poordad F, Wong M, De Vera ME, Simon D, Rosenthal L, Jayaweera D, Johnson LB, Olthoff KM, Stosor V, Sherman KE, **Eghtesad B**, Harland R, Regenstein F, Hamilton JP, Pruett TL, Roland M, Stock P. Survival and risk of severe hepatitis C virus (HCV) recurrence in liver transplant (LT) recipients coinfecting with human immunodeficiency virus (HIV) and HCV. (NIH multicenter study). Oral presentation at the 60th annual meeting of the American Association for the Study of Liver Diseases. Oct. 30-Nov. 3, 2009, Boston, USA

105) **Eghtesad B**. Interventional and surgical treatments of hepatocellular carcinoma. Presented at the Egyptian Forum of Liver Diseases (FELD) Nov. 11-13, 2009. Cairo, Egypt. (Invited speaker)

106) **Eghtesad B**. Surgical aspects of liver transplantation. Presented at the Egyptian Forum of Liver Diseases (FELD) Nov. 11-13, 2009. Cairo, Egypt. (Invited speaker)

107) **Eghtesad B**. Composite Tissue Allotransplantation: A New Frontier in Reconstructive Surgery. Presented at the International Transplant Nurse Society meeting. May 2, 2010. San Diego, CA, USA. (Invited speaker)

108) Shiba H, Hashimoto K, Kelly D, Fujiki M, Arakawa Y, **Eghtesad B**, Miller C, Fung J. Risk stratification of hepatitis C virus recurrence after liver transplantation by a new scoring system. Oral presentation at the American Transplant Congress, May 1-5, 2010, San Diego, USA

109) Askar M, Avery R, Corey R, Schold J, **Eghtesad B**, Flechner S, Klingman L, Teresi G, Pidwell D, Fung J, Srinivas T. Allosensitization is associated with increased risk of infectious complications post simultaneous liver/kidney transplantation. Oral presentation at the American Transplant Congress, May 1-5, 2010, San Diego, USA

110) Painter W, Mossad S, Siemionow M, **Eghtesad B**, Djohan R, Papay F, Avery R. First use of CMX001, a novel antiviral drug for suppression of cytomegalovirus infection in solid organ transplant patients. Oral presentation at the American Transplant Congress, May 1-5, 2010, San Diego, USA

111) Kelly D, Shiba H, Irefin S, Zhu X, **Eghtesad B**, Quintini C, Zhu X, Eghtesad B, Quintini C, Aucejo F, Vogt D, Winans C, Hashimoto K, Miller C, Fung J. Hepatic blood flow following reperfusion is an important predictor of ischemia/reperfusion injury. Oral presentation at the 16th

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

annual meeting of the International Liver Transplantation Society, June 16-19, 2010, Hong Kong, China

112) Hashimoto K, **Egtesad B**, Gunasekaran G, Fujiki M, Diago T, Quintini C, Aucejo F, Kelly D, Winans C, Vogt D, Parker B, Irefin S, Miller C, Fung J. Update report of the effect of tissue plasminogen activator in liver transplantation from donation after cardiac death donors. Oral presentation at the 16th annual meeting of the International Liver Transplantation Society, June 16-19, 2010, Hong Kong, China

113) **Egtesad B**. Surgical options in hepatocellular carcinoma. Oral presentation at the International GIT & Liver Cancer Conference, July 29-30, 2010, Cairo, Egypt (Invited Speaker)

114) **Egtesad B**. Downstaging for hepatocellular carcinoma: role in liver transplantation. Oral presentation at the International GIT & Liver Cancer Conference, July 29-30, 2010, Cairo, Egypt (Invited Speaker)

115) **Egtesad B**, Hashimoto K, Fung J. Using livers from donation after cardiac death donors – Are we getting better? Presentation at the Transplant workshop, 61st annual meeting of the American Association for the Study of Liver Disease, October 30, 2010, Boston, USA (Invited Speaker)

116) **Egtesad B**. Liver Transplantation: A long journey. Presentation at the 10th International Congress on Gastroenterology and Hepatology. November 10-12, 2010, Tehran, Iran. (Invited speaker for the opening session)

117) **Egtesad B**. Liver Transplantation for Hepatocellular Carcinoma. Presentation at the Transplant Program, Shiraz University of Medical Sciences. Nov 11, 2010, Shiraz, Iran. (Invited Speaker)

118) Modaresi J, Diago T, Fujiki M, Hodgkinson P, Hashimoto K, Quintini C, Aucejo F, Kelly D, Winans C, Vogt D, Miller C, Fung J, **Egtesad B**. Duct-to-duct biliary reconstruction in patients with primary sclerosing cholangitis undergoing liver transplantation. Presentation at the 11th annual Americas Hepato-Pancreato-Biliary Congress, Annual Scientific Session and Postgraduate Program. March 10-13, 2011 Miami Beach, USA

119) Askar M, Smith G, Schold J, Klingman L, Flechner S, **Egtesad B**, Miller Z, Fung J, Srinivas T. Positive T-cell flow crossmatch post liver transplantation is a predictor of increased risk of antibody mediated rejection of the kidney in recipients of combined liver-kidney

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

transplant: single center 15 years' experience. Oral presentation at the American Transplant Congress, April 30th – May 4th, 2011, Philadelphia, USA

120) El Gazzaz G, Ibarra R, Sanabria J, Menon N, **Egtesad B**, Hashimoto K, Quintini C, Miller C, Fung J, Aucejo F. Radiologic-histological correlation of hepatocellular carcinoma (HCC) treated via pre-liver transplant locoregional therapy. Oral presentation at the American Transplant Congress, April 30th – May 4th, 2011, Philadelphia, USA

121) Brown C, Quintini C, Diago T, Hashimoto K, Aucejo F, **Egtesad B**, Kelly D, Fung J, Miller C. Intraoperative flow measurements facilitate the detection of celiac axis stenosis in patients undergoing orthotopic liver transplantation. Oral presentation at the American Transplant Congress, April 30th – May 4th, 2011, Philadelphia, USA

122) Modaresi J, Diago T, Fujiki M, Hodgkinson P, Hashimoto K, Aucejo F, Kelly D, Quintini C, Winans C, Vogt D, Zein N, Miller C, Fung J, **Egtesad B**. Duct-to-duct biliary reconstruction in patients with primary sclerosing cholangitis undergoing liver transplantation. Oral presentation at the American Transplant Congress, April 30th – May 4th, 2011, Philadelphia, USA

123) Askar M, Fung J, Miller C, **Egtesad B**, Zein N, Schold J. The impact of positive T-cell crossmatch on liver transplant recipient outcomes. Oral presentation at the American Transplant Congress, April 30th – May 4th, 2011, Philadelphia, USA

124) **Egtesad B**, Yerian L. Rejection vs. Hepatitis C. Oral presentation at the 10th Congress of the Iranian Society of Transplantation IRSOT, May 17-19, 2011, Shiraz, Iran (Invited speakers)

125) **Egtesad B**. Management of organ donors in the ICU before organ recovery. Oral presentation at the 10th Congress of the Iranian Society of Transplantation IRSOT, May 17-19, 2011, Shiraz, Iran (Invited speaker)

126) **Egtesad B**. Intestinal transplantation. Oral presentation at the 10th Congress of the Iranian Society of Transplantation IRSOT, May 17-19, 2011, Shiraz, Iran (Invited speaker)

127) **Egtesad B**. How to start a new liver transplant program? "Liver Transplant Worldwide". Oral presentation at the 10th Congress of the Iranian Society of Transplantation IRSOT, May 17-19, 2011, Shiraz, Iran (Invited speaker)

128) **Egtesad B**, Forrest K, Fujiki M, Diago T, Hodgkinson P, Hashimoto K, Quintini C, Aucejo F, Kelly D, Winans C, Vogt D, Miller C, Fung J. A pilot randomized controlled clinical trial of Thymoglobulin (r-ATG) induction with extended delay of calcineurin inhibitor therapy in
10/17/2022

Bijan Egtesad, M.D.
Curriculum Vitae

liver transplantation. Oral presentation at the International Liver Transplantation Society, June 22-25, 2011, Valencia, Spain

129) Miller C, D'Amico G, Brown C, Diago T, Hashimoto K, Aucejo F, **Egtesad B**, Kelly D, Fung J, Quintini C. Splenic artery embolization for the treatment of refractory ascites after liver transplantation. Oral presentation at the International Liver Transplantation Society, June 22-25, 2011, Valencia, Spain

130) **Egtesad B**. Surgical perspectives of liver transplantation. Gastroenterology/Hepatology conference. Cleveland Clinic. Aug 10, 2011

131) **Egtesad B**. Immunosuppression management in liver transplantation. Oral presentation at the 11th Iranian Congress of Gastroenterology and Hepatology. October 5-7, 2011, Tabriz, Iran (Invited speaker)

132) **Egtesad B**. Ethics in organ transplantation. Oral presentation at the 11th Iranian Congress of Gastroenterology and Hepatology. October 5-7, 2011, Tabriz, Iran (Invited speaker)

133) **Egtesad B**. Graft vs. Host Disease in liver transplantation. Transplant rounds. Cleveland Clinic. Nov. 1st, 2011

134) Fung J, Bollinger J, Miller C, **Egtesad B**. Future prospects in immunosuppression for liver transplantation. Oral presentation at the ILTS Transplant Course. AASLD, Nov. 4, 2011, San Francisco, USA

135) **Egtesad B**, Askar M, Bollinger K, Hashimoto K, Kelly D, Aucejo C, Quintini C, Avery R, Miller C, Fung J. Graft-Versus-Host disease (GVHD) following liver transplantation: Comparison of two eras. Liver. Oral presentation at the International Liver Transplantation Society, 17th Annual International Congress, May 16-19, 2012, San Francisco, USA

136) Kelly D, Bennett R, Vass K, McCoy J, Kerepesi K, Waby A, **Egtesad B**, Hashimoto K, Aucejo F, Quintini C, Miller C, Fung J. Liver transplantation in a new era: Improving quality of care and reducing length of stay. Oral presentation at the International Liver Transplantation Society, 17th Annual International Congress, May 16-19, 2012, San Francisco, USA

137) Hashimoto K, Quintini C, Aucejo F, Fujiki M, Diago T, Watson M, Kelly D, Winans C, **Egtesad B**, Fung J, Miller C. Split liver transplantation using hemiliver grafts: A single US

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

center experience in the MELD era. Oral presentation at the International Liver Transplantation Society, 17th Annual International Congress, May 16-19, 2012, San Francisco, USA

138) **Eghtesad B**, Askar M, Bollinger K, Hashimoto K, Kelly D, Aucejo C, Quintini C, Mossad S, Miller C, Fung J. Graft-Versus-Host disease (GVHD) following liver transplantation: Comparison of two eras. Oral presentation at the American Transplant Congress, June 2-6, 2012, Boston, USA

139) **Eghtesad B**. Disease recurrence after liver transplantation. Oral presentation at the 12th Iranian Congress of Gastroenterology and Hepatology (ICGH-2012), November 27-30, 2012, Tehran, Iran (Invited speaker)

140) **Eghtesad B**, Fung J, Yerian L. Recurrent Hepatitis C after Liver Transplantation. 13th Congress of the Middle east Society of Organ Transplantation. December 12-15, 2012, Abu Dhabi, UAE (Invited speaker)

141) **Eghtesad B**. New advances in immunosuppression in liver transplantation. 2nd Congress on Hepatobiliary Surgery and Liver Transplantation. October 9-10, 2013, Tehran, Iran. (Invited speaker)

142) **Eghtesad B**. Immunosuppression in transplantation of the liver. Iranian Congress of Gastroenterology and Hepatology (Postgraduate Course). November 26, 2013, Tehran, Iran (Invited speaker).

143) Dugum M, Zein N, Lopez R, Romero-Morrero C, Aucejo F, **Eghtesad B**, Confer B, Hanouneh I. Achieving equity among patients with and without hepatocellular carcinoma (HCC) who are listed for liver transplantation: A scoring system utilizing MELD and Alpha fetoprotein(AFP). Oral presentation at the American Association for the Study of Liver Disease, November 6-11, 2014, Boston, USA

144) **Eghtesad B**. Futility for liver transplantation and liver resection: When is enough enough? Oral presentation at the Transplant Surgery Workshop. American Association for the Study of Liver Disease, November 6-11, Boston, USA (Invited Speaker)

145) El-Gazza G, Schold J, Nazzal M, Kawamura N, Spaggiari M, Hashimoto K, Quintini C, Aucejo F, Kelly D, Fujiki M, Wians C, Diago T, Miller C, Fung J, **Eghtesad B**. Liver transplantation using pediatric organ donation after circulatory death- An analysis of the national registry. Oral presentation at the World Transplant Congress. July 26-31, 2014, San Francisco, USA

10/17/2022

Bijan Egtesad, M.D.
Curriculum Vitae

146) **Egtesad B.** Optimal use of organs recovered from donation after cardiac death donors. Ohio Solid Organ Transplant Consortium Annual Meeting. September 19, 2014

147) **Egtesad B.** Treatment of hepatitis C in the era of DAAs – Perspectives in liver transplantation. “Hepatology State of the Art Lecture”. Presented at the 6th Tehran Hepatitis Congress (THC6), May 27-29, 2015, Tehran, Iran (Invited Speaker).

148) **Egtesad B.** Treatment of hepatitis C recurrence after liver transplantation – indications and outcomes. Presented at the 6th Tehran Hepatitis Congress (THC6), May 30, 2015, Shiraz, Iran (Invited Speaker)

149) **Egtesad B.** Approach to portal vein thrombosis in liver transplantation. Presented at the 3rd Hepato-pancreato-biliary and Liver Transplantation Congress November 4-6, 2015, Tehran, Iran (Invited Speaker)

150) **Egtesad B.** Futility in Liver Transplantation. Presented at the 3rd Hepato-pancreato-biliary and Liver Transplantation Congress November 4-6, 2015, Tehran, Iran (Invited Speaker)

151) **Egtesad B.** Liver transplantation for metastatic colorectal cancer. Presented at AHPBA Annual Meeting March 29 – April 2, 2017. Miami, USA. (Invited Speaker)

152) **Egtesad B.** Use of DCD donors in expansion of donor pool. Presented at the 3rd International Congress of organ Transplantation, May 16-19, 2017, Shiraz, Iran (Invited speaker)

153) **Bijan Egtesad.** Disease recurrence after liver transplantation. Lecture Series in Transplantation. Cleveland Clinic, July 6, 2017

154) **Bijan Egtesad.** Expanded criteria donors. Lecture Series in Transplantation. Cleveland Clinic, August 31, 2017

155) **Egtesad B.** Expanded criteria donors in the era of organ shortage. Is there a role in possible expansion of Iranian donor pool for liver transplantation? Presented at 7th International Tehran Hepatitis Conference (THC7), September 6-8, 2017, Tehran, Iran (Invited Speaker)

156) **Egtesad B.** Liver transplantation for hepatocellular carcinoma – New look. Presented at International Hepatitis Conference (THC7) September 10, Birjand, Iran (Invited Speaker)

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

157) **Eghtesad, B.** Immunosuppression and future therapies in liver transplantation. Presented at Fourth International Tehra Hepato-Pancreato-Biliary and Liver Transplantation Congress, October 31 – November 3, 2017, Tehran, Iran (Invited Speaker)

158) **Eghtesad B.** Expanded Criteria Donors in Liver Transplantation. Presented at Fourth International Tehra Hepato-Pancreato-Biliary and Liver Transplantation Congress, October 31 – November 3, 2017, Tehran, Iran (Invited Speaker)

159) **Eghtesad B.** Liver transplantation for hepatic metastasis from colon cancer. Presented at Fourth International Tehran Hepato-Pancreato-Biliary and Liver Transplantation Congress, October 31 – November 3, 2017, Tehran, Iran (Invited Speaker)

160) **Eghtesad B.** Immunosuppressive therapy in transplantation. Ohio Association of Physician Assistants. April 13-14 2018, Cleveland, Ohio (Invited Speaker)

161) **Eghtesad B.** Medical/Surgical optimization of the liver transplant candidates in the ICU: “The Window Period”. Respiratory Institute Education day, Cleveland Clinic. Nov. 14, 2018, Cleveland, Ohio

162) **Eghtesad B.** Pushing the envelope: Innovation in medical oncology. LDLT Vs. Deceased donors in colorectal liver metastases and intrahepatic Cholangiocarcinoma. AASLD/ILTS Transplant Course. American Association for the Study of Liver Diseases, The Liver Meeting, November 9-13, 2018, SanFrancisco, USA (Invited Speaker)

163) **Eghtesad B.** Immunosuppression:Past and Future. Presentation at the 7th Annual James Ted Engle Pediatric Liver Transplant Lectureship Series. Oct. 21, 2020. Cleveland Ohio (Invited Speaker).

Poster Presentations:

1) Ukah FO, Merhav H, Kramer D, **Eghtesad B**, Samimi F, Ferezza E, Linden P, Mieles L, Selby R Early Outcome of Liver Transplantation in Patients with a History of Spontaneous Bacterial Peritonitis. Poster presentation 16th International Congress of the Transplantation Society, Paris, France, August 16-21, 1992.

2) Bronsther O, Ersoz S, Tugcu M, **Eghtesad B**, Gurakar A, Van Thiel DH. The Incidence and Timing of Recurrent Hepatitis B Virus in Primary Orthotopic Liver Transplant Recipients

10/17/2022

Bijan Eghtesad, M.D.

Curriculum Vitae

Treated with FK-506. Poster presentation at the American Society of Transplant Physicians, Houston, Texas, May 17-19, 1993. Abstract published in the Proceeding of A.S.T.P.

3) Samimi F, Fung JJ, Irish W, **Egtesad B**, Demetris J, Bronsther O, Selby R, Tzakis A, Starzl TE. Role of Splenectomy in Orthotopic Liver Transplantation. Poster presentation at the 6th Congress of the European Society of Organ Transplantation, Rodos, Greece, October 25-28, 1993.

4) Bronsther O, CasavillaA, **Egtesad B**, Irish W, Van Thiel DH, Starzl TE. Changing Concepts About Whom and When Orthotopic Liver Transplant Should be Offered. Poster presentation at the American Association for the Study of Liver Disease, Chicago, Illinois, November 4-7, 1993.

5) **Egtesad B**, Scotti C, Irish W, Todo S, Samimi F, Aldrighetti L, Malek-Hosseini A, Rakela J, Starzl TE, Fung JJ. Liver Transplantation for Hepatitis B Surface Antigen Positive(HBsAg+) Chronic Liver Disease Under FK-506 (Tacrolimus). Poster presentation at the American Association for the Study of Liver Disease. Chicago, Illinois, November 11-15, 1994. (Abstract published in Hepatology 20: No. 4, Pt. 2, Abstract 135)

6) Morris SC, **Egtesad B**, Ramos H, Wheeler DE, Gibel LJ, Smith AY, Harford AM, Malhotra D. Hemolytic Uremic Syndrome (HUS), in a Renal Transplant Recipient. Poster Presentation at the American College of Physicians, New Mexico Chapter Meeting, Albuquerque, New Mexico. November 1995.

7) Hays WS, Glew RH, **Egtesad B**, Johnston DH. Cytosolic B-glucosidase as a marker of hepatocyte injury. Poster presentation at the American Association for the Study of Liver Disease. Chicago, Illinois, November 8-12, 1996.

8) Morris S, Chittajallu R, **Egtesad B**, Camacho K, Wheeler D, Coan S, Ramos H. Liver Transplantation in New Mexico. Poster Presentation at the American College of Physician. The New Mexico Chapter Meeting. Albuquerque, New Mexico, Dec. 5-6, 1996.

9) Gibel LJ, **Egtesad B**, Smith AY, Malhotra D, Haq M, Harford AM. Single Kidney Transplants from Donors with Low Estimated Creatinine Clearance. Poster presentation at the International Transplant Congress; Society for Organ Sharing. Washington, D.C. July 8-13, 1997.

10) **Egtesad B**, Harford AM, Gibel LJ, Ramos HC, Smith AY, Haq M, Demarest P, Malhotra D. Use of Tacrolimus as the Primary Immunosuppression After Renal Transplant in Native Americans and Hispanics. Poster presentation at the International Congress on Immunosuppression, Orlando, Florida, Dec. 11-13 1997.

10/17/2022

Bijan Eghtesad, M.D.

Curriculum Vitae

- 11) Mazariegos GV, **Eghtesad B**, Ashrafi M, Arzate J, Osorio G, Reyes J. Incidence, Management and Outcome of Serious Pancreatitis Following Pediatric Liver Transplantation. Poster Presentation at the Third International Congress on Pediatric Transplantation. July 8-10, 1998, Boston, MA.

- 12) **Eghtesad B**, Mazariegos GV, Geraci L, Cacciarelli T, Reyes J. Liver Transplantation in Pediatric Patients for Wilson Disease. Poster presentation at the Third International Congress on Pediatric Transplantation, July 8-10, 1998, Boston, MA.

- 13) Kieran J, Coan S, Rossaro L, Hecker W, **Eghtesad B**. Pattern of Referral for Liver Transplantation in New Mexico. Poster presentation at the American College of Physicians, New Mexico Chapter Meeting. Nov. 18, 1999, Albuquerque, NM.

- 14) **Eghtesad B**, Varghese E, Brand J, Hecker W, Narva A, Gibel L Malhotra D, Harford A. Increased Incidence of Post-transplant Diabetes in Pediatric Native American Kidney Transplant Recipients on Tacrolimus. Poster presentation at the 19th workshop of the study group on Artificial Delivery System, Pancreas and Islet Transplantation (AIDSPIT) of the European Association for the Study of Diabetes (EASD), Jan 23-25, 2000, Igls, Austria.

- 15) Jain AB, Kashyap R, Dodson F, Hamad I, **Eghtesad B**, Fung JJ. Prospective Randomized Trial of Tacrolimus and Steroid vs. Tacrolimus, Steroid and Mycophenolate Mofetil in Primary Liver Transplantation. Poster presentation in Festschrift Symposium in Honor of Thomas E Starzl, April 27-28 2001, Pittsburgh, PA.

- 16) Jain AB, Reyes J, Kashyap R, Mazariegos G, **Eghtesad B**, Fung JJ. Tacrolimus Offers Virtual Freedom from Chronic Rejection after Primary Liver Transplantation (LTX) in Children and Adults in Long-Term Follow-up. Poster presentation at Festschrift Symposium in Honor of Thomas E Starzl, April 27-28 2001, Pittsburgh, PA.

- 17) Jain A, Kashyap R, **Eghtesad B**, Costa G, Fung JJ. Question of Steroid Withdrawal under Tacrolimus for Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) after Liver Transplantation and Long-term Survival. Poster presentation. International Liver transplantation Society Meeting July 11-13, 2001, ELTA Licage Berlin, Germany.

- 18) Jain A, Kashyap R, **Eghtesad B**, Khan A, Obiad S, Fung JJ. Need for Ribavirin Dose Adjustment in Relation to Renal Function for Treatment of Recurrent HCV Infection in Post Liver Transplant Patients. Poster Presentation. International Liver transplantation Society meeting July 11-13, 2001, ELTA Licage Berlin, Germany.

- 19) Jain A, Kashyap R, Hamad I, **Eghtesad B**, Potdar S, Khan A, Fung JJ. Prospective

10/17/2022

Bijan Eghtesad, M.D.

Curriculum Vitae

Randomized Trial of Tacrolimus and Steroid vs Tacrolimus, Steroid and Mycophenolate Mofetil in Primary Liver Transplantation. Accepted as poster presentation 10th European Society of Transplantation Congress (ESOT), October 6-11, 2001, Lisboa, Portugal.

20) Jain A, Kashyap R, **Egtesad B**, Obaid S, Venkataramanan R, Khan A, Fung JJ. Ribavirin Dose Adjustment in Relation to Renal Function is Mandatory for Treatment of Recurrent HCV Infection in Post Liver Transplant Patients. Accepted as poster. 52nd Annual Meeting and Postgraduate Course, American Association for the Study of Liver Disease (AASLD), November 9-13, 2001, Dallas, TX, USA.

21) Jain A, Kashyap R, **Egtesad B**, Fridell J, Fung J. Question of Steroid Withdrawal Under Tacrolimus for Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis after Liver Transplantation and Long-term Survival. Poster presentation. The 2nd International Congress on Immunosuppression. December 6-8, 2001, San Diego, California, USA.

22) **Egtesad B**, Kapoor V, Peterson M, Geller D, Cacciarelli T, Marsh W, Reyes J, Fung JJ. Correlation between Mangafodipir-Trisodium-Enhanced MR and Intraoperative Cholangiography in Assessment of the Donor Biliary Anatomy in Adult-to-Adult Live Donor Liver Transplantation. Accepted as poster presentation at the American Transplant Congress, April 26-May 1, 2002, Washington D.C. USA.

23) **Egtesad B**, Daly I, Broznick BA, Geller DA, Cacciarelli TV, Fontes P, Bonham CA, Dodson SF, Jain AK, Marsh WJ, Fung JJ. Utilization of Livers from Non-heart-beating Donors – A Single Center Experience. Accepted for poster presentation at the XIX International Congress of Transplantation Society, August 18-23, 2002, Miami, FL, USA.

24) **Egtesad B**, Fung JJ, Reyes J, Cacciarelli TV, Fontes P, Jain AK, Marsh WJ, Demetris AJ, Murase N, Mazariegos GV, Gayowski T, Abu-Elmagd K, Starzl TE. Liver Transplantation under a Tolerogenic Regimen of Preconditioning with Thymoglobulin and Post-transplant Tacrolimus. Accepted for poster presentation at the XIX International Congress of Transplantation Society, August 18-23, 2002, Miami, FL, USA

25) Jain AK, Scantlebury V, Shapiro R, **Egtesad B**, Pokharna R, Reyes J, Podtar S, Flohr J, Fung J. Pregnancy Post Liver, Kidney, and Kidney + Pancreas Transplant under Tacrolimus. Accepted for poster presentation at the XIX International Congress of Transplantation Society, August 18-23, 2002, Miami, FL, USA.

26) Planinsic RM, Hilmi I, Aggarwal S, **Egtesad B**, Fung JJ. Timing of Epidural Catheter Removal in Living Related Liver Donors. Accepted for poster presentation at the International Liver Transplantation Meeting, June 13-15, 2002, Chicago, IL, USA.

10/17/2022

Bijan Eghtesad, M.D.

Curriculum Vitae

27) Cacciarelli, TV, Jain AK, **Egtesad B**, Planinsic Raymond, Kormos R, Fung JJ. Simultaneous Heart-Liver Transplantation: A Worthwhile Effort? Poster presentation at the 53rd annual meeting of the American Association for the Study of Liver Disease. Nov. 1-5, 2002, Boston, MA, USA.

28) **Egtesad B**, Daly I, Broznick BA, Geller DA, Cacciarelli TV, Fontes P, Bonham CA, Dodson SF, Jain AK, Marsh WJ, Fung JJ. Utilization of Livers from Non-heart-beating Donors – A Single Center Experience. Poster presentation at the XIX International Congress of the Transplantation Society, August 25-30, 2002, Miami FL, USA.

29) Jain AK, Scantlebury V, Shapiro R, **Egtesad B**, Pokharna R, Reyes J, Potdar S, Flohr J, Fung J. Pregnancy post Liver, Kidney and Kidney + Pancreas Transplant under Tacrolimus. Poster presentation at the XIX International Congress of the Transplantation Society. Miami, FL, August 25-30, 2002.

30) Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Cacciarelli T, **Egtesad B**, Fung J. The Incidence of Post-Transplant Lymphoproliferative Disorder (PTLD) in Children and Adults Under Tacrolimus: 2000 Consecutive Liver Transplant Patients. Poster presentation at the American Society of Transplant Surgeons (winter meeting), Jan 24-26, 2003, Miami FL, USA.

31) Cacciarelli T, Vesta F, **Egtesad B**, Fung J. Disease Recurrence and Long-Term outcome of Patients Undergoing Liver Transplantation for Budd-Chiari Syndrome. Poster presentation at the American Transplant Congress. May 30-June 4, 2003, Washington D.C., USA

32) **Egtesad B**, Marcos A, Flynn B, Fontes P, Cacciarelli T, Marsh W, DeVera M, Shakil O, Murase N, Demetris A, Fung J, Starzl T. Liver Transplantation under a Tolerogenic Regimen of Preconditioning with Alemtuzumab and Post-Transplant Tacrolimus. Poster presentation at the 54th annual meeting of the American Association for the Study of Liver Disease, Oct. 24-28, 2003, Boston MA, USA

33) Aggarwal S, Nicolau R, Planinsic R, Boucek C, Hilmi I, Ghalasani A, Soaita A, **Egtesad B**. HTK Vs UW Preservative Solution: Hemodynamic and Metabolic Changes during Orthotopic Liver Transplantation. Poster presentation at the International Anesthesia Research Society. March 22-26, 2003, New Orleans LA, USA

34)) Aggarwal S, Nicolau R, Planinsic R, Boucek C, Hilmi I, Soaita A, **Egtesad B**. HTK Vs UW Preservative Solution: Hemodynamic and Metabolic Changes during Orthotopic Liver Transplantation (Part II). Poster presentation at the International Anesthesia Research Society. March 27-31, 2004, Tampa, FL, USA

10/17/2022

Bijan Eghtesad, M.D.

Curriculum Vitae

35) Jain AK, Nalesnik MA, Reyes J, Pokharna R, Mazariegos GV, Cacciarelli T, Marsh W, Fontes P, DeVera M, Marcos A, **Egtesad B**, Fung JJ. Post-transplant Lymphoproliferative Disorder (PTLD) in Children and Adults under Tacrolimus: 2000 consecutive Liver Transplant Patients, 12 Years Experience. Poster presentation at the International Liver Transplantation Society (ILTS), June 19-21, 2003, Barcelona, Spain.

36) Jain AK, Venkataramanan R, Gadowski M, **Egtesad B**, Marcos A, Fung JJ. Use of Mycophenolate Mofetil (MMF) for Tacrolimus-Related Chronic Nephrotoxicity in Post Liver Transplantation (LTD) Patients: Long-term Prospective Trial with Minimum Six Years Follow-up. . Poster presentation at the International Liver Transplantation Society (ILTS), June 19-21, 2003, Barcelona, Spain.

37) Kelly D, Demetris J, **Egtesad B**, Marsh W, Patel K, Novelli P, Planinsic R, Fung J, Marcos A. The Pathologic End of the Spectrum of Small-for-Size Graft Syndrome in Adult Living Donor Liver Transplantation. Poster presentation at the American Transplant Congress, May, 15-19, 2004, Boston , Massachusetts, USA.

38) **Egtesad B**, Mayher D, Guggenheimer J. A Survey of Dental Care Protocols Among U.S. Organ Transplant Centers. Poster presentation at the American Transplant Congress, May, 15-19, 2004, Boston, Massachusetts, USA.

39) Jain A, Venkataramana R, **Egtesad B**, Shakil O, Kashyap R, Marcos A, Fung J. Prevalence of Ribavirin Concentration in Plasma/Blood in Post Liver Transplant Patients Infected with Hepatitis C. Poster presentation at the American Transplant Congress, May, 15-19, 2004, Boston, MA, USA.

40) Murase N, Metes D, Zeevi A, Bentlejewski C, Guaspari D, Macedo C, Farren A, McGregor P, **Egtesad B**, Fontes P, Marcos A, Woodward J, Demetris A, Fung J, Starzl T. Immunomonitoring of Liver Recipients Treated with Tolerance-Enhancing Regimen of Immunosuppression. Poster presentation at the American Transplant Congress, May, 15-19, 2004, Boston, MA, USA.

41) Kwak E, Husain S, Paterson D, Fontes P, Cacciarelli T, Marcos A, Fung J, **Egtesad B**. Efficacy of CMV Antigenemia Directed Preemptive Therapy with Ganciclovir at One Year in Liver Transplant Recipients Pretreated with Thymoglobulin or Alemtuzumab. Poster presentation at the American Transplant Congress, May, 15-19, 2004, Boston, MA, USA.

42) Vasta F, Fung J, **Egtesad B**, Blisard D, Demetris A, Cacciarelli T. Short- and Long-term Outcome of Orthotopic Liver Transplantation Using Hepatitis C Virus-Infected Allografts. Poster presentation at the American Transplant Congress, May, 15-19, 2004, Boston, MA, USA.

10/17/2022

Bijan Eghtesad, M.D.

Curriculum Vitae

43) Jain A, Reyes J, Kashyap R, Marcos A, Mazariegos G, **Eghtesad B**, Fontes P, Cacciarelli T, Marsh W, deVera M, Fung J. Early and Late, Surgical/Non-surgical, Immunological/Non-immunological Complications after Liver Transplantation and its Impact on Graft and Patient Survival in Adults and Children: An Analysis of 1000 Consecutive Patients with more than 10 Years Mean Follow-up Poster presentation at the 10th International Liver Transplantation Society (ILTS), June 9-12, 2004, Kyoto, Japan.

44) deVera M, Patel K, Fontes P, Marsh W, **Eghtesad B**, Marcos A, Fung J. Long-Term Impact of Steatotic Donor Livers on Patient and Allograft Survival. Poster presentation at the 10th International Liver Transplantation Society (ILTS), June 9-12, 2004, Kyoto, Japan.

45) deVera M, Patel K, Fontes P, Marsh W, **Eghtesad B**, Marcos A, Fung J. Liver Transplantation for Methotrexate-Induced Cirrhosis. Poster presentation at the 10th International Liver Transplantation Society (ILTS), June 9-12, 2004, Kyoto, Japan.

46) **Eghtesad B**, Marcos, A, Fung J, Fontes P, Ton K, DeVera M, Marsh W, Gayowski T, Shakil O, Demetris A, Murase N, Starzl T. The Use of Alemtuzumab Induction and Tacrolimus Monotherapy in Liver Transplantation. Poster presentation at the 55th Annual meeting of the American Association for the Study of Liver Disease, Oct 29-Nov 2, 2004, Boston, MA, USA.

47) Shakil O, Shahid H, Berk B, **Eghtesad B**, Marcos A, Fung J. A Trial of Pegylated Interferon and Ribavirin among Liver Transplant recipients with Hepatitis C: Reasons for Screening Failure and Low Enrollment. . Poster presentation at the 55th Annual meeting of the American Association for the Study of Liver Disease, Oct 29-Nov 2, 2004, Boston, MA, USA.

48) Murase N, Metes D, Zeevi A, Bentejewski C, Guaspari D, Van Dyke A, McGregor P, **Eghtesad B**, Shapiro R, Fontes P, Marcos A, Woodward J, Demetris AJ, Starzl TE. Immunomonitoring in Allograft Recipients Treated with Depleting Antibodies. Poster presentation at the America Transplant Congress, May 21-25, 2005, Seattle, WA, USA.

49) DeVera ME, **Eghtesad B**, Tom K, Lignoski P, Fontes P, Marsh W, Marcos A. Liver Transplantation of HBcAb-positive and HCV-positive Allografts. . Poster presentation at the America Transplant Congress, May 21-25, 2005, Seattle, WA, USA.

50) Nakagava S, Kelly D, Aucejo FN, Parker B, **Eghtesad B**, Winans C, Vogt D, Henderson JM, Fung JJ, Miller CM. Liver transplantation for extended criteria recipient. Poster presentation at the International Liver Transplantation Society meeting, May 3-6, 2006, Milan, Italy.

51) Rohaninejad M, **Eghtesad B**, Tom K, Kadry Z, Morshedi M, Gruttadauri ,Marsh W, Fung J, Gridelli B, Marcos A. Biliary duct complications in right lobe living donor liver transplantation. Poster presentation at the 2006 World Transplant Congress July 22-27, 2006, Boston, MA, USA.

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

52) Kelly DM, Hussain S, Karapetian A, Cocieru A, Alster J, Corry R, **Eghtesad B**, Vogt D, Winans C, Cooke D, Miller C, Fung JJ. Basiliximab induction negates effect of a positive T-cell cross-match on acute rejection rates in liver transplant recipients receiving tacrolimus based immunosuppression. Poster presentation at the 57th Annual Meeting of the American Association for the Study of Liver Disease (AASLD), October 27-31, Boston MA, USA.

53) Avery R, Corey R, Long J, Hall G, Gordon S, Schmitt S, Mossad S, Mawhorter S, Fung J, Miller C, Fraser T, Fatica C, Johnson L, **Eghtesad B**. Persistence of VRE infection in liver transplant recipients treated with Daptomycin. Poster presentation at the annual meeting of the American Transplant Congress, May 2007, San Francisco, USA.

54) Corey R, Schmitt S, **Eghtesad B**, Miller C, Gordon S, Fatica C, Fraser T, Mawhorter S, Mossad S, Winans C, Vogt D, Aucejo F, Johnson L, Fung J, Avery R. Infections in liver transplant recipients undergoing in-hospital re-transplantation and/or pre-transplant hospitalization. Poster presentation at the annual meeting of the American Transplant Congress, May 2007, San Francisco, USA.

55) Aucejo F, Nakagawa S, Quintini C, Hashimoto K, Hirose K, **Eghtesad B**, Vogt D, Winans C, Kelly D, Fung F, Miller C. Triple-phase computer tomography (CT) and intra-operative flow measurements (IFM) are essential in the management of porto-systemic shunts during liver transplantation. Poster presentation at the annual meeting of the American Transplant Congress, May 2007, San Francisco, USA.

56) Hirose K, Aucejo F, Hashimoto K, Quintini C, Nakagawa S, Corey R, Bescath K, **Eghtesad B**, Kelly D, Fung J, Miller C. Very low values of Cylex immune cell function assay is associated with early post-operative death following liver transplantation. Poster presentation at the annual meeting of the American Transplant Congress, May 2007, San Francisco, USA.

57) Hirose K, Aucejo F, Quintini C, Hashimoto K, Nakagawa S, Bennett R, Winans C, **Eghtesad B**, Vogt D, Fung J, Miller C. Outcomes of liver transplantation for hepatocellular carcinoma under the MELD allocation system. Poster presentation at the 13th annual meeting of the International Liver Transplantation Society, June 2007, Rio de Janeiro, Brazil.

58) Nakagawa S, Ahmed N, Aucejo F, **Eghtesad B**, Kelly D, Fung J, Miller C. Diagnosis and management of post-transplant portal vein stenosis. Poster presentation at the 13th annual meeting of the International Liver Transplantation Society, June 2007, Rio de Janeiro, Brazil.

59) Hirose K, Aucejo F, Hashimoto K, Quintini C, Nakagawa S, Corey R, Bescath K, **Eghtesad B**, Kelly D, Fung J, Miller C. Very low values of Cylex immune cell function assay is associated

10/17/2022

Bijan Eghtesad, M.D.

Curriculum Vitae

with early post-operative death following liver transplantation. Poster presentation at the 13th annual meeting of the International Liver Transplantation Society, June 2007, Rio de Janeiro, Brazil.

60) Quintini C, Cocieru A, Aucejo F, Hirose K, Hashimoto K, Nakagawa S, Diego Uso T, **Egtesad B**, Winans C, Vogt D, Kelly D, Fung J, Miller C. Alcoholic cirrhosis as a risk factor for development of biliary complications in liver transplantation. Poster presentation at the 13th annual meeting of the International Liver Transplantation Society, June 2007, Rio de Janeiro, Brazil.

61) Aucejo F, Nakagawa S, Hashimoto K, Hirose K, Quintini C, Kelly D, **Egtesad B**, Fung J, Miller C. Computed tomography (CT) and intraoperative flow measurements (IFM) in the management of portosystemic shunts during liver transplantation. Poster presentation at the 13th annual meeting of the International Liver Transplantation Society, June 2007, Rio de Janeiro, Brazil.

62) Avery R, Corey R, Long J, Hall G, Gordon S, Schmitt S, Mossad S, Mawhorter S, Fung J, Miller C, Fraser T, Johnson L, **Egtesad B**. Persistence of VRE infection in liver transplant recipients treated with Daptomycin. Poster presentation at the 13th annual meeting of the International Liver Transplantation Society, June 2007, Rio de Janeiro, Brazil.

63) Quintini C, Aucejo F, Hashimoto K, Hirose K, Diago Uso T, Nakagawa S, Sopko N, Rosenblum J, **Egtesad B**, Kelly D, Winans C, Vogt D, Fung J, Miller C. Outcomes of liver transplantation in the morbidly obese. Poster presentation at the 13th annual meeting of the International Liver Transplantation Society, June 2007, Rio de Janeiro, Brazil.

64) Corey R, Schmitt S, **Egtesad B**, Miller C, Gordon S, Fatica C, Fraser T, Mawhorter S, Mossad S, Winans C, Vogt D, Aucejo F, Johnson L, Fung J, Avery R. Infections in liver transplant recipients undergoing in-hospital re-transplantation and /or with re-transplant hospitalization. Poster presentation at the 13th annual meeting of the International Liver Transplantation Society, June 2007, Rio de Janeiro, Brazil.

65) Askar M, Avery R, Corey R, Dawn T, Pidwell D, Zein N, **Egtesad B**, Fung J, Miller C. The association between immunoglobulin-like receptor “B” haplotype and post-transplant infections among liver transplant recipients. Poster presentation at the American Transplant Congress, May 2008, Toronto, Canada.

66) Askar M, Corey R, Avery R, Dawn T, Pidwell D, **Egtesad B**, Miller C, Fung J, Zein N. Lack of killer immunoglobulin-like receptor KIR2DS2 and possibly other genes within the “B” haplotype predict poor response to antiviral therapy in liver transplant recipients with recurrent HCV infection. Poster presentation at the American Transplant Congress, May 2008, Toronto, Canada.

10/17/2022

Bijan Egtesad, M.D.
Curriculum Vitae

- 67) Hashimoto K, Hirose K, Diago T, Aucejo F, Quintini C, Ding P, Corey R, **Egtesad B**, Kelly D, Fung J, Miller C. Impact of Cylex immune cell function assay in predicting acute cellular rejection and recurrence of HCV in liver transplantation. Poster presentation at the American Transplant Congress, May 2008, Toronto, Canada.
- 68) Quintini C, Kauzman L, Hashimoto K, Ding P, Diago T, Sopko N, Rosenblum J, Aucajo F, Winans C, Kelly D, **Egtesad B**, Vogt D, Fung J, Miller C. Liver transplantation in morbidly obese (BMI > 40). Poster presentation at the 14th International Liver Transplantation Society Congress, July 2008, Paris, France.
- 69) Aucejo F, Kim R, Zein N, Diago T, Quintini C, Hashimoto K, Hirose K, Hanouneh I, Lopez R, Kelly D, **Egtesad B**, Fung J, Miller C, Yerian L. Vascular endothelial growth factor receptor 2 (VEGFr2) expression in non-tumorous cirrhotic liver is higher when when hepatocellular carcinoma (HCC) is beyond Millan Criteria. Poster presentation at the 14th International Liver Transplantation Society Congress, July 2008, Paris, France.
- 70) Hashimoto K, Hirose K, Diago T, Aucejo F, Quintini C, Ding P, Corey R, **Egtesad B**, Kelly D, Fung J, Miller C. Impact of Cylex immune cell function assay in predicting acute cellular rejection and recurrence of HCV in liver transplantation. Poster presentation at the 14th International Liver Transplantation Society Congress, July 2008, Paris, France.
- 71) Aucejo F, Zein N, Diago T, Quintini C, Hashimoto K, **Egtesad B**, Fung J, Miller C, Yerian L. Liver vascular endothelial growth factor receptor 2 (VEGFr2) expression is unrelated to hepatitis C (HCV) infection in hepatocellular carcinoma (HCC)/cirrhosis. Poster presentation at the 14th International Liver Transplantation Society Congress, July 2008, Paris, France.
- 72) Alkhouri N, Hupertz V, **Egtesad B**, Fung J, Carter-kent C, Radhakrishnan K. Reversal of proten-losing enteropathy after liver transplantation in a child with idiopathic familial neonatal hepatitis. Poster presentation at the 5th congress of the International Pediatric Transplant Association. April 18-21, 2009, Istanbul, Turkey
- 73) Ahmed N, Quintini C, Hashimoto K, **Egtesad B**. Impact of transplant rotation on surgical resident training. Poster presentation at the 15th annual international Congress of the International Liver Transplantation Society. July 8-11, 2009, New York, USA
- 74) Tellioglu G, **Egtesad B**, Alster J, Yao D, Lin S, Fung J. Histidine-tryptophan-ketoglutarate solution vs. University of Wisconsin solution for deceased donor liver transplantation: Analysis of UNOS database. Poster presentation at the 15th annual international Congress of the International Liver Transplantation Society. July 8-11, 2009, New York, USA

10/17/2022

Bijan Egtesad, M.D.

Curriculum Vitae

75) Hupertz V, Gulati R, **Egtesad B**. Liver transplantation reverses portal hypertension associated hypoalbuminemia and growth failure in a patient with ARPKD. Poster presentation at the 15th annual international Congress of the International Liver Transplantation Society. July 8-11, 2009, New York, USA

76) Ahmed N, Hashimoto K, Aucejo F, Quintini C, Miller C, **Egtesad B**. Impact of transplant rotation on surgical resident training. Poster presentation at the American Transplant Congress. May 30 - June 3, 2009, Boston, USA

77) Kelly D, Shiba H, Irefin S, Zhu X, **Egtesad B**, Quintini C, Zhu X, Egtesad B, Quintini C, Aucejo F, Vogt D, Winans C, Hashimoto K, Miller C, Fung J. Hepatic blood flow following reperfusion is an important predictor of ischemia/reperfusion injury. Poster presentation at the American Transplant congress, May 1-5, 2010, San Diego, USA

78) Hashimoto K, Quintini C, **Egtesad B**, Radhakrishnan K, Feinberg L, Hupertz V, Tzakis A, Miller C, Fung J. Near total enterectomy for life-threatening complications of intestinal failure: a potential option as a bridge to intestinal transplantation. Poster presentation at the American Transplant congress, May 1-5, 2010, San Diego, USA

79) Gordon C, Siemionow M, **Egtesad B**, Fung J. A novel cadaver study quantifying the potential antigenic skin component accompanying face and upper extremity transplantation. Poster presentation at the American Transplant congress, May 1-5, 2010, San Diego, USA

80) Corey R, Van Duin D, Budev M, Starling R, Goldfarb D, **Egtesad B**, Fung J, Avery R. Infections in recipients of both thoracic and abdominal organ transplant. Poster presentation at the American Transplant congress, May 1-5, 2010, San Diego, USA

81) Fujiki M, **Egtesad B**, Diago T, Gunasekaran G, Hashimoto K, Quintini C, Kelly D, Fung J, Miller C, Aucejo F. Absolute absence of hepatocellular carcinoma enhancement in post TACE CT scan is not synonym of complete tumor necrosis. Poster presentation at the American Transplant congress, May 1-5, 2010, San Diego, USA

82) Shiba H, Hashimoto K, Kelly D, Fujiki M, Arakawa Y, **Egtesad B**, Miller C, Fung J. Risk stratification of hepatitis C virus recurrence after liver transplantation. Poster presentation at the 16th annual meeting of the International liver Transplantation society, June 16-19, 2010, Hong Kong, China

83) Fujiki M, **Egtesad B**, Diago T, Gunasekaran G, Hashimoto K, Quintini C, Kelly D, Fung J, Miller C, Aucejo F. Absolute absence of hepatocellular carcinoma enhancement in post TACE CT scan is not synonym of complete tumor necrosis. Poster presentation at the 16th annual meeting of the International liver Transplantation society, June 16-19, 2010, Hong Kong, China

10/17/2022

Bijan Eghtesad, M.D.

Curriculum Vitae

84) **Egtesad B**, Forrest K, Fujiki M, Diago T, Hodgkinson P, Hashimoto K, Quintini C, Aucejo F, Kelly D, Winans C, Vogt D, Miller C, Fung J. A pilot randomized controlled clinical trial of Thymoglobulin (r-ATG) induction with extended delay of calcineurin inhibitor therapy in liver transplantation. Poster presentation at the American Transplant Congress, Apr 30th – May 4th, 2011, Philadelphia, USA

85) Kelly D, Arakawa Y, Karpetian A, Quintini C, Hashimoto K, **Egtesad B**, Aucejo F, Vogt D, Winans C, Miller C, Fung J. The impact of Basiliximab induction therapy negates the effect of positive T-cell crossmatch on ACR in adult OLT recipients. Poster presentation at the American Transplant Congress, Apr 30th – May 4th, 2011, Philadelphia, USA

86) Zhu X, Shiba C, Quintini C, Hashimoto K, Aucejo F, **Egtesad B**, Miller C, Fung J, Kelly D. Low dose adenosine increases hepatic artery flow (HAF) in liver transplant recipients. Poster presentation at the American Transplant Congress, Apr 30th – May 4th, 2011, Philadelphia, USA

87) Diago T, Brown C, D'Amico G, Quintini C, Aucejo F, Hashimoto K, Kelly D, **Egtesad B**, Miller C, Fung J. Reno-portal bypass in patients with severe portal vein thrombosis and large splenorenal shunts: Should it represent the revascularization of choice? Poster presentation at the American Transplant Congress, Apr 30th – May 4th, 2011, Philadelphia, USA

88) Quintini C, Brown C, D'Amico G, Diago T, Aucejo F, Hashimoto K, **Egtesad B**, Kelly D, Miller C, Fung J. Preliminary experience with side-to-side cavo-cavostomy in liver transplantation an endovascular stapler. Poster presentation at the American Transplant Congress, Apr 30th – May 4th, 2011, Philadelphia, USA

89) Kelly D, Bennett R, **Egtesad B**, Yu C, Boerner D, McCoy J, Brown N, Miller C, Fung J, Kattan M. A new approach in a new era: Predicting discharge disposition following liver transplantation. Poster presentation at the American Transplant Congress, Apr 30th – May 4th, 2011, Philadelphia, USA

90) Fujiki M, Aucejo F, Hicks C, Diago T, Hodgkinson P, Hashimoto K, Quintini C, Kelly D, Winans D, Vogt D, **Egtesad B**, Fung J, Miller C. Comparable analysis of trans-arterial chemoembolotherapy for Hepatocellular carcinoma before liver transplantation: Drug eluting beads (DEB) vs. trans-arterial chemoembolization. Poster presentation at the American Transplant Congress, Apr 30th – May 4th, 2011, Philadelphia, USA

91) Brown C, Quintini C, D'Amico G, Diago T, Fujiki M, Hodgkinson P, Hashimoto K, Aucejo F, Kelly D, **Egtesad B**, Fung J, Miller C. Strategies to decrease the rate of hepatic artery thrombosis in liver transplant recipients: The importance of intraoperative flow measurements. Poster presentation at the International Liver Transplantation Society, June 22-25, 2011, Valencia, Spain

10/17/2022

Bijan Eghtesad, M.D.

Curriculum Vitae

92) Quintini C, Brown C, D'Amico G, Diago T, Fujiki M, Hodgkinson P, Hashimoto K, Aucejo F, Kelly D, **Egtesad B**, Fung J, Miller C. Splenic artery embolization is a safe procedure and improves intrahepatic arterial perfusion in liver transplant patients. Poster presentation at the International Liver Transplantation Society, June 22-25, 2011, Valencia, Spain

93) Modaresi J, Diago T, Fujiki M, Hodgkinson P, Hashimoto K, Aucejo F, Kelly D, Quintini C, Winans C, Vogt D, Zein N, Miller C, Fung J, **Egtesad B**. Duct-to-duct biliary reconstruction in patients with primary sclerosing cholangitis undergoing liver transplantation. Poster presentation at the International Liver Transplantation Society, June 22-25, 2011, Valencia, Spain

94) Fujiki M, Shiba H, Hashimoto K, Arakawa Y, Diago T, Quintini C, **Egtesad B**, Fung J, Miller C. Do donation after cardiac death liver allografts affect severe hepatitis C recurrence early after liver transplantation? Poster presentation at the International Liver Transplantation Society, June 22-25, 2011, Valencia, Spain

95) Fujiki M, Aucejo F, Hicks C, Diago T, Hodgkinson P, Hashimoto K, Quintini C, Kelly D, Winans D, Vogt D, **Egtesad B**, Fung J, Miller C. Comparable analysis of trans-arterial chemoembolotherapy for Hepatocellular carcinoma before liver transplantation: Drug eluting beads (DEB) vs. trans-arterial chemoembolization. Poster presentation at the International Liver Transplantation Society, June 22-25, 2011, Valencia, Spain

96) Kelly D, Bennett R, Vass K, McCoy J, Kerepesi K, Waby A, **Egtesad B**, Hashimoto K, Aucejo F, Quintini C, Miller C, Fung J. Multidisciplinary approach to improving quality of care and reducing length of stay. Poster presentation at the American Transplant Congress, June 2-6, 2012, Boston, USA

97) Hashimoto K, Quintini C, Aucejo F, Fujiki M, Diago T, Watson M, Kelly D, Winans C, **Egtesad B**, Fung J, Miller C. Split liver transplantation using hemiliver grafts: A single US center experience in the MELD era. Poster presentation at the American Transplant Congress, June 2-6, 2012, Boston, USA

98) Modaresi Esfeh J, Kovacs C, Hanouneh I, Dalal D, Koval C, **Egtesad B**, Zein N, Menon KVN. Impact of pre-transplant rifaximin therapy on post-liver transplant infections. Poster presentation at the American Transplant Congress, June 2-6, 2012, Boston, USA

99) Watson M, Fujiki M, Diago T, Hashimoto K, Quintini C, Aucejo F, Kelly D, Winans C, Miller C, Fung J, **Egtesad B**. Comparison of induction with Basiliximab and early start of calcineurin inhibitors to induction with rATG and delayed CNI therapy after liver transplantation in patients with hepatorenal syndrome on hemodialysis – a pilot study. Poster presentation at the American Transplant Congress, June 2-6, 2012, Boston, USA

10/17/2022

Bijan Eghtesad, M.D.

Curriculum Vitae

100) El-Gazzaz G, Purysko A, Narayanan M, Hashimoto K, Quintini C, Kelly D, **Egtesad B**, Miller C, Fung J, Aucejo F, Remer E. Does radiological appearance of hepatocellular carcinoma (HCC) affect the outcome of locoregional therapy (LRT) in patients undergoing liver transplantation? Poster presentation at the American Association for the Study of Liver Disease (AASLD), November 9-13, 2012, Boston, USA

101) Watson M, Fujiki M, Diago T, Hashimoto K, Kelly D, Aucejo F, Quintini C, Winans C, Bollinger J, Miller C, Fung J, **Egtesad B**. Induction with anti-thymocyte globulin and delayed calcineurin inhibitor therapy in patients with renal failure prior to liver transplant improves outcomes. Poster presentation at the American Association for the Study of Liver Disease (AASLD), November 9-13, 2012, Boston, USA

102) Qui J, Thapaliya S, Runkana A, Yang Y, Tsien C, Mohan M, **Egtesad B**, Mozdziak P, McDonald C, McCullough A, Nadga Prasad S, Dasarathy S. Sarcopenia of cirrhosis is mediated by hyperammonemia induced NF κ B regulated transcriptional upregulation of myostatin expression. Poster presentation at the American Association for the Study of Liver Disease (AASLD), November 9-13, 2012, Boston, USA

103) Qui J, Tsien C, Thapaliya S, Narayanan A, Almasaan A, **Egtesad B**, McCullough A, McDonald C, Nadga Prasad S, Wehl C, Singh K, Dasarathy S. Hyperammonemia mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Poster presentation at the American Association for the Study of Liver Disease (AASLD), November 9-13, 2012, Boston, USA

104) Zein NN, Hanouneh IA, Bishop PD, Samaan M, **Egtesad B**, Quintini C, Miller C, Yerian L, Klatter R. Three-dimensional print of a liver for preoperative planning in living donor liver transplantation. Poster presentation at the American Association for the Study of Liver Disease (AASLD), November 1-5, 2013, Washington DC, USA

105) Dugum M, Hanouneh IA, Lopez R, Aucejo F, **Egtesad B**, Zein NN. Hepatocellular carcinoma (HCC) in the setting of chronic hepatitis B virus infection (HBV): Recurrence and survival rates following liver transplantation. Poster presentation at the American Association for the Study of Liver Disease (AASLD), November 1-5, 2013, Washington DC, USA

106) Kawamura N, Nazzal M, El-Gazzaz G, Spaggiari M, Fujiki M, Diago T, Aucejo F, Hashimoto K, Quintini C, Winans C, Egtesad B, Miller C, Fung J, Alkouri N, Kelly D. Non-alcoholic fatty liver disease (NAFLD) recurrence after liver transplantation (OLT) for non-alcoholic steatohepatitis (NASH). Poster presentation at the American Association for the Study of Liver disease. November 6-11, 2014, Boston, USA

107) Yaseen M, Hanouneh I, John B, Guirguis J, Egtesad B, Fung J, Zein N. Safety and efficacy of all-oral sofosbuvir-based regimen to treat HCV recurrence post-liver transplantation.

10/17/2022

Bijan Egtesad, M.D.

Curriculum Vitae

Poster presentation at the American Association for the Study of Liver disease. November 6-11, 2014, Boston, USA

133) Liu Q, Nasser A, Kelly D, Hashimoto K, Egtesad B, Diago T, Irefin S, Cywinski J, Baldwin W, Fung J, Abu-Elmagd K, Miller C, Quintini C. Normothermic machine perfusion (NMP) promotes early graft function and biliary epithelial regeneration after liver transplantation of porcine liver undergoing 1hr warm ischemia (WI). Poster presentation at the World Transplant Congress, July 26-31, 2014 San Francisco.

134) Presser N, Watson M, Bollinger J, Fujiki M, Diago T, Aucejo F, Quintini C, Hashimoto K, Kelly D, Winans C, Miller C, Fung J, Egtesad B. Induction with antithymocyte globulin (rATG) and delayed calcineurin inhibitor therapy in patients with acute renal failure/dysfunction pre-liver transplantation allows for sustained renal recovery post transplant. Poster presentation at the World Transplant Congress, July 26-31, 2014 San Francisco

135) Firl D, Schold J, Egtesad B, Fung J. Recipient age modulates effect of donor risk on graft loss in deceased donor liver transplantation. Poster presentation at the World Transplant Congress, July 26-31, 2014 San Francisco.

136) Bollinger J, Plavney D, Zein N, Hashimoto K, Diago T, Kelly D, Quintini C, Aucejo F, Fujiki M, Winans C, Kerepesi K, Waby A, Miller C, Fung J, Egtesad B. Liver transplantation using anti-HBc positive donors: A single center experience. Poster presentation at the World Transplant Congress, July 26-31, 2014 San Francisco.

137) Nasser A, Liu Q, Urcuyo D, Mediaris S, El-Gazzaz G, Egtesad B, Fung J, Abu-Elmagd K, Miller C, Walsh M, Quintini C. Establishing an Ex-vivo pancreas perfusion model on discarded human grafts. Poster presentation at the World Transplant Congress, July 26-31, 2014 San Francisco

138) Zhang W, Kim R, Quintini C, Hashimoto K, Fujiki T, Diago T, Egtesad B, Miller C, Fung J, Tan A, Narayanan M, Aucejo F. Plasma vascular endothelial growth factor (VEGF) predicts vascular invasion in patients with hepatocellular carcinoma undergoing liver transplantation. Poster presentation at the World Transplant Congress, July 26-31, 2014 San Francisco

139) Know JH, Hanouneh I, Allende D, Yerian L, Diago T, **Egtesad B**, Zein N. DeNovo autoimmune hepatitis following liver transplantation. Poster presentation at the Digestive Disease Week, May 16-19, 2015 Washington DC

140) Know HJ, Hanouneh I, Allende D, Yerian L, Diago T, **Egtesad B**, Zein N. Plasma cell hepatitis following liver transplantation in patients with chronic hepatitis C virus infection. Poster presentation at the Digestive Disease Week, May 16-19, 2015 Washington DC

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

141) Alkhuri N, Hanouneh I, Zein N, Lopez R, Kelly D, **Egtesad B**, Fung J. Liver transplantation for nonalcoholic steatohepatitis (NASH) in children and young adults: The true burden of pediatric nonalcoholic fatty liver disease. Poster presentation at the Digestive Disease Week, May 16-19, 2015 Washington DC

142) Samaan M, **Egtesad B**, Quintini C, Kissiedu J, Hanouneh I, Klatte R, Miller C, Zein N. #D printing liver models for precise resection of complex hepatic tumors. Poster presentation at the American Association for the Study of Liver Disease November 13-17, 2015, San Francisco

143) Louwers L, Palaios E, El-Gazzaz G, Spagiari M, **Egtesad B**, Kelly D. Objective measurements of Karnofsky performance status in end stage liver disease patients. Poster presentation at the American Association for the Study of Liver Disease November 13-17, 2015, San Francisco

144) Dugum M, Zein N, Dugum A, Lopez R, **Egtesad B**, Hanouneh I. Association of pre-transplant body mass index (BMI) with survival benefit of liver transplantation. Poster presentation at the American Association for the Study of Liver Disease November 13-17, 2015, San Francisco

145) Dugum M, Zein N, Dugum A, Lopez R, **Egtesad B**, Hanouneh I. Predicting futility of liver transplantation: scoring system based on liver transplantation survival benefit. Poster presentation at the American Association for the Study of Liver Disease November 13-17, 2015, San Francisco

146) Hajifathalian K, Arora Z, Humberson A, Barnes D, McCullough A, Zein N, **Egtesad B**, Hanouneh I. Ohio solid organ transplantation consortium (OSOTC) criteria for liver transplantation in patients with alcoholic liver disease. Poster presentation at the American Association for the Study of Liver Disease November 13-17, 2015, San Francisco

147) Spagiari M, Shaaban M, El-Gazzaz G, Louwers L, Palaios E, Quintini C, Aucejo F, Hashimoto K, Diago T, Fujiki M, **Egtesad B**, Miller C, Perilla M, Kelly D. How intra-operative factors affect kidney recovery after simultaneous liver-kidney transplantation. Poster presentation at the American Association for the Study of Liver Disease November 13-17, 2015, San Francisco

Research Projects:

A) University of New Mexico (1998-2000):

10/17/2022

Bijan Egtesad, M.D.

Curriculum Vitae

HRRC 00-202 (University of New Mexico), “A Randomized, Open-Label Preference Study of Gengraf compared to Neoral in Stable Solid-Organ Transplant Subjects (The PREFER, study, M99-133)”

B) University of Pittsburgh, Starzl Transplantation Institute (2001-2004):

Grant from Abbott Laboratories. (Co-Investigator, study completed in NM).

Serum Storage for Liver Transplant Recipients and for Liver Transplantation (Principal Investigator). IRB # 951096-9909.

A Phase III, Controlled, Multicenter, Randomized, Parallel-Group, Single-Blind Study to compare the Safety and Hemostatic Efficacy of the Fibrin Sealant, Beriplast P, with Standard Care of Thrombin-Soaked Gelfoam in the Treatment of Bleeding from the Hepatic Fossa in Subjects Undergoing Elective Liver Resection Surgery. (Co-Investigator, using the sealant in the operating room on our liver resection patients)

A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Dose Exploratory Trial Evaluating the Safety and Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven) in the reduction of bleeding in Subjects Undergoing Orthotopic Liver Transplantation (F7LIVER-1256,2/6/01) (PCRN# 2001-0028). (Co-Investigator, study completed)

Low-Dose Ex-Vivo X-Irradiation of the Intestine Allograft and Simultaneous Bone Marrow Cell Infusion to Enhance Intestinal/Multivisceral Allograft Survival. IRB Protocol # 990950. (Co-Investigator, working with the small bowel transplant team on the outcome analysis)

A prospective Study of Clinical, Pathologic, and Virologic Course of Liver Transplant Candidates and Recipients with Hepatitis C. IRB # 000388 (Co-Investigator, still enrolling patients in the study and following these patients in our clinics).

Enhancement of Liver Allograft Survival by Single Perioperative Infusion of Bone Marrow Cells from the Same Donor. IRB # 960233 (Co-Investigator) (Study completed).

Development of Tests to Assess Immune Modulation Following Organ Transplantation. IRB # 010853. (Co-Investigator, I have been following all these patients in clinic and presenting them to the meeting on a weekly basis)

Clinical, Immunologic and Pharmacologic Consequences of Solid Organ Transplantation in People with HIV Infection. (Co-Investigator, close follow-up on all these patients and adjustment of their immunosuppression based on their anti-HIV drugs, control of their liver function and treatment of their co-existing hepatitis B or C, if indicated)

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

Adult to Adult Living Donor Liver Transplantation Cohort Study (Co-investigator). Involvement in laboratory aspects of living donor liver transplantation and liver regeneration in both donors and recipients. Active follow-up on all our patients (donors and recipients)

Study of Clinical, Immunological, and Pathological outcome Data from Living Donor/Recipient Organ Transplantation. IRB # 0403110 (Co-Investigator)

Polyomavirus after Liver Transplantation. University of Pittsburgh IRB # 021206. (Co-investigator, ongoing study)

Obtainment of peripheral blood from normal healthy volunteers, candidates on waiting list and immunosuppressed organ allograft recipients to study the feasibility of transforming their B cells with HBV and loading dendritic cells for the *Ex Vivo* Generation of autologous cytotoxic lymphocytes. (Co-investigator, ongoing project)

UPMC TE Starzl Transplant Registry (Co-investigator, ongoing project, IRB# 0307037)

The effect of intraoperative changes in blood flow on graft function and biliary complications in living related liver transplantation. Co-investigator, ongoing project, IRB# 0403053)

C) Cleveland Clinic Foundation (2005-Present):

Liver and Kidney Transplantation in HIV-Positive patients (NIH, Multi-Center Study). (Co-Investigator). Closed

A Prospective, Open-Label, Multi-center, Randomized Trial of the Efficacy and Safety of a Long-Term Calcineurin Inhibitor Free Maintenance Regimen with Mycophenolate Mofetil and sirolimus in Recipients of an Orthotopic Liver Transplant. (ML18423) (Co-Investigator). (Closed to enrollment)

A Multi-center, Randomized, Open-Label Study to Compare the Development of Liver Fibrosis at 12 Months after Transplantation for Hepatitis C Cirrhosis in Patients receiving either Neoral or Prograf. (COLO400A2426) (Principal Investigator) (Closed to enrollment)

Immunosuppression with Campath-1H and Tacrolimus in Liver Transplantation (ILEX Oncology, Inc and NIAID, Immune Tolerance Network (ITN)), IRB 7782 (Co-Investigator). (Closed to enrollment)

Evaluation of HepaGam B™ in combination with antiviral treatment in hepatitis B liver transplant patients. (HB-009) (Co-Investigator), (Closed to enrollment)

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

A randomized, double-blind study to assess the efficacy and safety of prophylactic use of Maribavir vs. oral ganciclovir for the prevention of Cytomegalovirus disease in recipients of orthotopic liver transplantation. (1263-301) (Co-Investigator) (Closed to enrollment)

Study of the antiviral activity of entecavir in patients receiving liver transplant due to chronic hepatitis B virus infection. (AI463109) (Co-Investigator) Closed

A 24-month multi-center, randomized, open-label study to evaluate the efficacy and safety of concentration controlled everolimus with corticosteroids in combination with minimization or elimination of Tacrolimus in *de novo* liver transplant recipients compared to Tacrolimus and corticosteroid. (CARD001H2304) (Co-Investigator), Closed. Manuscripts published

Survival rates and biliary complications in recipients of livers recovered from donation after cardiac death (DCD) donors. (Principal Investigator). Closed.

The Cleveland Clinic protocol for human upper extremity allotransplantation. (Co-Investigator), New study.

Impact of timing of hepatic artery re-perfusion on biliary complications. A retrospective, chart review study. (Principal Investigator), Closed

Management of celiac artery stenosis during liver transplantation. A retrospective, chart review study. (Principal Investigator), on going study

Clinical outcomes of combined liver transplantation. A retrospective, chart review study. Co-Investigator. On going study

New desensitization protocol for human intestinal transplant candidates with high panel reactive antibody. Co-Investigator Ongoing study

Patient perception of nutritional counseling during evaluation for liver transplantation. A prospective study. Co-Investigator

Prevalence and outcome of malnutrition in cirrotic patients undergoing evaluation for liver transplantation. A prospective study. Co-Investigator

Recurrence of liver disease following orthotopic liver transplantation. A retrospective study. Co-Investigator.

A randomized control clinical trial of low-dose Thymoglobulin and extended delay of calcineurin inhibitor therapy for renal protection after liver transplantation. CCF IRB # 09-432, Principal

10/17/2022

Bijan Eghtesad, M.D.

Curriculum Vitae

Investigator. (Research grant \$147,000, Genzyme Pharmaceuticals). Closed to enrollment.

Manuscript in preparation.

Enhancing DCD Utilization with Thrombolytic therapy focusing on liver and kidney transplantation. CCF IRB # 10-365, Principal Investigator. (Grant approved by HRSA \$730,000 for 3 years). Closed to enrollment. One manuscript out. Second one in preparation.

A Phase II randomized, double-blind, placebo controlled study of the clinical effectiveness of a human monoclonal antibody against hepatitis C virus E2 glycoprotein (MBL-HCV1) in hepatitis C infected patients undergoing liver transplantation. CCF IRB # 10-1079, Principal Investigator (Research grant \$125,000 for 5 patients enrolled, Mass Biologics, Boston MA) (Closed – retracted from study due to lack of progress and financial issues related to lack of enrollment because of restricted inclusion criteria)

A phase II open-label study of the clinical effectiveness of a human monoclonal antibody against hepatitis C virus E2 glycoprotein (MBL-HCV1) in hepatitis C infected patients undergoing liver transplantation. CCF IRB # 12-329, Principal Investigator. (Research grant \$150,000, Mass Biologic, Boston MA) (Closed – retracted from study due to lack of progress and financial issues related to lack of enrollment because of restricted inclusion criteria)

Hemophilia Liver Transplantation Observational Study (HOTS)”

AIDS Clinical Studies and Epidemiology Study Section. Protocol No. PRO12060248

Principal Investigator for Cleveland Clinic Center. (CCF IRB # 14-200) Enrollment finished.

Manuscript published (Liver Transplantation)

A Randomized Controlled Clinical Trial of Thymoglobulin® and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection after Liver Transplantation

A Multi-Center Study CCF IRB # 15-943 \$1,300,000 total budget. Beginning of enrollment. A 3-year study at 4 centers. CCF the main center.

Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act

Safeguards and Research Criteria for Transplantation of Organs Infected with

HIV. Multicenter study across the US. NIH sponsored study. CCF IRB level

Stressed Induced Cardiomyopathy in Liver Transplantation. Registry Data/Ongoing (CCF IRB # 15-284)

How Intraoperative Factors Affect the Simultaneous Liver and Kidney Transplant outcomes: A Single Institution Matched Case Control Study. Registry Data/Ongoing Study (CCF IRB # 14-952)

10/17/2022

Bijan Eghtesad, M.D.

Curriculum Vitae

Phase 3b, Open label, Safety, and Immunogenicity Study of SARSCo V2 mRNA-1273 Vaccine in adult Solid Organ Transplant Recipients and Healthy Controls. Multicenter Study. Sponsored by Moderna Pharmaceuticals. (CCF IRB # 21-812)

Appointments:

A) Cleveland Clinic Appointments:

Member, Appointment and Promotion Committee. Digestive Disease Institute (No more activities)

Member, Quality Performance/Standardization Database/Outcomes Committee, Digestive Disease Institute (No more activities)

Member, Donation and Transplantation Task Force (ongoing)

Member, Pharmacy and Therapeutics Committee 2006-2010

Chair, Transplant Pharmacy and Therapeutics Committee 2006-2010

Vice Chairman, Digestive Disease Institute Research Committee (2010-2017)

Director, ASTS Transplant Fellowship Program, Cleveland Clinic (2007-2018)

Director, ASTS Transplant Fellowship Program, Cleveland Clinic (2022-....)

B) Off Campus Appointments:

Associate Medical Director, New Mexico Donor Services (1999-2000)

New Mexico Donor Program, Board of Directors (1995-2000)

UNOS Region 5 Regional Review Board member (1997-2000)

UNOS Region 2 Regional Review Board member (2001-2002)

UNOS: Region 10 Regional Review Board member (Substitute) (2005-present)

UNOS: Organ Availability Committee (2010-2013)

10/17/2022

Bijan Eghtesad, M.D.

Curriculum Vitae

Board of Directors, LifBanc, North-Eastern Ohio Organ Procurment Organization, Cleveland, Ohio (2006-2015)

National Organ Donation and Transplantation Breakthrough Collaborative Committee (Member, Cleveland Clinic Team)

Fellowship Training Committee - American Society of Transplant Surgeons (ASTS), 2013-2016

Surgery and Liver Transplantation Committee – American Association for the Study of Liver Diseases (AASLD), 2013-2016

Liver Transplantation and Surgery Special Interest Groups (SIG) Steering Committee - American Association for the Study of Liver Diseases (AASLD), 2017-2020

Surgery and Liver Transplantation Committee – American Association for the Study of Liver Diseases (AASLD), 2016-2019

Ambassador of the Transplantation Society for Iran. The Transplantation Society (TTS), 2016 – Present

Council member, International Liver Transplantation Society (ILTS), 2018-2023

Chair, Global Subcommittee, Liver Transplantation and Surgery, Special Interest Group (SIG) (AASLD) 2018-2020

Chair-Elect of the Surgery and Liver Transplantation Committee, American Association for the Study of Liver Diseases (AASLD), 2019-2020

Chair, Surgery and Liver Transplantation Committee, American Association for the Study of Liver Diseases (AASLD), 2020-2022

Chair, Membership and Communication Committee, International Liver Transplantation Society (ILTS), 2019-2022

International Liver Transplantation Society (ILTS), Award Committee, 2018-2022

American Association for the Study of Liver Diseases (AASLD), Scientific Program Committee, Annual Liver Meeting, 2020-2022

Chair of the Education Committee of the Ohio Solid Organ Transplant Consortium (OSOTC) 2020-

10/17/2022

Bijan Eghtesad, M.D.
Curriculum Vitae

10/17/2022